Category Archive Urology

Stage 5 Kidney Disease – Causes, Symptoms, Treatment

Stage 5 kidney disease development of chronic renal and its progression to this terminal disease remains a significant source of reduced quality of life and significant premature mortality. Chronic kidney disease (CKD) is a debilitating disease, and standards of medical care involve aggressive monitoring for signs of disease progression and early referral to specialists for dialysis or possible renal transplant. The Kidney Disease Improving Global Outcomes (KDIGO) foundation guidelines define CKD using kidney damage markers, specifically markers that determine proteinuria and glomerular filtration rate. By definition, the presence of both of these factors (glomerular filtration rate [GFR] less than 60 mL/min and albumin greater than 30 mg per gram of creatinine) along with abnormalities of kidney structure or function for greater than three months signifies chronic kidney disease. End-stage renal disease, moreover, is defined as a GFR less than 15 mL/min.

Staging

Kidney Disease: Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guidelines: CKD classification considers the GFR level and the severity of albuminuria.

  • Stage 1: Kidney damage with normal GFR (greater than 90 ml/min)
  • Stage 2: Mild reduction in GFR (60-89 ml/min)
  • Stage 3a: Moderate reduction in GFR (45 to 59 ml/min)
  • Stage 3b: Moderate reduction in GFR (30 to 44 ml/min)
  • Stage 4: Severe reduction in GFR (15 to 29 ml/min)
  • Stage 5: Renal failure (GFR less than 15 ml/min)

As a part of kidney disease staging, your doctor also may test whether protein is present in your urine.

Kidney disease stage GFR, mL/min Kidney function
National Kidney Foundation
Stage 1 90 or above Normal or near-normal kidney function
Stage 2 60 to 89 Mild loss of kidney function
Stage 3a 45 to 59 Mild to moderate loss of kidney function
Stage 3b 30 to 44 Moderate to severe loss of kidney function
Stage 4 15 to 29 Severe loss of kidney function
Stage 5 Less than 15 Kidney failure

Causes of Stage 5 Kidney Disease

Many chronic diseases can cause end-stage renal disease. In the United States, diabetes mellitus is the leading cause. Other causes include hypertension, glomerulonephritis, polycystic kidney disease, prolonged obstruction of the urinary tract, vesicoureteral reflux, recurrent pyelonephritis, and certain medications, including non-steroidal anti-inflammatory drugs (NSAIDs), calcineurin inhibitors, and antiretrovirals.

The decline of kidney function is gradual and initially may present asymptomatically. The natural history of renal failure depends on the etiology of the disease but ultimately involves early homeostatic mechanisms involving hyperfiltration of the nephrons. As nephrons become damaged, the kidney increases the rate of filtration in the residual normal ones. As a result, the patient with mild renal impairment can show normal creatinine values, and the disease can go undetected for some time. This adaptive mechanism will run its course and eventually cause damage to the glomeruli of the remaining nephrons. At this point, antihypertensives such as ACEs or ARBs may be beneficial in slowing the progress of the disease and preserving renal function.

Factors that may worsen renal injury include:

  • Glomerulonephritis (gloe-mer-u-low-nuh-FRY-tis), an inflammation of the kidney’s filtering units (glomeruli)
  • Interstitial nephritis (in-tur-STISH-ul nuh-FRY-tis), an inflammation of the kidney’s tubules and surrounding structures
  • Polycystic kidney disease
  • Prolonged obstruction of the urinary tract, from conditions such as enlarged prostate, kidney stones and some cancers
  • Vesicoureteral (ves-ih-koe-yoo-REE-tur-ul) reflux, a condition that causes urine to back up into your kidneys
  • Recurrent kidney infection also called pyelonephritis (pie-uh-low-nuh-FRY-tis)
  • Nephrotoxins (NSAIDs)
  • Systemic hypertension
  • Proteinuria
  • Dehydration
  • Smoking
  • Hyperlipidemia
  • Uncontrolled diabetes
  • Hyperphosphatemia
  • Chronic glomerulonephritis
  • Chronic pyelonephritis
  • Rapidly progressive glomerulonephritis
  • Nephropathy of pregnancy/pregnancy toxemia
  • Unclassifiable nephritis
  • Polycystic kidney disease
  • Nephrosclerosis
  • Malignant hypertension
  • Diabetic nephropathy
  • Systemic lupus erythematosus nephritis
  • Amyloidal kidney
  • Gouty kidney
  • Renal failure due to a congenital abnormality of metabolism
  • Renal/urinary tract tuberculosis
  • Renal/urinary tract calculus
  • Renal/urinary tract tumor
  • Obstructive urinary tract disease
  • Myeloma
  • Renal hypoplasia

Symptoms of Stage 5 Kidney Disease

Early in chronic kidney disease, you may have no signs or symptoms. As chronic kidney disease progresses to end-stage renal disease, signs and symptoms might include:

  • Nausea
  • Vomiting
  • Loss of appetite
  • Fatigue and weakness
  • Sleep problems
  • Changes in how much you urinate
  • Decreased mental sharpness
  • Muscle twitches and cramps
  • Swelling of feet and ankles
  • Persistent itching
  • Chest pain, if fluid builds up around the lining of the heart
  • Shortness of breath, if fluid builds up in the lungs
  • High blood pressure (hypertension) that’s difficult to control

Signs and symptoms of kidney disease are often nonspecific, meaning they can also be caused by other illnesses. Because your kidneys are highly adaptable and able to compensate for lost function, signs and symptoms may not appear until irreversible damage has occurred.

You may experience a wide range of symptoms, including

  • a decrease in how much you urinate
  • inability to urinate
  • fatigue
  • malaise, or a general ill feeling
  • headaches
  • unexplained weight loss
  • loss of appetite
  • nausea and vomiting
  • dry skin and itching
  • changes in skin color
  • bone pain
  • confusion and difficulty concentrating
  • bruising easily
  • frequent nosebleeds
  • numbness in your hands and feet
  • bad breath
  • excessive thirst
  • frequent hiccups
  • the absence of menstrual cycles
  • sleeping problems, such as obstructive sleep apnea and restless leg syndrome (RLS)
  • low libido or impotence
  • edema, or swelling, especially in your legs and hands

See your doctor right away if any of these symptoms interfere with your life, especially if you can’t urinate or sleep, are vomiting frequently, or feel weak and unable to do daily tasks.

Diagnosis of Stage 5 Kidney Disease

History and Physical

End-stage renal disease can present with a constellation of signs and symptoms. Some include volume overload refractory to diuretics, hypertension poorly responsive to medication, anemia, mineral and bone disorders, and metabolic derangements including hyperkalemia, hyponatremia, metabolic acidosis, hypo/hypercalcemia, and hyperphosphatemia. Uremic toxicity can present as anorexia, nausea, vomiting, bleeding diatheses, pericarditis, uremic neuropathy or encephalopathy, seizure, coma, and death. Uremic toxicity is an indication for urgent dialysis.

In general, ESRD symptoms appear in stages 4 and 5 when the GFR is less than 30 ml/min. Some patients with nephrotic syndrome and cystic renal disease may present earlier.

Depression is ubiquitous in patients with ESRD and should be screened for on presentation.

Lab Test and Imaging

ESRD changes the results of many tests. People receiving dialysis will need these and other tests done often:

  • Potassium
  • Sodium
  • Albumin
  • Phosphorous
  • Calcium
  • Cholesterol
  • Magnesium
  • Electrolytes
  • A physical exam – during which your doctor measures your height, weight, and blood pressure and also looks for signs of problems with your heart or blood vessels and conducts a neurological exam.
  • Blood tests – Complete blood count (CBC) and measure the number of waste products, such as creatinine and urea, in your blood.
  • Urine tests – to check the level of the protein albumin in your urine — a high albumin level may indicate kidney disease.
  • Urinalysis – This test helps your doctor check for protein and blood in your urine. These substances indicate that your kidneys aren’t processing waste properly.
  • Serum creatinine test – This test helps your doctor check whether creatinine is building up in your blood. Creatinine is a waste product that your kidneys should filter out of your body.
  • Blood urea nitrogen test – This test helps your doctor check how much nitrogen is in your blood.
  • Estimated glomerular filtration rate (GFR) – This test allows your doctor to estimate how well your kidneys filter waste.
  • Imaging tests – such as ultrasound, magnetic resonance imaging or computed tomography (CT) scan, to assess your kidneys’ structure and size and look for abnormalities.
  • Removing a sample of kidney tissue (biopsy) – to examine under a microscope to learn what type of kidney disease you have and how much damage there is.

Chronic kidney disease is diagnosed when there is evidence of kidney damage for at least three months or in any patient with a GFR of less than 60 mL/min for that same amount of time.

To calculate GFR, three equations are commonly used (the MDRD [Modification of Diet in Renal Disease Study], CKD-EPI, and Cockcroft-Gault formula). However, the best estimate of GFR is the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation, which adjusts for age, race, and gender. However, it is important to note that the formula tends to underestimate the actual GFR at a GFR greater than 60 mL/min.

To quantitate albuminuria, a spot urine protein/creatinine ratio can be done. A value higher than 30 mg of albumin per gram of creatinine is considered abnormal, while values greater than 300mg/g are considered severely impaired renal function. Additionally, a 24-hour urine protein can also be performed. A value greater than 3.5 g is concerning for nephrotic range proteinuria.

Further evaluation of kidney disease can include a renal ultrasound, complete blood count (CBC), basic metabolic panel (BMP), urinalysis, and/or kidney biopsy. An ultrasound can provide data estimating size, obstructions, stones, cystic renal disease, mass lesions, echogenicity, and cortical thinning. Blood work will determine if there is secondary anemia and will detect evidence of electrolyte derangement. In cases of severe anemia secondary to CKD, erythropoiesis-stimulating agents should be started at a hemoglobin level below 10 g/dL. Finally, a renal biopsy may be necessary if the etiology remains unclear.

Treatment of Stage 5 Kidney Disease

Treatment of end-stage renal disease involves correcting parameters at the level of the patient’s presentation. Interventions aimed at slowing the rate of kidney disease should be initiated and can include:

  • Treating the underlying cause and managing blood pressure and proteinuria. Blood pressure should be targeted to a systolic blood pressure less than 130 mmHg and diastolic blood pressure less than 80 mmHg in adults with or without diabetes mellitus whose urine albumin excretion exceeds 30 mg for 24 hours. For diabetic patients with proteinuria, an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) should be started in cases where urine albumin values range between 30 and 300 mg in 24 hours and greater than 300 mg in 24 hours. These drugs slow the disease progression, particularly when initiated before the GFR decreases to less than 60 mL/min or before plasma creatinine concentration exceeds 1.2 and 1.5 in women and men, respectively.
  • Other targets in preventive care and monitoring should include tight glycemic control, cardiovascular risk reduction, and general lifestyle recommendations such as smoking cessation and dietary restriction. Glycemic control is critical. A hemoglobin A1C of less than 7% is generally recommended to prevent or delay microvascular complications in this population. Management with sodium-glucose transporter 2 (SGLT-2) inhibitors may reduce the disease burden in those with type II diabetes mellitus.
  • Treatment of chronic metabolic acidosis with supplemental renal bicarbonate also may slow the progression of end-stage renal disease.
  • Patients with CKD tend to have dyslipidemia, particularly hypertriglyceridemia. Monitoring fasting lipid panels and initiation of cholesterol-lowering agents such as HMG-CoA reductase inhibitors should be done early in the course of the disease.
  • Lifestyle modification and dietary restrictions are routinely recommended. Adhering to a low salt diet (less than 2 g/day), a renal diet (avoiding foods that are high in phosphorus), and restricting daily protein to 0.8 g per kg body weight per day is essential to managing disease burden.
  • Hypocalcemia should also be monitored. A 25-OH vitamin D level less than 10 ng/mL warrants initiation of ergocalciferol 50,000 IU weekly for 6 to 8 weeks before switching to cholecalciferol 800 to 1000 IU daily.

Kidney transplant

A kidney transplant is a surgical procedure to place a healthy kidney from a live or deceased donor into a person whose kidneys no longer function properly. A kidney transplant is often the treatment of choice for end-stage renal disease, compared with a lifetime on dialysis.

The kidney transplant process takes time. It involves finding a donor, living or deceased, whose kidney best matches your own. You then undergo a surgical procedure to place the new kidney in your lower abdomen and attach the blood vessels and ureter — the tube that links the kidney to the bladder — that will allow the new kidney to function.

You’ll spend several days to a week in the hospital. After leaving the hospital, you’ll have frequent checkups as your recovery continues. You’ll take a number of medications to help keep your immune system from rejecting your new kidney and to reduce the risk of post-surgery complications, such as infection.

After a successful kidney transplant, your new kidney filters your blood, and you no longer need dialysis.

Dialysis

Dialysis does some of the work of your kidneys when your kidneys can’t do it themselves. This includes removing extra fluids and waste products from your blood, restoring electrolyte levels, and helping control your blood pressure.

Dialysis options include peritoneal dialysis and hemodialysis.

  • Peritoneal dialysis – During peritoneal dialysis, blood vessels in your abdominal lining (peritoneum) fill in for your kidneys with the help of a fluid that washes in and out of the peritoneal space. Peritoneal dialysis is done in your home.
  • Hemodialysis – During hemodialysis, a machine does some of the work of the kidneys by filtering harmful wastes, salts, and fluid from your blood. Hemodialysis may be done at a center or in your home.[rx]

For dialysis to be successful, you may need to make lifestyle changes, such as following certain dietary recommendations.

Supportive care

With supportive care, your symptoms are managed so that you feel better. You may choose supportive care alone or combine it with other treatment options.

Without either dialysis or a transplant, kidney failure progresses, eventually leading to death. In some people, the disease progresses slowly over months and years, while in others the disease progresses quickly.

Potential future treatments

Regenerative medicine holds the potential to fully heal damaged tissues and organs, offering solutions and hope for people who have conditions that today are beyond repair.

Regenerative medicine approaches include:

  • Boosting the body’s natural ability to heal itself
  • Using healthy cells, tissues, or organs from a living or deceased donor to replace damaged ones
  • Delivering specific types of cells or cell products to diseased tissues or organs to restore tissue and organ function

For people with kidney disease, regenerative medicine approaches may be developed in the future to help slow the progression of the disease.

Complications

Kidney damage, once it occurs, can’t be reversed. Potential complications can affect almost any part of your body and can include:

  • Fluid retention, which could lead to swelling in your arms and legs, high blood pressure, or fluid in your lungs (pulmonary edema)
  • A sudden rise in potassium levels in your blood (hyperkalemia), which could impair your heart’s ability to function and may be life-threatening
  • Heart and blood vessel (cardiovascular) disease
  • Weak bones and an increased risk of bone fractures
  • Anemia
  • Decreased sex drive, erectile dysfunction or reduced fertility
  • Damage to your central nervous system, which can cause difficulty concentrating, personality changes or seizures
  • Decreased immune response, which makes you more vulnerable to infection
  • Pericarditis, an inflammation of the saclike membrane that envelops your heart (pericardium)
  • Pregnancy complications that carry risks for the mother and the developing fetus
  • Irreversible damage to your kidneys (end-stage kidney disease), eventually requiring either dialysis or a kidney transplant for survival

Health problems that can result from ESRD include

  • Anemia
  • Bleeding from the stomach or intestines
  • Bone, joint, and muscle pain
  • Changes in blood sugar (glucose)
  • Damage to nerves of the legs and arms
  • Fluid buildup around the lungs
  • High blood pressure, heart attack, and heart failure
  • High potassium level
  • Increased risk of infection
  • Liver damage or failure
  • Malnutrition
  • Miscarriages or infertility
  • Restless legs syndrome
  • Stroke, seizures, and dementia
  • Swelling and edema
  • Weakening of the bones and fractures related to high phosphorous and low calcium levels

Prevention

If you have kidney disease, you may be able to slow its progress by making healthy lifestyle choices:

  • Lose weight if you need to
  • Be active most days
  • Eat a balanced diet of nutritious, low-sodium foods
  • Control your blood pressure
  • Take your medications as prescribed
  • Have your cholesterol levels checked every year
  • Control your blood sugar level
  • Don’t smoke or use tobacco products
  • Get regular checkups

References

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

End-Stage Kidney Disease – Causes, Symptoms, Treatment

End-stage kidney disease development of chronic renal and its progression to this terminal disease remains a significant source of reduced quality of life and significant premature mortality. Chronic kidney disease (CKD) is a debilitating disease, and standards of medical care involve aggressive monitoring for signs of disease progression and early referral to specialists for dialysis or possible renal transplant. The Kidney Disease Improving Global Outcomes (KDIGO) foundation guidelines define CKD using kidney damage markers, specifically markers that determine proteinuria and glomerular filtration rate. By definition, the presence of both of these factors (glomerular filtration rate [GFR] less than 60 mL/min and albumin greater than 30 mg per gram of creatinine) along with abnormalities of kidney structure or function for greater than three months signifies chronic kidney disease. End-stage renal disease, moreover, is defined as a GFR less than 15 mL/min.

Staging

Kidney Disease: Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guidelines: CKD classification considers the GFR level and the severity of albuminuria.

  • Stage 1: Kidney damage with normal GFR (greater than 90 ml/min)
  • Stage 2: Mild reduction in GFR (60-89 ml/min)
  • Stage 3a: Moderate reduction in GFR (45 to 59 ml/min)
  • Stage 3b: Moderate reduction in GFR (30 to 44 ml/min)
  • Stage 4: Severe reduction in GFR (15 to 29 ml/min)
  • Stage 5: Renal failure (GFR less than 15 ml/min)

As a part of kidney disease staging, your doctor also may test whether protein is present in your urine.

Kidney disease stage GFR, mL/min Kidney function
National Kidney Foundation
Stage 1 90 or above Normal or near-normal kidney function
Stage 2 60 to 89 Mild loss of kidney function
Stage 3a 45 to 59 Mild to moderate loss of kidney function
Stage 3b 30 to 44 Moderate to severe loss of kidney function
Stage 4 15 to 29 Severe loss of kidney function
Stage 5 Less than 15 Kidney failure

Causes of End-Stage Kidney Disease

Many chronic diseases can cause end-stage renal disease. In the United States, diabetes mellitus is the leading cause. Other causes include hypertension, glomerulonephritis, polycystic kidney disease, prolonged obstruction of the urinary tract, vesicoureteral reflux, recurrent pyelonephritis, and certain medications, including non-steroidal anti-inflammatory drugs (NSAIDs), calcineurin inhibitors, and antiretrovirals.

The decline of kidney function is gradual and initially may present asymptomatically. The natural history of renal failure depends on the etiology of the disease but ultimately involves early homeostatic mechanisms involving hyperfiltration of the nephrons. As nephrons become damaged, the kidney increases the rate of filtration in the residual normal ones. As a result, the patient with mild renal impairment can show normal creatinine values, and the disease can go undetected for some time. This adaptive mechanism will run its course and eventually cause damage to the glomeruli of the remaining nephrons. At this point, antihypertensives such as ACEs or ARBs may be beneficial in slowing the progress of the disease and preserving renal function.

Factors that may worsen renal injury include:

  • Glomerulonephritis (gloe-mer-u-low-nuh-FRY-tis), an inflammation of the kidney’s filtering units (glomeruli)
  • Interstitial nephritis (in-tur-STISH-ul nuh-FRY-tis), an inflammation of the kidney’s tubules and surrounding structures
  • Polycystic kidney disease
  • Prolonged obstruction of the urinary tract, from conditions such as enlarged prostate, kidney stones and some cancers
  • Vesicoureteral (ves-ih-koe-yoo-REE-tur-ul) reflux, a condition that causes urine to back up into your kidneys
  • Recurrent kidney infection also called pyelonephritis (pie-uh-low-nuh-FRY-tis)
  • Nephrotoxins (NSAIDs)
  • Systemic hypertension
  • Proteinuria
  • Dehydration
  • Smoking
  • Hyperlipidemia
  • Uncontrolled diabetes
  • Hyperphosphatemia
  • Chronic glomerulonephritis
  • Chronic pyelonephritis
  • Rapidly progressive glomerulonephritis
  • Nephropathy of pregnancy/pregnancy toxemia
  • Unclassifiable nephritis
  • Polycystic kidney disease
  • Nephrosclerosis
  • Malignant hypertension
  • Diabetic nephropathy
  • Systemic lupus erythematosus nephritis
  • Amyloidal kidney
  • Gouty kidney
  • Renal failure due to a congenital abnormality of metabolism
  • Renal/urinary tract tuberculosis
  • Renal/urinary tract calculus
  • Renal/urinary tract tumor
  • Obstructive urinary tract disease
  • Myeloma
  • Renal hypoplasia

Symptoms of End-Stage Kidney Disease

Early in chronic kidney disease, you may have no signs or symptoms. As chronic kidney disease progresses to end-stage renal disease, signs and symptoms might include:

  • Nausea
  • Vomiting
  • Loss of appetite
  • Fatigue and weakness
  • Sleep problems
  • Changes in how much you urinate
  • Decreased mental sharpness
  • Muscle twitches and cramps
  • Swelling of feet and ankles
  • Persistent itching
  • Chest pain, if fluid builds up around the lining of the heart
  • Shortness of breath, if fluid builds up in the lungs
  • High blood pressure (hypertension) that’s difficult to control

Signs and symptoms of kidney disease are often nonspecific, meaning they can also be caused by other illnesses. Because your kidneys are highly adaptable and able to compensate for lost function, signs and symptoms may not appear until irreversible damage has occurred.

You may experience a wide range of symptoms, including

  • a decrease in how much you urinate
  • inability to urinate
  • fatigue
  • malaise, or a general ill feeling
  • headaches
  • unexplained weight loss
  • loss of appetite
  • nausea and vomiting
  • dry skin and itching
  • changes in skin color
  • bone pain
  • confusion and difficulty concentrating
  • bruising easily
  • frequent nosebleeds
  • numbness in your hands and feet
  • bad breath
  • excessive thirst
  • frequent hiccups
  • the absence of menstrual cycles
  • sleeping problems, such as obstructive sleep apnea and restless leg syndrome (RLS)
  • low libido or impotence
  • edema, or swelling, especially in your legs and hands

See your doctor right away if any of these symptoms interfere with your life, especially if you can’t urinate or sleep, are vomiting frequently, or feel weak and unable to do daily tasks.

Diagnosis of End-Stage Kidney Disease

History and Physical

End-stage renal disease can present with a constellation of signs and symptoms. Some include volume overload refractory to diuretics, hypertension poorly responsive to medication, anemia, mineral and bone disorders, and metabolic derangements including hyperkalemia, hyponatremia, metabolic acidosis, hypo/hypercalcemia, and hyperphosphatemia. Uremic toxicity can present as anorexia, nausea, vomiting, bleeding diatheses, pericarditis, uremic neuropathy or encephalopathy, seizure, coma, and death. Uremic toxicity is an indication for urgent dialysis.

In general, ESRD symptoms appear in stages 4 and 5 when the GFR is less than 30 ml/min. Some patients with nephrotic syndrome and cystic renal disease may present earlier.

Depression is ubiquitous in patients with ESRD and should be screened for on presentation.

Lab Test and Imaging

ESRD changes the results of many tests. People receiving dialysis will need these and other tests done often:

  • Potassium
  • Sodium
  • Albumin
  • Phosphorous
  • Calcium
  • Cholesterol
  • Magnesium
  • Electrolytes
  • A physical exam – during which your doctor measures your height, weight, and blood pressure and also looks for signs of problems with your heart or blood vessels and conducts a neurological exam.
  • Blood tests – Complete blood count (CBC) and measure the number of waste products, such as creatinine and urea, in your blood.
  • Urine tests – to check the level of the protein albumin in your urine — a high albumin level may indicate kidney disease.
  • Urinalysis – This test helps your doctor check for protein and blood in your urine. These substances indicate that your kidneys aren’t processing waste properly.
  • Serum creatinine test – This test helps your doctor check whether creatinine is building up in your blood. Creatinine is a waste product that your kidneys should filter out of your body.
  • Blood urea nitrogen test – This test helps your doctor check how much nitrogen is in your blood.
  • Estimated glomerular filtration rate (GFR) – This test allows your doctor to estimate how well your kidneys filter waste.
  • Imaging tests – such as ultrasound, magnetic resonance imaging or computed tomography (CT) scan, to assess your kidneys’ structure and size and look for abnormalities.
  • Removing a sample of kidney tissue (biopsy) – to examine under a microscope to learn what type of kidney disease you have and how much damage there is.

Chronic kidney disease is diagnosed when there is evidence of kidney damage for at least three months or in any patient with a GFR of less than 60 mL/min for that same amount of time.

To calculate GFR, three equations are commonly used (the MDRD [Modification of Diet in Renal Disease Study], CKD-EPI, and Cockcroft-Gault formula). However, the best estimate of GFR is the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation, which adjusts for age, race, and gender. However, it is important to note that the formula tends to underestimate the actual GFR at a GFR greater than 60 mL/min.

To quantitate albuminuria, a spot urine protein/creatinine ratio can be done. A value higher than 30 mg of albumin per gram of creatinine is considered abnormal, while values greater than 300mg/g are considered severely impaired renal function. Additionally, a 24-hour urine protein can also be performed. A value greater than 3.5 g is concerning for nephrotic range proteinuria.

Further evaluation of kidney disease can include a renal ultrasound, complete blood count (CBC), basic metabolic panel (BMP), urinalysis, and/or kidney biopsy. An ultrasound can provide data estimating size, obstructions, stones, cystic renal disease, mass lesions, echogenicity, and cortical thinning. Blood work will determine if there is secondary anemia and will detect evidence of electrolyte derangement. In cases of severe anemia secondary to CKD, erythropoiesis-stimulating agents should be started at a hemoglobin level below 10 g/dL. Finally, a renal biopsy may be necessary if the etiology remains unclear.

Treatment of End-Stage Kidney Disease

Treatment of end-stage renal disease involves correcting parameters at the level of the patient’s presentation. Interventions aimed at slowing the rate of kidney disease should be initiated and can include:

  • Treating the underlying cause and managing blood pressure and proteinuria. Blood pressure should be targeted to a systolic blood pressure less than 130 mmHg and diastolic blood pressure less than 80 mmHg in adults with or without diabetes mellitus whose urine albumin excretion exceeds 30 mg for 24 hours. For diabetic patients with proteinuria, an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) should be started in cases where urine albumin values range between 30 and 300 mg in 24 hours and greater than 300 mg in 24 hours. These drugs slow the disease progression, particularly when initiated before the GFR decreases to less than 60 mL/min or before plasma creatinine concentration exceeds 1.2 and 1.5 in women and men, respectively.
  • Other targets in preventive care and monitoring should include tight glycemic control, cardiovascular risk reduction, and general lifestyle recommendations such as smoking cessation and dietary restriction. Glycemic control is critical. A hemoglobin A1C of less than 7% is generally recommended to prevent or delay microvascular complications in this population. Management with sodium-glucose transporter 2 (SGLT-2) inhibitors may reduce the disease burden in those with type II diabetes mellitus.
  • Treatment of chronic metabolic acidosis with supplemental renal bicarbonate also may slow the progression of end-stage renal disease.
  • Patients with CKD tend to have dyslipidemia, particularly hypertriglyceridemia. Monitoring fasting lipid panels and initiation of cholesterol-lowering agents such as HMG-CoA reductase inhibitors should be done early in the course of the disease.
  • Lifestyle modification and dietary restrictions are routinely recommended. Adhering to a low salt diet (less than 2 g/day), a renal diet (avoiding foods that are high in phosphorus), and restricting daily protein to 0.8 g per kg body weight per day is essential to managing disease burden.
  • Hypocalcemia should also be monitored. A 25-OH vitamin D level less than 10 ng/mL warrants initiation of ergocalciferol 50,000 IU weekly for 6 to 8 weeks before switching to cholecalciferol 800 to 1000 IU daily.

Kidney transplant

A kidney transplant is a surgical procedure to place a healthy kidney from a live or deceased donor into a person whose kidneys no longer function properly. A kidney transplant is often the treatment of choice for end-stage renal disease, compared with a lifetime on dialysis.

The kidney transplant process takes time. It involves finding a donor, living or deceased, whose kidney best matches your own. You then undergo a surgical procedure to place the new kidney in your lower abdomen and attach the blood vessels and ureter — the tube that links the kidney to the bladder — that will allow the new kidney to function.

You’ll spend several days to a week in the hospital. After leaving the hospital, you’ll have frequent checkups as your recovery continues. You’ll take a number of medications to help keep your immune system from rejecting your new kidney and to reduce the risk of post-surgery complications, such as infection.

After a successful kidney transplant, your new kidney filters your blood, and you no longer need dialysis.

Dialysis

Dialysis does some of the work of your kidneys when your kidneys can’t do it themselves. This includes removing extra fluids and waste products from your blood, restoring electrolyte levels, and helping control your blood pressure.

Dialysis options include peritoneal dialysis and hemodialysis.

  • Peritoneal dialysis – During peritoneal dialysis, blood vessels in your abdominal lining (peritoneum) fill in for your kidneys with the help of a fluid that washes in and out of the peritoneal space. Peritoneal dialysis is done in your home.
  • Hemodialysis – During hemodialysis, a machine does some of the work of the kidneys by filtering harmful wastes, salts, and fluid from your blood. Hemodialysis may be done at a center or in your home.[rx]

For dialysis to be successful, you may need to make lifestyle changes, such as following certain dietary recommendations.

Supportive care

With supportive care, your symptoms are managed so that you feel better. You may choose supportive care alone or combine it with other treatment options.

Without either dialysis or a transplant, kidney failure progresses, eventually leading to death. In some people, the disease progresses slowly over months and years, while in others the disease progresses quickly.

Potential future treatments

Regenerative medicine holds the potential to fully heal damaged tissues and organs, offering solutions and hope for people who have conditions that today are beyond repair.

Regenerative medicine approaches include:

  • Boosting the body’s natural ability to heal itself
  • Using healthy cells, tissues, or organs from a living or deceased donor to replace damaged ones
  • Delivering specific types of cells or cell products to diseased tissues or organs to restore tissue and organ function

For people with kidney disease, regenerative medicine approaches may be developed in the future to help slow the progression of the disease.

Complications

Kidney damage, once it occurs, can’t be reversed. Potential complications can affect almost any part of your body and can include:

  • Fluid retention, which could lead to swelling in your arms and legs, high blood pressure, or fluid in your lungs (pulmonary edema)
  • A sudden rise in potassium levels in your blood (hyperkalemia), which could impair your heart’s ability to function and may be life-threatening
  • Heart and blood vessel (cardiovascular) disease
  • Weak bones and an increased risk of bone fractures
  • Anemia
  • Decreased sex drive, erectile dysfunction or reduced fertility
  • Damage to your central nervous system, which can cause difficulty concentrating, personality changes or seizures
  • Decreased immune response, which makes you more vulnerable to infection
  • Pericarditis, an inflammation of the saclike membrane that envelops your heart (pericardium)
  • Pregnancy complications that carry risks for the mother and the developing fetus
  • Irreversible damage to your kidneys (end-stage kidney disease), eventually requiring either dialysis or a kidney transplant for survival

Health problems that can result from ESRD include

  • Anemia
  • Bleeding from the stomach or intestines
  • Bone, joint, and muscle pain
  • Changes in blood sugar (glucose)
  • Damage to nerves of the legs and arms
  • Fluid buildup around the lungs
  • High blood pressure, heart attack, and heart failure
  • High potassium level
  • Increased risk of infection
  • Liver damage or failure
  • Malnutrition
  • Miscarriages or infertility
  • Restless legs syndrome
  • Stroke, seizures, and dementia
  • Swelling and edema
  • Weakening of the bones and fractures related to high phosphorous and low calcium levels

Prevention

If you have kidney disease, you may be able to slow its progress by making healthy lifestyle choices:

  • Lose weight if you need to
  • Be active most days
  • Eat a balanced diet of nutritious, low-sodium foods
  • Control your blood pressure
  • Take your medications as prescribed
  • Have your cholesterol levels checked every year
  • Control your blood sugar level
  • Don’t smoke or use tobacco products
  • Get regular checkups

References

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

Urinary System – Anatomy, Structure, Functions

The urinary system’s function is to filter blood and create urine as a waste by-product. The organs of the urinary system include the kidneys, renal pelvis, ureters, bladder and urethra. The body takes nutrients from food and converts them to energy.

The urinary system is the kidneys of our body’s sewage treatment plant. They filter toxins out of the body, as well as other substances that we no longer need. These waste products leave your body in the urine produced in your kidneys. This is how water and substances like urea, uric acid, salts, and amino acids are removed from the blood. Every day, all of the blood in your body (between five and six liters) passes through the kidneys about 300 times. So your kidneys filter about 1,700 liters of blood per day in total. This leads to the daily production of about 170 liters of primary urine (glomerular filtrate) – which later becomes urine.

Inside the kidney, there is a renal medulla, which has small tubules and larger collecting tubes running through it. As the primary urine flows through this system of tubes, the kidney cells re-absorb about 99 percent of the fluid in it, as well as many substances that can still be used, and at the same time release other substances. About 1.7 liters of urine are produced like this each day. The urine passes from the kidneys through the ureter into the urinary bladder, where it is stored.

Overview of the Urinary System

The urinary system works with the lungs, skin, and intestines to maintain the balance of chemicals and water in the body. Adults eliminate about 27 to 68 fluid ounces (800 to 2,000 milliliters) per day based on typical daily fluid intake of 68 ounces (2 liters), National Institutes of Health (NIH). Other factors in urinary system function include fluid lost through perspiring and breathing. In addition, certain types of medications, such as diuretics that are sometimes used to treat high blood pressure, can also affect the amount of urine a person produces and eliminates. Some beverages, such as coffee and alcohol, can also cause increased urination in some people.

The primary organs of the urinary system are the kidneys, which are bean-shaped organs that are located just below the rib cage in the middle of the back. The kidneys remove urea — a waste product formed by the breakdown of proteins — from the blood through small filtering units called nephrons. Each nephron consists of a ball formed of small blood capillaries, called a glomerulus, and a small tube called a renal tubule. Urea, together with water and other waste substances, forms the urine as it passes through the nephrons and down the renal tubules of the kidney.

Muscles in the ureter walls continually tighten and relax to force urine away from the kidneys, according to the NIH. A backup of urine can cause a kidney infection. Small amounts of urine are emptied into the bladder from the ureters about every 10 to 15 seconds.

The bladder is a hollow, balloon-shaped organ that is located in the pelvis. It is held in place by ligaments attached to other organs and the pelvic bones, according to the Kidney & Urology Foundation of America. The bladder stores urine until the brain signals the bladder that the person is ready to empty it. A normal, healthy bladder can hold up to 16 ounces (almost half a liter) of urine comfortably for two to five hours.

To prevent leakage, circular muscles called sphincters close tightly around the opening of the bladder into the urethra, the tube that allows urine to pass outside the body. The only difference between the female and male urinary system is the length of the urethra, according to Merck Manuals. In females, the urethra is about 1.5 to 2 inches long (3.8 to 5.1 cm) and sits between the clitoris and the vagina. In males, it is about 8 inches (20 cm) long, runs the length of the penis and opens at the end of the penis. The male urethra is used to eliminate urine as well as semen during ejaculation.

The urinary system maintains blood homeostasis by filtering out excess fluid and other substances from the bloodstream and secreting waste.

Structure

The urinary system refers to the structures that produce and transport urine to the point of excretion. In the human urinary system, there are two kidneys that are located between the dorsal body wall and parietal peritoneum on both the left and right sides.

The formation of urine begins within the functional unit of the kidney, the nephrons. Urine then flows through the nephrons, through a system of converging tubules called collecting ducts. These collecting ducts then join together to form the minor calyces, followed by the major calyces that ultimately join the renal pelvis. From here, urine continues its flow from the renal pelvis into the ureter, transporting urine into the urinary bladder. The anatomy of the human urinary system differs between males and females at the level of the urinary bladder. In males, the urethra begins at the internal urethral orifice in the trigone of the bladder, continues through the external urethral orifice, and then becomes the prostatic, membranous, bulbar, and penile urethra. Urine exits through the external urethral meatus. The female urethra is much shorter, beginning at the bladder neck and terminating in the vaginal vestibule.

Key Points

The renal system eliminates wastes from the body, controls levels of electrolytes and metabolites, controls the osmoregulation of blood volume and pressure and regulates blood pH.

The renal system organs include the kidneys, ureter, bladder, and urethra. Nephrons are the main functional component of the kidneys.

The respiratory and cardiovascular systems have certain functions that overlap with renal system functions.

Metabolic wastes and excess ions are filtered out of the blood, combined with water, and leave the body in the form of urine.

A complex network of hormones controls the renal system to maintain homeostasis.

Key Terms

  • ureter: These are two long, narrow ducts that carry urine from the kidneys to the urinary bladder.
  • osmoregulation: The most important function of the renal system, in which blood volume, blood pressure, and blood osmolarity (ion concentration) is maintained in homeostasis.

The Renal System

The renal system, which is also called the urinary system, is a group of organs in the body that filters out excess fluid and other substances from the bloodstream. The purpose of the renal system is to eliminate wastes from the body, regulate blood volume and pressure, control levels of electrolytes and metabolites, and regulate blood pH.

The renal system organs include the kidneys, ureters, bladder, and urethra. Metabolic wastes and excess ions are filtered out of the blood, along with water, and leave the body in the form of urine.

This is an illustration of the major organs of the renal system. In this schematic view of the urinary system, shown in descending order, we see the kidney, ureter, bladder, and urethra. 

Components of the renal system: Here are the major organs of the renal system.

Renal System Functions

The renal system has many functions. Many of these functions are interrelated with the physiological mechanisms in the cardiovascular and respiratory systems.

  • Removal of metabolic waste products from the body (mainly urea and uric acid).
  • Regulation of electrolyte balance (e.g., sodium, potassium, and calcium).
  • Osmoregulation controls the blood volume and body water contents.
  • Blood pressure homeostasis: The renal system alters water retention and thirst to slowly change blood volume and keep blood pressure in a normal range.
  • Regulation of acid-base homeostasis and blood pH, a function shared with the respiratory system.

Many of these functions are related to one another as well. For example, water follows ions via an osmotic gradient, so mechanisms that alter sodium levels or sodium retention in the renal system will alter water retention levels as well.

Organs of the Renal System

Kidneys and Nephrons

Kidneys are the most complex and critical part of the urinary system. The primary function of the kidneys is to maintain a stable internal environment (homeostasis) for optimal cell and tissue metabolism. The kidneys have an extensive blood supply from the renal arteries that leave the kidneys via the renal vein.

Nephrons are the main functional component inside the parenchyma of the kidneys, which filter blood to remove urea, a waste product formed by the oxidation of proteins, as well as ions like potassium and sodium. The nephrons are made up of capsule capillaries (the glomerulus) and a small renal tube.

The renal tube of the nephron consists of a network of tubules and loops that are selectively permeable to water and ions. Many hormones involved in homeostasis will alter the permeability of these tubules to change the amount of water that is retained by the body.

Kidney and urinary system parts and their functions

  • Two kidneys. This pair of purplish-brown organs is located below the ribs toward the middle of the back. Their function is to:
    • Remove waste products and drugs from the body
    • Balance the body’s fluids
    • Release hormones to regulate blood pressure
    • Control production of red blood cells

The kidneys remove urea from the blood through tiny filtering units called nephrons. Each nephron consists of a ball formed of small blood capillaries, called a glomerulus, and a small tube called a renal tubule. Urea, together with water and other waste substances, forms the urine as it passes through the nephrons and down the renal tubules of the kidney.

  • Two ureters. These narrow tubes carry urine from the kidneys to the bladder. Muscles in the ureter walls continually tighten and relax forcing urine downward, away from the kidneys. If urine backs up, or is allowed to stand still, a kidney infection can develop. About every 10 to 15 seconds, small amounts of urine are emptied into the bladder from the ureters.
  • Bladder. This triangle-shaped, hollow organ is located in the lower abdomen. It is held in place by ligaments that are attached to other organs and the pelvic bones. The bladder’s walls relax and expand to store urine, and contract and flatten to empty urine through the urethra. The typical healthy adult bladder can store up to two cups of urine for two to five hours.

Upon examination, specific “landmarks” are used to describe the location of any irregularities in the bladder. These are:

  • Trigone: a triangle-shaped region near the junction of the urethra and the bladder
  • Right and left lateral walls: walls on either side of the trigone
  • Posterior wall: back wall
  • Dome: roof of the bladder
  • Two sphincter muscles. These circular muscles help keep urine from leaking by closing tightly like a rubber band around the opening of the bladder.
  • Nerves in the bladder. The nerves alert a person when it is time to urinate or empty the bladder.
  • Urethra. This tube allows urine to pass outside the body. The brain signals the bladder muscles to tighten, which squeezes urine out of the bladder. At the same time, the brain signals the sphincter muscles to relax to let urine exit the bladder through the urethra. When all the signals occur in the correct order, normal urination occurs.

Human Osmoregulation

The kidneys play a very large role in human osmoregulation by regulating the amount of water reabsorbed from the glomerular filtrate in kidney tubules, which is controlled by hormones such as antidiuretic hormone (ADH), renin, aldosterone, and angiotensin I and II.

A basic example is that a decrease in water concentration of blood is detected by osmoreceptors in the hypothalamus, which stimulates ADH release from the pituitary gland to increase the permeability of the wall of the collecting ducts and tubules in the nephrons. Therefore, a large proportion of water is reabsorbed from fluid to prevent a fair proportion of water from being excreted.

The extent of blood volume and blood pressure regulation facilitated by the kidneys is a complex process. Besides ADH secretion, the renin-angiotensin feedback system is critically important to maintain blood volume and blood pressure homeostasis.

Function

The main functions of the urinary system and its components are to:

  • Regulate blood volume and composition (e.g. sodium, potassium and calcium)
  • Regulate blood pressure.
  • Regulate pH homeostasis of the blood.
  • Contributes to the production of red blood cells by the kidney.
  • Help synthesize calcitriol (the active form of Vitamin D).
  • Stores waste products (mainly urea and uric acid) before it and other products are removed from the body.

References

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

Prostate Enlargement – Causes, Symptoms, Treatment

Prostate enlargement/Benign prostatic hyperplasia (BPH) is a commonest, urological,  nonmalignant overgrowth or hyperplasia of prostate tissue with abnormal stromal and epithelial cell proliferation in the prostate transition zone surrounding the urethra that affecting the aging male associated with unregulated proliferation of connective tissue, smooth muscle, and glandular epithelium within the prostatic transition zone.[] A glandular element composed of secretory ducts and acini, and a stromal element composed primarily of collagen and smooth muscle. During the development of the prostate, the epithelium and mesenchyme are under the control of testicular androgens and interact to form an organized secretory organ. In BPH, cellular proliferation leads to increased prostate volume and increased stromal smooth muscle tone. The first phase consists of an increase in BPH nodules in the periurethral zone and the second a significant increase in the size of glandular nodules.[]

ANATOMY

According to McNeal’s model of the prostate (7), four different anatomical zones may be distinguished that have anatomy-clinical correlation (Figure 2):

  • The peripheral zone – is the area forming the posteroinferior aspect of the gland and represents 70% of the prostatic volume. It is the zone where the majority (60-70%) of prostate cancers form.
  • The central zone – represents 25% of the prostate volume and contains the ejaculatory ducts. It is the zone that usually gives rise to inflammatory processes (eg prostatitis).
  • The transitional zone – represents only 5% of the total prostatic volume. This is the zone where benign prostatic hypertrophy occurs and consists of two lateral lobes together with periurethral glands. Approximately 25% of prostatic adenocarcinomas also occur it this zone.
  • The anterior zone – predominantly fibromuscular with no glandular structures.

The prostate weighs approximately 20g by the age of 20 and has the shape of an inverted cone, with the base at the bladder neck and the apex at the urogenital diaphragm. The prostatic urethra does not follow a straight line as it runs through the center of the prostate gland but it is actually bent anteriorly approximately 35 degrees at the verumontanum (where the ejaculatory ducts join the prostate).

Causes of Prostate Enlargement

The cause of benign prostatic hyperplasia is not well understood; however, it occurs mainly in older men. Benign prostatic hyperplasia does not develop in men whose testicles were removed before puberty. For this reason, some researchers believe factors related to aging and the testicles may cause benign prostatic hyperplasia.

  • Produce Testosterone – Throughout their lives, men produce testosterone, a male hormone, and small amounts of estrogen, a female hormone. As men age, the amount of active testosterone in their blood decreases, which leaves a higher proportion of estrogen. Scientific studies have suggested that benign prostatic hyperplasia may occur because the higher proportion of estrogen within the prostate increases the activity of substances that promote prostate cell growth.
  • Dihydrotestosterone (DHT) – a male hormone that plays a role in prostate development and growth. Some research has indicated that even with a drop in blood testosterone levels, older men continue to produce and accumulate high levels of DHT in the prostate. This accumulation of DHT may encourage prostate cells to continue to grow. Scientists have noted that men who do not produce DHT do not develop benign prostatic hyperplasia.
  • Metabolic syndrome – refers to conditions that include hypertension, glucose intolerance/insulin resistance, and dyslipidemia. Meta-analysis has demonstrated those with metabolic syndrome and obesity have significantly higher prostate volumes. Further studies looking at men with elevated levels of glycosylated hemoglobin (Hba1c) have demonstrated an increased risk of LUTS. Limitations of these studies are that there were no subsequent significant differences in IPSS, and the effect of diabetes on LUTS has been shown to be multifactorial in nature. Further studies are therefore required to establish causation in these individuals.
  • Obesity – has been shown to be associated with an increased risk of BPH in observational studies. The exact cause is unclear but is likely multifactorial in nature as obesity makes up one aspect of metabolic syndrome. Proposed mechanisms include increased levels of systemic inflammation and increased levels of estrogens.
  • Genetic predisposition – to BPH has been demonstrated in cohort studies, first-degree relatives in one study demonstrated a four-fold increase in the risk of BPH compared to control. These findings have demonstrated consistency in twin studies looking at the disease severity of BPH, with higher rates of LUTS seen in monozygotic twins.
  • Diet – Studies indicate that dietary patterns may affect development of BPH, but further research is needed to clarify any important relationship.[rx] Studies from China suggest that greater protein intake may be a factor in development of BPH. Men older than 60 in rural areas had very low rates of clinical BPH, while men living in cities and consuming more animal protein had a higher incidence.[rx][rx] On the other hand, a study in Japanese-American men in Hawaii found a strong negative association with alcohol intake, but a weak positive association with beef intake.[rx] In a large prospective cohort study in the US (the Health Professionals Follow-up Study), investigators reported modest associations between BPH (men with strong symptoms of BPH or surgically confirmed BPH) and total energy and protein, but not fat intake.[rx]
  • Degeneration – Benign prostatic hyperplasia is an age-related disease. Misrepair-accumulation aging theory[rx][rx] suggests that the development of benign prostatic hyperplasia is a consequence of fibrosis and weakening of the muscular tissue in the prostate.[rx] The muscular tissue is important in the functionality of the prostate and provides the force for excreting the fluid produced by prostatic glands. However, repeated contractions and dilations of myofibers will unavoidably cause injuries and broken myofibers. Myofibers have a low potential for regeneration; therefore, collagen fibers need to be used to replace the broken myofibers.

Symptoms of Prostate Enlargement

Lower urinary tract symptoms suggestive of benign prostatic hyperplasia may include

  • urinary frequency—urination eight or more times a day
  • urinary urgency—the inability to delay urination
  • trouble starting a urine stream
  • a weak or an interrupted urine stream
  • dribbling at the end of urination
  • nocturia—frequent urination during periods of sleep
  • urinary retention
  • urinary incontinence—the accidental loss of urine
  • pain after ejaculation or during urination
  • urine that has an unusual color or smell
  • a blocked urethra
  • Weak urine stream
  • Straining to urinate
  • Wakening during the night to urinate (nocturia)
  • Affected man’s perceived quality of life
  • incomplete bladder emptying
  • nocturia, which is the need to urinate two or more times per night
  • dribbling at the end of your urinary stream
  • incontinence, or leakage of urine
  • the need to strain when urinating
  • a weak urinary stream
  • a sudden urge to urinate
  • a slowed or delayed urinary stream
  • painful urination
  • blood in the urine
  • a bladder that is overworked from trying to pass urine through the blockage
  • The size of the prostate does not always determine the severity of the blockage or symptoms. Some men with greatly enlarged prostates have a little blockage and few symptoms, while other men who have minimally enlarged prostates have a greater blockage and more symptoms.
  • Less than half of all men with benign prostatic hyperplasia have lower urinary tract symptoms.

Sometimes men may not know they have a blockage until they cannot urinate. This condition, called acute urinary retention, can result from taking over-the-counter cold or allergy medications that contain decongestants, such as pseudoephedrine and oxymetazoline. A potential side effect of these medications may prevent the bladder neck from relaxing and releasing urine. Medications that contain antihistamines, such as diphenhydramine, can weaken the contraction of bladder muscles and cause urinary retention, difficulty urinating, and painful urination. When men have partial urethra blockage, urinary retention also can occur as a result of alcohol consumption, cold temperatures, or a long period of inactivity.

Diagnosis of Prostate Enlargement

A health care provider diagnoses benign prostatic hyperplasia based on

Personal and Family History

Taking a personal and family medical history is one of the first things a health care provider may do to help diagnose benign prostatic hyperplasia. A health care provider may ask a man

  • what symptoms are present
  • when the symptoms began and how often they occur
  • whether he has a history of recurrent UTIs
  • what medications he takes, both prescription and over the counter
  • how much liquid he typically drinks each day
  • whether he consumes caffeine and alcohol
  • about his general medical history, including any significant illnesses or surgeries

Physical Exam

A physical exam may help diagnose benign prostatic hyperplasia. During a physical exam, a health care provider most often

  • examines a patient’s body, which can include checking for
  • discharge from the urethra
  • enlarged or tender lymph nodes in the groin
  • a swollen or tender scrotum
  • taps on specific areas of the patient’s body
  • performs a digital rectal exam

A digital rectal exam, or rectal exam, is a physical exam of the prostate. To perform the exam, the health care provider asks the man to bend over a table or lie on his side while holding his knees close to his chest. The health care provider slides a gloved, lubricated finger into the rectum and feels the part of the prostate that lies next to the rectum. The man may feel slight, brief discomfort during the rectal exam. A health care provider most often performs a rectal exam during an office visit, and men do not require anesthesia. The exam helps the health care provider see if the prostate is enlarged or tender or has any abnormalities that require more testing.

In the elective setting, the examination should include abdominal examination (looking for a palpable bladder/loin pain) and examination of external genitalia (meatal stenosis or phimosis). The examination should then conclude with a digital rectal examination making a note in particular of the size, shape (how many lobes), and consistency (smooth/hard/nodular) of the prostate (BPH is characterized by a smoothly enlarged prostate).

Further bedside evaluation includes

  • Urine dipstick (rule out other causes such as infection)
  • Post-void residual volume (whether the bladder is emptied properly)
  • IPSS (international prostate symptom score)
  • Frequency-volume chart

Questionnaires

Both the American urological association symptom index and IPSS can be used to assess the impact of LUTS on quality of life. They are useful when quantifying the disease burden on the patient and can be used to stratify patients into disease categories for treatment. The IPSS stratifies patients into three groups on the basis of symptoms. They are mild (0-7), moderate (8-19), and severe (20-35). Those with more severe symptoms are less likely to benefit from conservative or medical measures.

Medical Tests

A health care provider may refer men to a urologist—a doctor who specializes in urinary problems and the male reproductive system—through the health care provider most often diagnoses benign prostatic hyperplasia on the basis of symptoms and a digital rectal exam. A urologist uses medical tests to help diagnose lower urinary tract problems related to benign prostatic hyperplasia and recommend treatment. Medical tests may include

  • Urinalysis. Urinalysis involves testing a urine sample. The patient collects a urine sample in a special container in a health care provider’s office or a commercial facility. A health care provider tests the sample during an office visit or sends it to a lab for analysis. For the test, a nurse or technician places a strip of chemically treated paper, called a dipstick, into the urine. Patches on the dipstick change color to indicate signs of infection in urine.
  • PSA blood test. A health care provider may draw blood for a PSA test during an office visit or in a commercial facility and send the sample to a lab for analysis. Prostate cells create a protein called PSA. Men who have prostate cancer may have a higher amount of PSA in their blood. However, a high PSA level does not necessarily indicate prostate cancer. In fact, benign prostatic hyperplasia, prostate infections, inflammation, aging, and normal fluctuations often cause high PSA levels. Much remains unknown about how to interpret a PSA blood test, the test’s ability to discriminate between cancer and prostate conditions such as benign prostatic hyperplasia, and the best course of action to take if the PSA level is high.
  • Urinary rate recording –  is a non-invasive way to determine the intensity or strength of the urinary stream. As discussed above, a maximum urinary flow rate of greater than 15 mL/s is considered nearly in the normal range, whereas a maximum flow rate of less than 10 mL/s is highly suggestive of outlet obstruction.
  • Measurement of postvoid residual urine – can be performed by transabdominal ultrasonography or in-and-out catheterization, the former being the preferred method. Postvoid residual urine values differ substantially over time within an individual and between individuals. They have not been shown to be reliable predictors of the natural history of the disease and/or the response to treatment. However, it is widely accepted that rising amounts of residual urine and decreasing voiding efficiency are associated with worsening of the condition and a greater likelihood of acute urinary retention with subsequent need for surgery.
  • Urodynamic tests. Urodynamic tests include a variety of procedures that look at how well the bladder and urethra store and release urine. A health care provider performs urodynamic tests during an office visit or in an outpatient center or a hospital. Some urodynamic tests do not require anesthesia; others may require local anesthesia. Most urodynamic tests focus on the bladder’s ability to hold urine and empty steadily and completely and may include the following uroflowmetry, which measures how rapidly the bladder releases urine postvoid residual measurement, which evaluates how much urine remains in the bladder after urination reduced urine flow or residual urine in the bladder, which often suggests urine blockage due to benign prostatic hyperplasia.
  • Prostate-Specific Antigen (PSA) – Prostate-specific antigen testing has been shown to predict prostate volume. Prostate-specific antigen (PSA) testing should be used with caution, however, and should not be done routinely in the investigation of BPH. Levels may be raised in a large range of conditions (large prostate, infection, catheterization, prostate cancer) and can cause undue anxiety or further unnecessary investigations for the patient. It is the author’s preference to conduct PSA testing in specific circumstances, i.e., where cancer is suspected (malignant feeling prostate, metastatic disease suspected) or a previous baseline established.
  • Ultrasound – Ultrasound scans are used to look for evidence of hydronephrosis and are indicated in patients with high residual volumes or renal impairment. Other indications include suspicion of urinary tract stones or the investigation of haematuria.
  • Flow Studies – Urine flow studies are used to determine the volume of urine passed over time. This can help establish whether there is objective evidence for obstruction to flow. Urodynamic studies are used to see how the bladder empties and fills. They can help further assess patients where the diagnosis is not certain or where a neurogenic/overactive bladder is suspected (i.e., neurological conditions that may affect the bladder, flow studies equivocal, diagnosis not clear).
  • Invasive pressure-flow studies or formal urodynamic studies – are the best tests to determine whether a patient is obstructed at the level of the bladder neck. Appropriate nomograms have been established for normative values regarding the pressure-flow parameters, and it is commonly accepted that the best marker of obstruction is the pressure within the bladder generated by the detrusor muscle at the time of the maximum urinary flow rate.,
  • Cystoscopy – Cystoscopy is a procedure that uses a tubelike instrument, called a cystoscope, to look inside the urethra and bladder. A urologist inserts the cystoscope through the opening at the tip of the penis and into the lower urinary tract. A urologist performs cystoscopy during an office visit or in an outpatient center or a hospital. The urologist will give the patient local anesthesia; however, in some cases, the patient may require sedation and regional or general anesthesia. A urologist may use cystoscopy to look for blockage or stones in the urinary tract.
  • Transrectal ultrasound – Transrectal ultrasound uses a device, called a transducer, that bounces safe, painless sound waves off organs to create an image of their structure. The health care provider can move the transducer to different angles to make it possible to examine different organs. A specially trained technician performs the procedure in a health care provider’s office, an outpatient center, or a hospital, and a radiologist—a doctor who specializes in medical imaging—interprets the images; the patient does not require anesthesia. Urologists most often use transrectal ultrasound to examine the prostate. In a transrectal ultrasound, the technician inserts a transducer slightly larger than a pen into the man’s rectum, next to the prostate. The ultrasound image shows the size of the prostate and any abnormalities, such as tumors. Transrectal ultrasound cannot reliably diagnose prostate cancer.
  • Biopsy – The biopsy is a procedure that involves taking a small piece of prostate tissue for examination with a microscope. A urologist performs the biopsy in an outpatient center or a hospital. The urologist will give the patient light sedation and local anesthetic; however, in some cases, the patient will require general anesthesia. The urologist uses imaging techniques such as ultrasound, a computerized tomography scan, or magnetic resonance imaging to guide the biopsy needle into the prostate. A pathologist—a doctor who specializes in examining tissues to diagnose diseases—examines the prostate tissue in a lab. The test can show whether prostate cancer is present.

Treatment of Prostate Enlargement

  • Active monitoring of symptoms (often called “watchful waiting”): If the symptoms are mild and there are no complications, it may be enough to change a few things in everyday life and go in for a check-up about once a year. This strategy helps in about 30 out of 100 men who seek medical help because of an enlarged prostate.
  • Herbal medicine products: There are several over-the-counter herbal products for the relief of symptoms associated with a benign enlarged prostate. Most of these products haven’t been well studied. Others have been studied but weren’t found to reduce prostate symptoms. So the German Society of Urology doesn’t generally recommend them for the treatment of benign enlarged prostates.

Men may not need treatment for a mildly enlarged prostate unless their symptoms are bothersome and affecting their quality of life. In these cases, instead of treatment, a urologist may recommend regular checkups. If benign prostatic hyperplasia symptoms become bothersome or present a health risk, a urologist most often recommends treatment.

Medications

  • Phytotherapy
  • Monotherapy
  • Alpha-blockers
  • 5-alpha reductase inhibitors
  • PDE5 Inhibitors
  •  Combination therapy:
  • Alpha-blocker + 5-alpha reductase inhibitor
  •  PDE5 inhibitor + Alpha-blocker (experimental)

H. Alpha-blockers, 5-alpha reductase inhibitors, and now phosphodiesterase-5 inhibitors provide significant symptomatic improvement for BPH, particularly when used in combination. A health care provider or urologist may prescribe medications that stop the growth of or shrink the prostate or reduce symptoms associated with benign prostatic hyperplasia:

  • alpha-blockers
  • phosphodiesterase-5 inhibitors
  • 5-alpha reductase inhibitors
  • combination medications

Alpha-blockers

Alpha 1-adrenoreceptors are present on prostate stromal smooth muscle and bladder neck. Alpha 1-adrenoreceptor blockage results in stromal smooth muscle relaxation addressing the dynamic component of BPH and thus improving flow. Examples include selective Alpha-blockers such as Tamsulosin (400mcg once daily) and Alfuzosin (10mg once daily). These medications relax the smooth muscles of the prostate and bladder neck to improve urine flow and reduce bladder blockage:

  • terazosin (Hytrin)
  • doxazosin (Cardura)
  • tamsulosin (Flomax)
  • alfuzosin (Uroxatral)
  • silodosin (Rapaflo)

Phosphodiesterase-5 inhibitors

Urologists prescribe these medications mainly for erectile dysfunction. Tadalafil (Cialis) belongs to this class of medications and can reduce lower urinary tract symptoms by relaxing smooth muscles in the lower urinary tract. Researchers are working to determine the role of erectile dysfunction drugs in the long-term treatment of benign prostatic hyperplasia. Alpha-reductase inhibitors such as finasteride (5mg once daily) and dutasteride block the conversion of testosterone to DHT.. This addresses the static component of BPH by causing shrinkage of the prostate and takes several weeks to show noticeable improvement, with six months needed for maximal effectiveness. As a result of treatment serum, PSA can be reduced by 50%, with prostate volume decreasing by up to 25%. This has been shown to alter the disease process and subsequent disease progression.

5-alpha reductase inhibitors

These medications block the production of DHT, which accumulates in the prostate and may cause prostate growth:

  • finasteride (Proscar)
  • dutasteride (Avodart)

These medications can prevent the progression of prostate growth or actually shrink the prostate in some men. Finasteride and dutasteride act more slowly than alpha-blockers and are useful for only moderately enlarged prostates.

Combination medications

Several studies, such as the Medical Therapy of Prostatic Symptoms (MTOPS) study, have shown that combining two classes of medications, instead of using just one, can more effectively improve symptoms, urinary flow, and quality of life. The combinations include

  • Finasteride and doxazosin
  • Dutasteride and tamsulosin (Jalyn), a combination of both medications that is available in a single tablet
  • Alpha-blockers and antimuscarinics

A urologist may prescribe a combination of alpha-blockers and antimuscarinics for patients with overactive bladder symptoms. Overactive bladder is a condition in which the bladder muscles contract uncontrollably and cause urinary frequency, urinary urgency, and urinary incontinence. Antimuscarinics are a class of medications that relax the bladder muscles.

Antimuscarinics

Bladder detrusor instability can develop in patients with worsening bladder outlet obstruction. This can result in increased urgency (overactive bladder) and frequency. Muscarinic receptor antagonists can help with these symptoms by blocking muscarinic receptors on detrusor muscle. This reduces smooth muscle tone and can improve symptoms in those with overactivity. Examples include solifenacin, tolterodine, and oxybutynin. Those who fail antimuscarinic treatment may be considered for mirabegron use (a Beta-3 adrenoreceptor agonist), which causes detrusor relaxation.

In practice, the combination of an alpha-blocker and alpha-reductase inhibitor is often used to achieve improvements in voiding symptoms. This is backed by studies confirming the effectiveness of combination therapy over monotherapy.

Additionally, central α-receptors and the effect of these agents on those receptors will likely play an additional role in the improvement of LUTS in men with BPH. Of the 3 α1-adrenergic receptor subtypes, α1A, α1B, and α1D, by far the most important in the prostate is the α1A receptor, constituting approximately 80% according to immunohistochemistry and other analytical methods.,

Among the available α1-adrenergic receptor blockers in the United States are the short-acting selective α1 blocker prazosin, the long-acting selective α1 blockers terazosin, doxazosin, alfuzosin, and the more subtype-selective α1A-receptor blocker tamsulosin. Although there are subtle differences between these drugs in terms of their side-effect profiles, they are fundamentally all equally effective in alleviating bothersome LUTS and improving urinary flow rates . Both terazosin (available as 1, 2, 5, and 10 mg) and doxazosin (available as 1, 2, 4, and 8 mg) require titration owing to the first dose effect to reach the maximum recommended doses of 10 and 8 mg, respectively. Tamsulosin is available in 0.4-mg tablets and might be increased to 2 tablets daily or 0.8 mg. Alfuzosin is available only as a single, 10-mg slow-release formulation, and no dose titration is recommended.

Antibiotics

Antibiotics may be used if your prostate becomes chronically inflamed from bacterial prostatitis related to BPH. Treating bacterial prostatitis with antibiotics may improve your symptoms of BPH by reducing the inflammation. However, antibiotics won’t help prostatitis or inflammation that is not caused by bacteria.

Minimally Invasive Procedures

Researchers have developed a number of minimally invasive procedures that relieve benign prostatic hyperplasia symptoms when medications prove ineffective. These procedures include

  • Minimally invasive procedures – can destroy enlarged prostate tissue or widen the urethra, which can help relieve the blockage and urinary retention caused by benign prostatic hyperplasia.
  • Urologists perform minimally invasive procedures  – using the transurethral method, which involves inserting a catheter—a thin, flexible tube—or cystoscope through the urethra to reach the prostate. These procedures may require local, regional, or general anesthesia. Although destroying troublesome prostate tissue relieves many benign prostatic hyperplasia symptoms, tissue destruction does not cure benign prostatic hyperplasia. A urologist will decide which procedure to perform based on the man’s symptoms and overall health.
  • Transurethral needle ablation – This procedure uses heat generated by radiofrequency energy to destroy prostate tissue. A urologist inserts a cystoscope through the urethra to the prostate. A urologist then inserts small needles through the end of the cystoscope into the prostate. The needles send radiofrequency energy that heats and destroys selected portions of prostate tissue. Shields protect the urethra from heat damage.
  • Transurethral microwave thermotherapy – This procedure uses microwaves to destroy prostate tissue. A urologist inserts a catheter through the urethra to the prostate, and a device called an antenna sends microwaves through the catheter to heat selected portions of the prostate. The temperature becomes high enough inside the prostate to destroy enlarged tissue. A cooling system protects the urinary tract from heat damage during the procedure.
  • High-intensity focused ultrasound – For this procedure, a urologist inserts a special ultrasound probe into the rectum, near the prostate. Ultrasound waves from the probe heat and destroy enlarged prostate tissue.
  • Transurethral electrovaporization – For this procedure, a urologist inserts a tube-like instrument called a resectoscope through the urethra to reach the prostate. An electrode attached to the resectoscope moves across the surface of the prostate and transmits an electric current that vaporizes prostate tissue. The vaporizing effect penetrates below the surface area being treated and seals blood vessels, which reduces the risk of bleeding.
  • Water-induced thermotherapy – This procedure uses heated water to destroy prostate tissue. A urologist inserts a catheter into the urethra so that a treatment balloon rests in the middle of the prostate. Heated water flows through the catheter into the treatment balloon, which heats and destroys the surrounding prostate tissue. The treatment balloon can target a specific region of the prostate while surrounding tissues in the urethra and bladder remain protected.
  • Prostatic stent insertion – This procedure involves a urologist inserting a small device called a prostatic stent through the urethra to the area narrowed by the enlarged prostate. Once in place, the stent expands like a spring, and it pushes back the prostate tissue, widening the urethra. Prostatic stents may be temporary or permanent. Urologists generally use prostatic stents in men who may not tolerate or be suitable for other procedures.

Surgery

For long-term treatment of benign prostatic hyperplasia, a urologist may recommend removing enlarged prostate tissue or making cuts in the prostate to widen the urethra. Urologists recommend surgery when

  • Medications and minimally invasive procedures are ineffective
  • Symptoms are particularly bothersome or severe
  • Complications arise

Although removing troublesome prostate tissue relieves many benign prostatic hyperplasia symptoms, tissue removal does not cure benign prostatic hyperplasia.

Surgery to remove enlarged prostate tissue includes

  • Transurethral resection of the prostate (TURP)
  • Laser surgery
  • Open prostatectomy
  • Transurethral incision of the prostate (TUIP)

A urologist performs these surgeries, except for open prostatectomy, using the transurethral method. Men who have these surgical procedures require local, regional, or general anesthesia and may need to stay in the hospital. The urologist may prescribe antibiotics before or soon after surgery to prevent infection. Some urologists prescribe antibiotics only when an infection occurs.

Immediately after benign prostatic hyperplasia surgery, a urologist may insert a special catheter, called a Foley catheter, through the opening of the penis to drain urine from the bladder into a drainage pouch.

  • TURP – With TURP, a urologist inserts a resectoscope through the urethra to reach the prostate and cuts pieces of enlarged prostate tissue with a wire loop. Special fluid carries the tissue pieces into the bladder, and the urologist flushes them out at the end of the procedure. TURP is the most common surgery for benign prostatic hyperplasia and considered the gold standard for treating blockage of the urethra due to benign prostatic hyperplasia.
  • Laser surgery – With this surgery, a urologist uses a high-energy laser to destroy prostate tissue. The urologist uses a cystoscope to pass a laser fiber through the urethra into the prostate. The laser destroys the enlarged tissue. The risk of bleeding is lower than in TURP and TUIP because the laser seals blood vessels as it cuts through the prostate tissue. However, laser surgery may not effectively treat greatly enlarged prostates.
  • Open prostatectomy – In an open prostatectomy, a urologist makes an incision, or cut, through the skin to reach the prostate. The urologist can remove all or part of the prostate through the incision. This surgery is used most often when the prostate is greatly enlarged, complications occur, or the bladder is damaged and needs repair. Open prostatectomy requires general anesthesia, a longer hospital stay than other surgical procedures for benign prostatic hyperplasia, and a longer rehabilitation period. The three open prostatectomy procedures are retropubic prostatectomy, suprapubic prostatectomy, and perineal prostatectomy. The recovery period for open prostatectomy is different for each man who undergoes the procedure.
  • TUIP – A TUIP is a surgical procedure to widen the urethra. During a TUIP, the urologist inserts a cystoscope and an instrument that uses an electric current or a laser beam through the urethra to reach the prostate. The urologist widens the urethra by making a few small cuts in the prostate and in the bladder neck. Some urologists believe that TUIP gives the same relief as TURP except with less risk of side effects. After surgery, the prostate, urethra, and surrounding tissues may be irritated and swollen, causing urinary retention. To prevent urinary retention, a urologist inserts a Foley catheter so urine can drain freely out of the bladder. A Foley catheter has a balloon on the end that the urologist inserts into the bladder. Once the balloon is inside the bladder, the urologist fills it with sterile water to keep the catheter in place. Men who undergo minimally invasive procedures may not need a Foley catheter. Bipolar diathermy has largely replaced monopolar diathermy techniques for TURP, with increased benefits such as resection in saline and reduced risk of “TUR syndrome.
  • HOLEP – Previously, open prostatectomy allowed adenoma to be removed or enucleated off its capsule. This can now be achieved with laser enucleation, referred to as HoLEP (Holmium laser enucleation of the prostate). Meta-analysis has shown improved Qmax (flow rate), reduction in post-void residual, and IPSS compared to TURP. Benefits include a lower transfusion rate with no increase in complications compared to TURP. However, limitations include specialized equipment required making it less readily available.
  • Urolift – Tissue-sparing approaches, such as Urolift, have also been developed. This can help minimize the risk of bleeding in co-morbid patients and the associated risks of more invasive surgery (such as anesthesia risk, prolonged surgery time, etc.). By compressing prostate lobes, the channel can be widened in the prostatic urethra, improving LUTS. Studies have shown benefits, including the possibility of day-case surgery, preserved sexual function, and improved symptom scores (IPSS), and flow rates (QMax).

The Foley catheter most often remains in place for several days. Sometimes, the Foley catheter causes recurring, painful, difficult-to-control bladder spasms the day after surgery. However, these spasms will eventually stop. A urologist may prescribe medications to relax bladder muscles and prevent bladder spasms. These medications include

  • Oxybutynin chloride (Ditropan)
  • Solifenacin (VESIcare)
  • Darifenacin (Enablex)
  • Tolterodine (Detrol)
  • Hyoscyamine (Levsin)
  • Propantheline bromide (Pro-Banthine)

Les Minimally invasive procedures

Some less invasive procedures are available according to patients’ preferences and co-morbidities. These are performed as outpatient procedures with local anesthesia.

  • Prostatic artery embolization – an endovascular procedure performed in interventional radiology.[rx] Through catheters, embolic agents are released in the main branches of the prostatic artery, in order to induce a decrease in the size of the prostate gland, thus reducing the urinary symptoms.[rx]
  • Water vapor thermal therapy – This is a newer office procedure for removing prostate tissue using steam aimed at preserving sexual function.
  • Prostatic urethral lift (marketed as UroLift) – This intervention consists of a system of a device and an implant designed to pull the prostatic lobe away from the urethra.[rx]
  • Transurethral microwave thermotherapy (TUMT) – is an outpatient procedure that is less invasive compared to surgery and involves using microwaves (heat) to shrink prostate tissue that is enlarged.[rx]
  • Temporary implantable nitinol device (TIND and iTIND) – is a device that is placed in the urethra that, when released, is expanded, reshaping reshaping the urethra and the bladder neck.[rx]
  • Open or robot-assisted prostatectomy – The surgeon makes an incision in your lower abdomen to reach the prostate and remove tissue. Open prostatectomy is generally done if you have a very large prostate, bladder damage or other complicating factors. The surgery usually requires a short hospital stay and is associated with a higher risk of needing a blood transfusion.

Alternative medicine

While herbal remedies are commonly used, a 2016 review found the herbs studied to be no better than placebo.[rx] Particularly, several systematic reviews found that Saw palmetto extract from Serenoa repens, while one of the most commonly used, is no better than placebo in both symptom relief and decreasing prostate size.[rx][rx][rx] Other ineffective herbal medicines include beta-sitosterol[rx] from Hypoxis rooperi (African star grass), pygeum (extracted from the bark of Prunus africana),[rx] pumpkin seeds (Cucurbita pepo) and stinging nettle (Urtica dioica) root.[rx] A systematic review of Chinese herbal medicines found that Chinese herbal medicine, either as monotherapy or an adjuvant therapy with Western medicine, was similar to either placebo or Western medicine in the treatment of BPH. Chinese herbal medicine was found to be superior to Western medicine in improving quality of life and reducing prostate volume.

Complications after surgery may include

  • Problems urinating – Men may initially have painful urination or difficulty urinating. They may experience urinary frequency, urgency, or retention. These problems will gradually lessen and, after a couple of months, urination will be easier and less frequent.
  • Urinary incontinence – As the bladder returns to normal, men may have some temporary problems controlling urination. However, long-term urinary incontinence rarely occurs. The longer urinary problems existed before surgery, the longer it takes for the bladder to regain its full function after surgery.
  • Bleeding and blood clots – After benign prostatic hyperplasia surgery, the prostate or tissues around it may bleed. Blood or blood clots may appear in the urine. Some bleeding is normal and should clear up within several days. However, men should contact a health care provider right away if they experience pain or discomfort their urine contains large clots their urine is so red it is difficult to see through. Blood clots from benign prostatic hyperplasia surgery can pass into the bloodstream and lodge in other parts of the body most often the legs. Men should contact a health care provider right away if they experience swelling or discomfort in their legs.
  • Infection – Use of a Foley catheter after benign prostatic hyperplasia surgery may increase the risk of a UTI. Anesthesia during surgery may cause urinary retention and also increase the risk of a UTI. In addition, the incision site of an open prostatectomy may become infected. A health care provider will prescribe antibiotics to treat infections.
  • Scar tissue – In the year after the original surgery, scar tissue sometimes forms and requires surgical treatment. Scar tissue may form in the urethra and cause it to narrow. A urologist can solve this problem during an office visit by stretching the urethra. Rarely, the opening of the bladder becomes scarred and shrinks, causing a blockage. This problem may require a surgical procedure similar to TUIP.
  • Sexual dysfunction – Some men may experience temporary problems with sexual function after benign prostatic hyperplasia surgery. The length of time for restored sexual function depends on the type of benign prostatic hyperplasia surgery performed and how long symptoms were present before surgery. Many men have found that concerns about sexual function can interfere with sex as much as benign prostatic hyperplasia surgery itself. Understanding the surgical procedure and talking about concerns with a health care provider before surgery often helps men regain sexual function earlier. Many men find it helpful to talk with a counselor during the adjustment period after surgery. Even though it can take a while for sexual function to fully return, with time, most men can enjoy sex again.
  • Recurring problems – Men may require further treatment if prostate problems, including benign prostatic hyperplasia, return. Problems may arise when treatments for benign prostatic hyperplasia leave a good part of the prostate intact. About 10 percent of men treated with TURP or TUIP require additional surgery within 5 years. About 2 percent of men who have an open prostatectomy require additional surgery within 5 years.

Lifestyle Changes

A health care provider may recommend lifestyle changes for men whose symptoms are mild or slightly bothersome. Lifestyle changes can include

  • reducing intake of liquids, particularly before going out in public or before periods of sleep
  • avoiding or reducing intake of caffeinated beverages and alcohol
  • avoiding or monitoring the use of medications such as decongestants, antihistamines, antidepressants, and diuretics
  • training the bladder to hold more urine for longer periods
  • exercising pelvic floor muscles
  • preventing or treating constipation

Complications of Benign prostatic hyperplasia

The complications of benign prostatic hyperplasia treatment depend on the type of treatment.

Medications used to treat benign prostatic hyperplasia may have side effects that sometimes can be serious. Men who are prescribed medications to treat benign prostatic hyperplasia should discuss possible side effects with a health care provider before taking the medications. Men who experience the following side effects should contact a health care provider right away or get emergency medical care:

  • hives
  • rash
  • itching
  • shortness of breath
  • rapid, pounding, or irregular heartbeat
  • painful erection of the penis that lasts for hours
  • swelling of the eyes, face, tongue, lips, throat, arms, hands, feet, ankles, or lower legs
  • difficulty breathing or swallowing
  • chest pain
  • dizziness or fainting when standing up suddenly
  • sudden decrease or loss of vision
  • blurred vision
  • sudden decrease or loss of hearing
  • chest pain, dizziness, or nausea during sexual activity

These side effects are mostly related to phosphodiesterase-5 inhibitors. Side effects related to alpha blockers include

  • dizziness or fainting when standing up suddenly
  • decreased sexual drive
  • problems with ejaculation

Minimally Invasive Procedures

Complications after minimally invasive procedures may include

  • UTIs
  • painful urination
  • difficulty urinating
  • an urgent or a frequent need to urinate
  • urinary incontinence
  • blood in the urine for several days after the procedure
  • sexual dysfunction
  • chronic prostatitis—long-lasting inflammation of the prostate
  • recurring problems such as urinary retention and UTIs

Most of the complications of minimally invasive procedures go away within a few days or weeks. Minimally invasive procedures are less likely to have complications than surgery.

Points to Remember

  • Common prostate problems include
    • prostatitis—inflammation, or swelling, of the prostate
    • benign prostatic hyperplasia (BPH)—an enlarged prostate due to something other than cancer
    • prostate cancer
  • Prostatitis is the most common prostate problem in men younger than age 50.
  • BPH is the most common prostate problem in men older than age 50.
  • The symptoms of a prostate problem may include problems with urinating and bladder control.
  • If you have chronic prostatitis, your symptoms may cause long-lasting pain and discomfort in
    • your penis or scrotum
    • the area between your scrotum and anus
    • your belly
    • your lower back
  • If you have bacterial prostatitis, your symptoms may come on quickly, or they may come on slowly and last a long time.
  • If you have BPH, you may need to wake up often to urinate when you sleep.
  • If you can’t urinate at all, you should get medical help right away.
  • Your doctor will know if you have a prostate problem based on the following:
    • your medical and family history
    • a physical exam, including a digital rectal exam of your prostate
    • tests on your urine, blood, and lower urinary tract
    • ultrasound
    • prostate biopsy
  • Treatment depends on the type of prostate problem you have.
  • If you have chronic prostatitis, your doctor will try treatments to lessen pain, discomfort, and inflammation.
  • If you have bacterial prostatitis, your doctor will give you an antibiotic, a medicine that kills bacteria.

References

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

Ureteroscopy – Indications, Procedures, Results

Ureteroscopy uses a ureteroscope to look inside the ureters and kidneys. Like a cystoscope, a ureteroscope has an eyepiece at one end, a rigid or flexible tube in the middle, and a tiny lens and light at the other end of the tube. However, a ureteroscope is longer and thinner than a cystoscope so the urologist can see detailed images of the lining of the ureters and kidneys. The ureters and kidneys are also part of the urinary tract.

Cystoscopy is a cystoscopy uses a cystoscope to look inside the urethra and bladder. A cystoscope is a long, thin optical instrument with an eyepiece at one end, a rigid or flexible tube in the middle, and a tiny lens and light at the other end of the tube. By looking through the cystoscope, the urologist can see detailed images of the lining of the urethra and bladder. The urethra and bladder are part of the urinary tract.

What is the urinary tract and how does it work?

The urinary tract is the body’s drainage system for removing urine, which is composed of wastes and extra fluid. In order for normal urination to occur, all body parts in the urinary tract need to work together in the correct order.

  • Kidneys – The kidneys are two bean-shaped organs, each about the size of a fist. They are located just below the rib cage, one on each side of the spine. Every day, the kidneys filter about 120 to 150 quarts of blood to produce about 1 to 2 quarts of urine. The kidneys work around the clock; a person does not control what they do.
  • Ureters – Ureters are the thin tubes of muscle—one on each side of the bladder—that carry urine from each of the kidneys to the bladder.
  • Bladder – The bladder, located in the pelvis between the pelvic bones, is a hollow, muscular, balloon-shaped organ that expands as it fills with urine. Although a person does not control kidney function, a person does control when the bladder empties. Bladder emptying is known as urination. The bladder stores urine until the person finds an appropriate time and place to urinate. A normal bladder acts like a reservoir and can hold 1.5 to 2 cups of urine. How often a person needs to urinate depends on how quickly the kidneys produce the urine that fills the bladder. The muscles of the bladder wall remain relaxed while the bladder fills with urine. As the bladder fills to capacity, signals sent to the brain tell a person to find a toilet soon. During urination, the bladder empties through the urethra, located at the bottom of the bladder. Three sets of muscles work together like a dam, keeping urine in the bladder.

The first set is the muscles of the urethra itself. The area where the urethra joins the bladder is the bladder neck. The bladder neck, composed of the second set of muscles known as the internal sphincter, helps urine stay in the bladder. The third set of muscles in the pelvic floor muscles also referred to as the external sphincter, which surrounds and supports the urethra.

To urinate, the brain signals the muscular bladder wall to tighten, squeezing urine out of the bladder. At the same time, the brain signals the sphincters to relax. As the sphincters relax, urine exits the bladder through the urethra.

Why is a cystoscopy or ureteroscopy performed?

A urologist performs a cystoscopy or ureteroscopy to find the cause of, and sometimes treat, urinary tract problems.

Cystoscopy. A urologist performs a cystoscopy to find the cause of urinary tract problems such as

  • frequent urinary tract infections (UTIs)
  • hematuria—blood in the urine
  • urinary frequency—urination eight or more times a day
  • urinary urgency—the inability to delay urination
  • urinary retention—the inability to empty the bladder completely
  • urinary incontinence—the accidental loss of urine
  • pain or burning before, during, or after urination
  • trouble starting urination, completing urination, or both
  • abnormal cells, such as cancer cells, found in a urine sample

During a cystoscopy, a urologist can see

  • stones—solid pieces of material in the bladder that may have formed in the kidneys or in the bladder when substances that are normally in the urine become highly concentrated.
  • abnormal tissue, polyps, tumors, or cancer in the urethra or bladder.
  • stricture, a narrowing of the urethra. Stricture can be a sign of an enlarged prostate in men or of scar tissue in the urethra.

During a cystoscopy, a urologist can treat problems such as bleeding in the bladder and blockage in the urethra. A urologist may also use cystoscopy to

  • remove a stone in the bladder or urethra.
  • remove or treat abnormal tissue, polyps, and some types of tumors.
  • take small pieces of urethral or bladder tissue for examination with a microscope—a procedure called a biopsy.
  • inject material into the wall of the urethra to treat urinary leakage.
  • inject medication into the bladder to treat urinary leakage.
  • obtain urine samples from the ureters.
  • perform retrograde pyelography—an x-ray procedure in which a urologist injects a special dye, called contrast medium, into a ureter to the kidney to create images of urinary flow. The test can show causes of obstruction, such as kidney stones and tumors.
  • remove a stent that was placed in the ureter after a ureteroscopy with biopsy or stone removal. A stent is a small, soft tube.

Ureteroscopy. In addition to the causes of urinary tract problems he or she can find with a cystoscope, a urologist performs a ureteroscopy to find the cause of urine blockage in a ureter or to evaluate other abnormalities inside the ureters or kidneys.

During a ureteroscopy, a urologist can see

  • a stone in a ureter or kidney
  • abnormal tissue, polyps, tumors, or cancer in a ureter or in the lining of a kidney

During a ureteroscopy, a urologist can treat problems such as urine blockage in a ureter. The urologist can also

  • remove a stone from a ureter or kidney
  • remove or treat abnormal tissue, polyps, and some types of tumors
  • perform a biopsy of a ureter or kidney

After a ureteroscopy, the urologist may need to place a stent in a ureter to drain urine from the kidney to the bladder while swelling in the ureter goes away. The stent, which is completely inside the body, may cause some discomfort in the kidney or bladder area. The discomfort is generally mild. The stent may be left in the ureter for a few days to a week or more. The urologist may need to perform a cystoscopy to remove the stent in the ureter.

How does a patient prepare for a cystoscopy or ureteroscopy?

In many cases, a patient does not need special preparations for a cystoscopy. A health care provider may ask the patient to drink plenty of liquids before the procedure, as well as urinate immediately before the procedure.

The patient may need to give a urine sample to test for a UTI. If the patient has a UTI, the urologist may treat the infection with antibiotics before performing a cystoscopy or ureteroscopy. A health care provider will provide instructions before the cystoscopy or ureteroscopy. These instructions may include

  • when to stop certain medications, such as blood thinners
  • when to stop eating and drinking
  • when to empty the bladder before the procedure
  • arranging for a ride home after the procedure

The urologist will ask about the patient’s medical history, current prescription and over-the-counter medications, and allergies to medications, including anesthetics. The urologist will talk about which anesthetic is best for the procedure and explain what the patient can expect after the procedure.

Indications of Cystoscopy

There are many indications for office-based cystourethroscopy. Most office cystoscopy is performed for diagnostic purposes. One of the most common reasons for a patient to be referred to a urologist is the presence of hematuria, gross or microscopic. Gross hematuria is defined as blood in the urine that can be seen with the naked eye. Microscopic hematuria is defined as 3 or greater red blood cells per high-powered field. Another common indication for regular cystoscopy is any history of malignancy including urethral, bladder, or upper tract UCC. This is often done on a surveillance basis with intervals depending on the type of cancer. Lower urinary tract symptoms (LUTS) are another indication of cystourethroscopy. These symptoms can include obstructive voiding symptoms, irritative voiding symptoms, urinary incontinence, chronic pelvic pain syndrome, or recurrent UTIs. Any trauma in which there is a concern for injury to the lower urinary tract necessitates cystourethroscopy, as well as any bladder abnormalities discovered during imaging studies. Removal of foreign bodies, for example, if a patient has an indwelling urinary stent that requires removal, hematospermia, azoospermia, or concern for a bladder or lower urinary tract fistula are also reasons for cystourethroscopy.

Rigid cystoscopy in the operating room is indicated for more therapeutic indications. In this setting, it is possible to have fluoroscopy and perform retrograde pyelography. There is also the ability to use multiple additional instruments including resectoscopes to perform procedures such as transurethral resection of bladder tumors, transurethral resection of the prostate, direct vision internal urethrotomy, injection of Botox into the detrusor muscle, and numerous other interventions. Further discussion of these different procedures is beyond the scope of this article.

Indications include:

  • Hematuria, gross or microscopic
  • Surveillance/evaluation of malignancy (bladder, urethra, upper tract UCC, abnormal cytology)
  • Lower Urinary Tract Symptoms (LUTS): The irritative voiding symptoms, obstructive voiding symptoms, urinary incontinence, chronic pelvic pain syndrome, recurrent UTIs
  • Trauma, abnormal imaging of bladder, concern for fistula, removal of foreign body, hematospermia, azoospermia

Contraindications of Cystoscopy

Contraindications to cystoscopy are relatively straightforward. If there is any evidence of acute urinary infection, the procedure would be contraindicated as it could put the patient at risk for developing sepsis from a urinary source. For this reason, it is recommended to obtain a urinalysis 5 to 7 days before any scheduled cystoscopy procedure. If a UTI is identified, the patient should be treated appropriately prior to the procedure. A contraindication for flexible cystoscopy in the office would be any intolerance to pain or discomfort with the procedure. This may necessitate a trip to the operating room (OR) for cystoscopy under anesthesia. A urethral stricture can sometimes make cystoscopy impossible, as the scope will not be able to pass.

Equipment

Cystoscopes come in both flexible and rigid options. They are manufactured in a variety of sizes expressed in French (Fr) gauge. A 1 French instrument has a circumference of one-third of a millimeter. Rigid cystoscopes use the Hopkins rod-lens optical system which has the advantage of providing improved optical clarity when compared with the fiberoptic bundles used in flexible cystoscopes. However, this is becoming less noticeable with the adoption of flexible digital cystoscopes. Visualization is also enhanced in the rigid model due to the greater irrigant flow rate. Rigid scopes also have larger working channels which allow for a wider variety of instruments that can be used with them. The advantage of the flexible scopes is that they are smaller in size and provide greater patient comfort, which is why they are used for routine flexible cystourethroscopy in the office setting. The flexible endoscope can also be passed easily with a patient in the supine position; whereas, in rigid cystoscopy, the patient must be in the frog-leg or lithotomy position. Another excellent advantage is the movement of the tip of the flexible cystoscope which allows for easier inspection of the bladder and negotiating around an elevated bladder neck or large median lobe of the prostate. With a rigid cystoscope, it is necessary to use multiple lenses with varying degrees of angle to achieve proper inspection of the entire bladder.

Rigid Cystourethroscopy

Rigid cystoscopes are produced in sets that consist of an optical lens, bridge, sheath, and obturator. These configurations are different depending on the vendor. Vendors that produce these sets include Karl Storz, Olympus, Gyrus/ACMI, and Wolf.

The optical lenses come with tip angles that range from 0 to 120 degrees. The most common lens degrees used during a typical rigid cystourethroscopy include the 30-degree lens and the 70-degree lens. The urethra is best visualized using the 0 to 12-degree lens. A 30-degree lens is most often used for therapeutic purposes. The 70 or 120-degree lens are often required to inspect the anterior and inferolateral walls, dome, and neck of the bladder.

The bridge connects the optical lens to the sheath. There are varying types of bridges. A diagnostic bridge has no working channels. Bridges used for therapeutic cases can have 1 to 2 working channels. An Albarran bridge is a specialized bridge that contains a lever that can deflect wires and catheters that pass through the working channel to facilitate ureteral orifice cannulation. This can sometimes be required in patients that have elevated bladder necks or large median lobes of the prostate. It can also be helpful when attempting to cannulate a transplanted ureter or ureters entering the bladder at odd locations.

The cystourethroscopy sheaths come in a variety of sizes. Sheaths can range in size from 15/17 Fr to 25 Fr. Smaller sheaths are ideal for diagnostic cystoscopy and cause less trauma. Larger sheaths are used for therapeutic procedures as they allow more irrigant flow and larger working channels for instruments. Each sheath has an obturator that blunts the distal end of the sheath for passage into the bladder without visual assistance. Blind endoscope passage is generally only recommended to be performed in a female.

Flexible Cystourethroscopy

Flexible cystoscopes range between 16 and 17 Fr. There are differences in all models with regard to their dip deflection, the direction of view, the field of view, working channel size, illumination and optics. Vendors that manufacture these scopes include Karl Storz, Olympus, and Wolf. Most models provide a field of view of approximately 120 degrees and do not have an offset lens. Tip deflection ranges between 120 to 210 degrees and can either be intuitive (same direction as lever deflection) or counterintuitive (opposite direction of lever deflection). The irrigation and instruments have to pass through the same working channel. This necessitates discontinuing the irrigation to pass a flexible grasper through the scope, for example. However, adaptors have been developed to allow the irrigation to be connected while passing instruments. The amount of irrigation is significantly decreased with the instrument passing through the channel. Photodynamic and narrow-band imaging capabilities are available in some models.

Both Karl Storz and Olympus produce fiberoptic and digital models. Digital scopes are now available in high definition (1920 x 1080 pixels) and standard definition (720 x 480 pixels). These scopes do not require focusing or white balancing. Studies have been performed to compare the resolution, contrast evaluation, depth of field, color representation and illumination of fiberoptic, standard, and high-definition flexible cystoscopes. One study demonstrated that the high definition scope had significantly higher resolution and depth of field, with slightly improved color representation and no difference in contrast evaluation. Illumination was significantly better in the fiberoptic models when compared to digital. A randomized study performed by Okhunov et al. in 2009 compared optics, performance, and durability of fiberoptic and standard-definition digital scopes. This showed a trend of surgeon optical ranking in favor of digital scopes. There was no difference in durability between models.

Irrigant material depends on the situation, but sterile water or normal saline is most commonly used. Nonionic irrigants (water, glycine, sorbitol) are required when using monopolar electrocautery. Isotonic irrigating fluids (normal saline/lactated ringers) can be used when using bipolar electrocautery instruments. This offers the advantage of eliminating the risk of electrolyte disturbance from systemic uptakes, such as Transurethral Resection of the Prostate (TURP) syndrome. Sterile water should be used when bladder samples are collected for cytologic evaluation.

Personnel

The personnel required for cystoscopy depends on if it is being performed in the office or the operating room. A simple office cystoscopy requires minimal personnel as there is no anesthesia. It is beneficial to have a nurse as an assistant, especially if doing procedures that can be performed more smoothly with an extra set of hands. For example, if performing a cystoscopy to remove an indwelling ureteral stent, it can be beneficial for the surgeon to operate the cystoscope and have his/her assistant operate the flexible grasper. This is not necessary, however. When performing cystoscopy in the operating room, it is necessary to have anesthesia staff as well as circulating nurses and possibly scrub techs for assistance.

Preparation

Informed consent must be obtained before the procedure. A urinalysis and urine culture is commonly performed before cystoscopy. The AUA best practice policy statement on antimicrobial prophylaxis does not recommend antibiotic administration for routine diagnostic cystoscopy in the absence of patient-related risk factors. The risk factors that require antimicrobial prophylaxis include:

  • Advanced age
  • Anatomic anomalies of the urinary tract
  • Chronic corticosteroid use
  • Colonized endogenous or exogenous material
  • Distant coexistent infection
  • Immunodeficiency
  • Poor nutritional status
  • Prolonged coexistent infection
  • Smoking history

Prophylaxis lasting less than 24 hours with either a fluoroquinolone or trimethoprim-sulfamethoxazole is recommended for therapeutic procedures. Two-line alternatives include an aminoglycoside with or without ampicillin, a first or second-generation cephalosporin, or amoxicillin/clavulanate.

Prior to the procedure, the skin should be prepared with an antiseptic agent. Both chlorhexidine gluconate and alcohol-based solutions can be damaging to mucous membranes and are therefore not recommended for use on the genitalia. Aqueous-based iodophor-containing products such as Betadine are safe on all skin surfaces and are most commonly used for preparation.

After application of the antiseptic agent, a lubricating gel is injected into the urethra. A plain or lidocaine gel may be used. One meta-analysis of four randomized trials found that patients who received lidocaine gel were 1.7 times less likely to experience moderate to severe pain during the procedure.

Technique

Before inserting the cystourethroscopy, the external genitalia is inspected for any lesions or anatomic abnormalities. In women, rigid cystourethroscopy insertion can be implemented using a sheath obturator. The scope will need to be directed anteriorly as it is advanced into the bladder. A flexible scope can be inserted similarly to a Foley catheter, with active deflection being used as needed.

In men, the penis is placed on the maximal stretch to straighten the urethra. When a rigid scope is passed, the penis is grasped with 5 fingers of the surgeon’s non-dominant hand. When a flexible scope is passed, the penis is pinched between the third and fourth digits of the non-dominant hand, allowing the thumb and index finger to be free to help guide the scope into the urethra. The penis should be angled 45 to 90 degrees relative to the abdominal wall as the scope passes through the anterior urethra. Once beyond the membranous urethra, the scope is directed anteriorly to enter the bladder. This is accomplished with active upward flexion when using the flexible scope and by dropping the distal end of the scope toward the operative table when using a rigid scope.

The lower urinary tract is systematically evaluated as the scope is advanced, with maximal irrigation running. The penile and bulbar urethra should be evaluated for any sign of stricture. The patient should be encouraged to relax when the scope is advanced through the membranous urethra. Once the scope is in the prostatic urethra, the verumontanum and utricle can be identified posteriorly. The size of the prostatic lobe, length of the prostatic urethra and presence of a median lobe or bladder neck obstruction should be noted.

Upon entering the bladder, the mucosa should be carefully inspected. When using a rigid cystoscope, generally a 30-degree scope is used initially to inspect as much of the bladder as can be visualized. The floor and trigone of the bladder are initially inspected, with the identification of the ureteral orifices, noting their location and number. Efflux from each ureter should be observed for the presence of blood. The remainder of the bladder should be inspected for bladder stones, trabeculation, bladder diverticula, erythematous patches or papillary/sessile bladder lesions. The surgeon can visualize the lateral walls by rotating the cystoscope and keeping the camera orientation fixed. The dome and posterolateral walls of the bladder are inspected using a 70 or 120-degree lens on a rigid scope, or by retroflection on a flexible scope. Prior to removing the scope, the bladder should be drained.

How is a cystoscopy or ureteroscopy performed?

A urologist performs a cystoscopy or ureteroscopy during an office visit or in an outpatient center or a hospital. For some patients, the urologist will apply an anesthetic gel around the urethral opening or inject a local anesthetic into the urethra. Some patients may require sedation or general anesthesia. The urologist often gives patients sedatives and general anesthesia for a

  • ureteroscopy
  • cystoscopy with biopsy
  • cystoscopy to inject material into the wall of the urethra
  • cystoscopy to inject medication into the bladder

For sedation and general anesthesia, a nurse or technician places an intravenous (IV) needle in a vein in the arm or hand to give the medication. Sedation helps the patient relax and be comfortable. General anesthesia puts the patient into a deep sleep during the procedure. The medical staff will monitor the patient’s vital signs and try to make him or her as comfortable as possible. During both procedures, a woman will lie on her back with the knees up and spread apart. During a cystoscopy, a man can lie on his back or be in a sitting position.

After the anesthetic has taken effect, the urologist gently inserts the tip of the cystoscope or ureteroscope into the urethra and slowly glides it through the urethra and into the bladder. A sterile liquid—water or saltwater, called saline—flows through the cystoscope or ureteroscope to slowly fill the bladder and stretch it so the urologist has a better view of the bladder wall. As the bladder fills with liquid, the patient may feel some discomfort and the urge to urinate. The urologist may remove some of the liquid from the bladder during the procedure. As soon as the procedure is over, the urologist may remove the liquid from the bladder or the patient may empty the bladder.

For a cystoscopy, the urologist examines the lining of the urethra as he or she passes the cystoscope into the bladder. The urologist then examines the lining of the bladder. The urologist can insert small instruments through the cystoscope to treat problems in the urethra and bladder or perform a biopsy.

For a ureteroscopy, the urologist passes the ureteroscope through the bladder and into a ureter. The urologist then examines the lining of the ureter. He or she may pass the ureteroscope all the way up into the kidney. The urologist can insert small instruments through the ureteroscope to treat problems in the ureter or kidney or perform a biopsy.

When a urologist performs a cystoscopy or a ureteroscopy to make a diagnosis, both procedures—including preparation—take 15 to 30 minutes. The time may be longer if the urologist removes a stone in the bladder or a ureter or if he or she performs a biopsy.

What can a patient expect after a cystoscopy or ureteroscopy?

After a cystoscopy or ureteroscopy, a patient may

  • have a mild burning feeling when urinating
  • see small amounts of blood in the urine
  • have mild discomfort in the bladder area or kidney area when urinating
  • need to urinate more frequently or urgently

These problems should not last more than 24 hours. The patient should tell a health care provider right away if bleeding or pain is severe or if problems last more than a day.

The health care provider may recommend that the patient

  • drink 16 ounces of water each hour for 2 hours after the procedure
  • take a warm bath to relieve the burning feeling
  • hold a warm, damp washcloth over the urethral opening to relieve discomfort
  • take an over-the-counter pain reliever

The health care provider may prescribe an antibiotic to take for 1 or 2 days to prevent an infection. A patient should report any signs of infection—including severe pain, chills, or fever—right away to the health care provider.

Most patients go home the same day as the procedure. Recovery depends on the type of anesthesia. A patient who receives only a local anesthetic can go home immediately. A patient who receives general anesthesia may have to wait 1 to 4 hours before going home. A health care provider usually asks the patient to urinate before leaving. In some cases, the patient may need to stay overnight in the hospital. A health care provider will provide discharge instructions for rest, driving, and physical activities after the procedure.

What are the risks of cystoscopy and ureteroscopy?

The risks of cystoscopy and ureteroscopy include

  • UTIs
  • abnormal bleeding
  • abdominal pain
  • a burning feeling or pain during urination
  • injury to the urethra, bladder, or ureters
  • urethral narrowing due to scar tissue formation
  • the inability to urinate due to swelling of surrounding tissues
  • complications from anesthesia

References

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

Cystoscopy – Indications, Procedure, Results

Cystoscopy is a cystoscopy uses a cystoscope to look inside the urethra and bladder. A cystoscope is a long, thin optical instrument with an eyepiece at one end, a rigid or flexible tube in the middle, and a tiny lens and light at the other end of the tube. By looking through the cystoscope, the urologist can see detailed images of the lining of the urethra and bladder. The urethra and bladder are part of the urinary tract.

Ureteroscopy – Ureteroscopy uses a ureteroscope to look inside the ureters and kidneys. Like a cystoscope, a ureteroscope has an eyepiece at one end, a rigid or flexible tube in the middle, and a tiny lens and light at the other end of the tube. However, a ureteroscope is longer and thinner than a cystoscope so the urologist can see detailed images of the lining of the ureters and kidneys. The ureters and kidneys are also part of the urinary tract.

What is the urinary tract and how does it work?

The urinary tract is the body’s drainage system for removing urine, which is composed of wastes and extra fluid. In order for normal urination to occur, all body parts in the urinary tract need to work together in the correct order.

  • Kidneys – The kidneys are two bean-shaped organs, each about the size of a fist. They are located just below the rib cage, one on each side of the spine. Every day, the kidneys filter about 120 to 150 quarts of blood to produce about 1 to 2 quarts of urine. The kidneys work around the clock; a person does not control what they do.
  • Ureters – Ureters are the thin tubes of muscle—one on each side of the bladder—that carry urine from each of the kidneys to the bladder.
  • Bladder – The bladder, located in the pelvis between the pelvic bones, is a hollow, muscular, balloon-shaped organ that expands as it fills with urine. Although a person does not control kidney function, a person does control when the bladder empties. Bladder emptying is known as urination. The bladder stores urine until the person finds an appropriate time and place to urinate. A normal bladder acts like a reservoir and can hold 1.5 to 2 cups of urine. How often a person needs to urinate depends on how quickly the kidneys produce the urine that fills the bladder. The muscles of the bladder wall remain relaxed while the bladder fills with urine. As the bladder fills to capacity, signals sent to the brain tell a person to find a toilet soon. During urination, the bladder empties through the urethra, located at the bottom of the bladder. Three sets of muscles work together like a dam, keeping urine in the bladder.

The first set is the muscles of the urethra itself. The area where the urethra joins the bladder is the bladder neck. The bladder neck, composed of the second set of muscles known as the internal sphincter, helps urine stay in the bladder. The third set of muscles in the pelvic floor muscles also referred to as the external sphincter, which surrounds and supports the urethra.

To urinate, the brain signals the muscular bladder wall to tighten, squeezing urine out of the bladder. At the same time, the brain signals the sphincters to relax. As the sphincters relax, urine exits the bladder through the urethra.

Why is a cystoscopy or ureteroscopy performed?

A urologist performs a cystoscopy or ureteroscopy to find the cause of, and sometimes treat, urinary tract problems.

Cystoscopy. A urologist performs a cystoscopy to find the cause of urinary tract problems such as

  • frequent urinary tract infections (UTIs)
  • hematuria—blood in the urine
  • urinary frequency—urination eight or more times a day
  • urinary urgency—the inability to delay urination
  • urinary retention—the inability to empty the bladder completely
  • urinary incontinence—the accidental loss of urine
  • pain or burning before, during, or after urination
  • trouble starting urination, completing urination, or both
  • abnormal cells, such as cancer cells, found in a urine sample

During a cystoscopy, a urologist can see

  • stones—solid pieces of material in the bladder that may have formed in the kidneys or in the bladder when substances that are normally in the urine become highly concentrated.
  • abnormal tissue, polyps, tumors, or cancer in the urethra or bladder.
  • stricture, a narrowing of the urethra. Stricture can be a sign of an enlarged prostate in men or of scar tissue in the urethra.

During a cystoscopy, a urologist can treat problems such as bleeding in the bladder and blockage in the urethra. A urologist may also use cystoscopy to

  • remove a stone in the bladder or urethra.
  • remove or treat abnormal tissue, polyps, and some types of tumors.
  • take small pieces of urethral or bladder tissue for examination with a microscope—a procedure called a biopsy.
  • inject material into the wall of the urethra to treat urinary leakage.
  • inject medication into the bladder to treat urinary leakage.
  • obtain urine samples from the ureters.
  • perform retrograde pyelography—an x-ray procedure in which a urologist injects a special dye, called contrast medium, into a ureter to the kidney to create images of urinary flow. The test can show causes of obstruction, such as kidney stones and tumors.
  • remove a stent that was placed in the ureter after a ureteroscopy with biopsy or stone removal. A stent is a small, soft tube.

Ureteroscopy. In addition to the causes of urinary tract problems he or she can find with a cystoscope, a urologist performs a ureteroscopy to find the cause of urine blockage in a ureter or to evaluate other abnormalities inside the ureters or kidneys.

During a ureteroscopy, a urologist can see

  • a stone in a ureter or kidney
  • abnormal tissue, polyps, tumors, or cancer in a ureter or in the lining of a kidney

During a ureteroscopy, a urologist can treat problems such as urine blockage in a ureter. The urologist can also

  • remove a stone from a ureter or kidney
  • remove or treat abnormal tissue, polyps, and some types of tumors
  • perform a biopsy of a ureter or kidney

After a ureteroscopy, the urologist may need to place a stent in a ureter to drain urine from the kidney to the bladder while swelling in the ureter goes away. The stent, which is completely inside the body, may cause some discomfort in the kidney or bladder area. The discomfort is generally mild. The stent may be left in the ureter for a few days to a week or more. The urologist may need to perform a cystoscopy to remove the stent in the ureter.

How does a patient prepare for a cystoscopy or ureteroscopy?

In many cases, a patient does not need special preparations for a cystoscopy. A health care provider may ask the patient to drink plenty of liquids before the procedure, as well as urinate immediately before the procedure.

The patient may need to give a urine sample to test for a UTI. If the patient has a UTI, the urologist may treat the infection with antibiotics before performing a cystoscopy or ureteroscopy. A health care provider will provide instructions before the cystoscopy or ureteroscopy. These instructions may include

  • when to stop certain medications, such as blood thinners
  • when to stop eating and drinking
  • when to empty the bladder before the procedure
  • arranging for a ride home after the procedure

The urologist will ask about the patient’s medical history, current prescription and over-the-counter medications, and allergies to medications, including anesthetics. The urologist will talk about which anesthetic is best for the procedure and explain what the patient can expect after the procedure.

Indications of Cystoscopy

There are many indications for office-based cystourethroscopy. Most office cystoscopy is performed for diagnostic purposes. One of the most common reasons for a patient to be referred to a urologist is the presence of hematuria, gross or microscopic. Gross hematuria is defined as blood in the urine that can be seen with the naked eye. Microscopic hematuria is defined as 3 or greater red blood cells per high-powered field. Another common indication for regular cystoscopy is any history of malignancy including urethral, bladder, or upper tract UCC. This is often done on a surveillance basis with intervals depending on the type of cancer. Lower urinary tract symptoms (LUTS) are another indication of cystourethroscopy. These symptoms can include obstructive voiding symptoms, irritative voiding symptoms, urinary incontinence, chronic pelvic pain syndrome, or recurrent UTIs. Any trauma in which there is a concern for injury to the lower urinary tract necessitates cystourethroscopy, as well as any bladder abnormalities discovered during imaging studies. Removal of foreign bodies, for example, if a patient has an indwelling urinary stent that requires removal, hematospermia, azoospermia, or concern for a bladder or lower urinary tract fistula are also reasons for cystourethroscopy.

Rigid cystoscopy in the operating room is indicated for more therapeutic indications. In this setting, it is possible to have fluoroscopy and perform retrograde pyelography. There is also the ability to use multiple additional instruments including resectoscopes to perform procedures such as transurethral resection of bladder tumors, transurethral resection of the prostate, direct vision internal urethrotomy, injection of Botox into the detrusor muscle, and numerous other interventions. Further discussion of these different procedures is beyond the scope of this article.

Indications include:

  • Hematuria, gross or microscopic
  • Surveillance/evaluation of malignancy (bladder, urethra, upper tract UCC, abnormal cytology)
  • Lower Urinary Tract Symptoms (LUTS): The irritative voiding symptoms, obstructive voiding symptoms, urinary incontinence, chronic pelvic pain syndrome, recurrent UTIs
  • Trauma, abnormal imaging of bladder, concern for fistula, removal of foreign body, hematospermia, azoospermia

Contraindications of Cystoscopy

Contraindications to cystoscopy are relatively straightforward. If there is any evidence of acute urinary infection, the procedure would be contraindicated as it could put the patient at risk for developing sepsis from a urinary source. For this reason, it is recommended to obtain a urinalysis 5 to 7 days before any scheduled cystoscopy procedure. If a UTI is identified, the patient should be treated appropriately prior to the procedure. A contraindication for flexible cystoscopy in the office would be any intolerance to pain or discomfort with the procedure. This may necessitate a trip to the operating room (OR) for cystoscopy under anesthesia. A urethral stricture can sometimes make cystoscopy impossible, as the scope will not be able to pass.

Equipment

Cystoscopes come in both flexible and rigid options. They are manufactured in a variety of sizes expressed in French (Fr) gauge. A 1 French instrument has a circumference of one-third of a millimeter. Rigid cystoscopes use the Hopkins rod-lens optical system which has the advantage of providing improved optical clarity when compared with the fiberoptic bundles used in flexible cystoscopes. However, this is becoming less noticeable with the adoption of flexible digital cystoscopes. Visualization is also enhanced in the rigid model due to the greater irrigant flow rate. Rigid scopes also have larger working channels which allow for a wider variety of instruments that can be used with them. The advantage of the flexible scopes is that they are smaller in size and provide greater patient comfort, which is why they are used for routine flexible cystourethroscopy in the office setting. The flexible endoscope can also be passed easily with a patient in the supine position; whereas, in rigid cystoscopy, the patient must be in the frog-leg or lithotomy position. Another excellent advantage is the movement of the tip of the flexible cystoscope which allows for easier inspection of the bladder and negotiating around an elevated bladder neck or large median lobe of the prostate. With a rigid cystoscope, it is necessary to use multiple lenses with varying degrees of angle to achieve proper inspection of the entire bladder.

Rigid Cystourethroscopy

Rigid cystoscopes are produced in sets that consist of an optical lens, bridge, sheath, and obturator. These configurations are different depending on the vendor. Vendors that produce these sets include Karl Storz, Olympus, Gyrus/ACMI, and Wolf.

The optical lenses come with tip angles that range from 0 to 120 degrees. The most common lens degrees used during a typical rigid cystourethroscopy include the 30-degree lens and the 70-degree lens. The urethra is best visualized using the 0 to 12-degree lens. A 30-degree lens is most often used for therapeutic purposes. The 70 or 120-degree lens are often required to inspect the anterior and inferolateral walls, dome, and neck of the bladder.

The bridge connects the optical lens to the sheath. There are varying types of bridges. A diagnostic bridge has no working channels. Bridges used for therapeutic cases can have 1 to 2 working channels. An Albarran bridge is a specialized bridge that contains a lever that can deflect wires and catheters that pass through the working channel to facilitate ureteral orifice cannulation. This can sometimes be required in patients that have elevated bladder necks or large median lobes of the prostate. It can also be helpful when attempting to cannulate a transplanted ureter or ureters entering the bladder at odd locations.

The cystourethroscopy sheaths come in a variety of sizes. Sheaths can range in size from 15/17 Fr to 25 Fr. Smaller sheaths are ideal for diagnostic cystoscopy and cause less trauma. Larger sheaths are used for therapeutic procedures as they allow more irrigant flow and larger working channels for instruments. Each sheath has an obturator that blunts the distal end of the sheath for passage into the bladder without visual assistance. Blind endoscope passage is generally only recommended to be performed in a female.

Flexible Cystourethroscopy

Flexible cystoscopes range between 16 and 17 Fr. There are differences in all models with regard to their dip deflection, the direction of view, the field of view, working channel size, illumination and optics. Vendors that manufacture these scopes include Karl Storz, Olympus, and Wolf. Most models provide a field of view of approximately 120 degrees and do not have an offset lens. Tip deflection ranges between 120 to 210 degrees and can either be intuitive (same direction as lever deflection) or counterintuitive (opposite direction of lever deflection). The irrigation and instruments have to pass through the same working channel. This necessitates discontinuing the irrigation to pass a flexible grasper through the scope, for example. However, adaptors have been developed to allow the irrigation to be connected while passing instruments. The amount of irrigation is significantly decreased with the instrument passing through the channel. Photodynamic and narrow-band imaging capabilities are available in some models.

Both Karl Storz and Olympus produce fiberoptic and digital models. Digital scopes are now available in high definition (1920 x 1080 pixels) and standard definition (720 x 480 pixels). These scopes do not require focusing or white balancing. Studies have been performed to compare the resolution, contrast evaluation, depth of field, color representation and illumination of fiberoptic, standard, and high-definition flexible cystoscopes. One study demonstrated that the high definition scope had significantly higher resolution and depth of field, with slightly improved color representation and no difference in contrast evaluation. Illumination was significantly better in the fiberoptic models when compared to digital. A randomized study performed by Okhunov et al. in 2009 compared optics, performance, and durability of fiberoptic and standard-definition digital scopes. This showed a trend of surgeon optical ranking in favor of digital scopes. There was no difference in durability between models.

Irrigant material depends on the situation, but sterile water or normal saline is most commonly used. Nonionic irrigants (water, glycine, sorbitol) are required when using monopolar electrocautery. Isotonic irrigating fluids (normal saline/lactated ringers) can be used when using bipolar electrocautery instruments. This offers the advantage of eliminating the risk of electrolyte disturbance from systemic uptakes, such as Transurethral Resection of the Prostate (TURP) syndrome. Sterile water should be used when bladder samples are collected for cytologic evaluation.

Personnel

The personnel required for cystoscopy depends on if it is being performed in the office or the operating room. A simple office cystoscopy requires minimal personnel as there is no anesthesia. It is beneficial to have a nurse as an assistant, especially if doing procedures that can be performed more smoothly with an extra set of hands. For example, if performing a cystoscopy to remove an indwelling ureteral stent, it can be beneficial for the surgeon to operate the cystoscope and have his/her assistant operate the flexible grasper. This is not necessary, however. When performing cystoscopy in the operating room, it is necessary to have anesthesia staff as well as circulating nurses and possibly scrub techs for assistance.

Preparation

Informed consent must be obtained before the procedure. A urinalysis and urine culture is commonly performed before cystoscopy. The AUA best practice policy statement on antimicrobial prophylaxis does not recommend antibiotic administration for routine diagnostic cystoscopy in the absence of patient-related risk factors. The risk factors that require antimicrobial prophylaxis include:

  • Advanced age
  • Anatomic anomalies of the urinary tract
  • Chronic corticosteroid use
  • Colonized endogenous or exogenous material
  • Distant coexistent infection
  • Immunodeficiency
  • Poor nutritional status
  • Prolonged coexistent infection
  • Smoking history

Prophylaxis lasting less than 24 hours with either a fluoroquinolone or trimethoprim-sulfamethoxazole is recommended for therapeutic procedures. Two-line alternatives include an aminoglycoside with or without ampicillin, a first or second-generation cephalosporin, or amoxicillin/clavulanate.

Prior to the procedure, the skin should be prepared with an antiseptic agent. Both chlorhexidine gluconate and alcohol-based solutions can be damaging to mucous membranes and are therefore not recommended for use on the genitalia. Aqueous-based iodophor-containing products such as Betadine are safe on all skin surfaces and are most commonly used for preparation.

After application of the antiseptic agent, a lubricating gel is injected into the urethra. A plain or lidocaine gel may be used. One meta-analysis of four randomized trials found that patients who received lidocaine gel were 1.7 times less likely to experience moderate to severe pain during the procedure.

Technique

Before inserting the cystourethroscopy, the external genitalia is inspected for any lesions or anatomic abnormalities. In women, rigid cystourethroscopy insertion can be implemented using a sheath obturator. The scope will need to be directed anteriorly as it is advanced into the bladder. A flexible scope can be inserted similarly to a Foley catheter, with active deflection being used as needed.

In men, the penis is placed on the maximal stretch to straighten the urethra. When a rigid scope is passed, the penis is grasped with 5 fingers of the surgeon’s non-dominant hand. When a flexible scope is passed, the penis is pinched between the third and fourth digits of the non-dominant hand, allowing the thumb and index finger to be free to help guide the scope into the urethra. The penis should be angled 45 to 90 degrees relative to the abdominal wall as the scope passes through the anterior urethra. Once beyond the membranous urethra, the scope is directed anteriorly to enter the bladder. This is accomplished with active upward flexion when using the flexible scope and by dropping the distal end of the scope toward the operative table when using a rigid scope.

The lower urinary tract is systematically evaluated as the scope is advanced, with maximal irrigation running. The penile and bulbar urethra should be evaluated for any sign of stricture. The patient should be encouraged to relax when the scope is advanced through the membranous urethra. Once the scope is in the prostatic urethra, the verumontanum and utricle can be identified posteriorly. The size of the prostatic lobe, length of the prostatic urethra and presence of a median lobe or bladder neck obstruction should be noted.

Upon entering the bladder, the mucosa should be carefully inspected. When using a rigid cystoscope, generally a 30-degree scope is used initially to inspect as much of the bladder as can be visualized. The floor and trigone of the bladder are initially inspected, with the identification of the ureteral orifices, noting their location and number. Efflux from each ureter should be observed for the presence of blood. The remainder of the bladder should be inspected for bladder stones, trabeculation, bladder diverticula, erythematous patches or papillary/sessile bladder lesions. The surgeon can visualize the lateral walls by rotating the cystoscope and keeping the camera orientation fixed. The dome and posterolateral walls of the bladder are inspected using a 70 or 120-degree lens on a rigid scope, or by retroflection on a flexible scope. Prior to removing the scope, the bladder should be drained.

How is a cystoscopy or ureteroscopy performed?

A urologist performs a cystoscopy or ureteroscopy during an office visit or in an outpatient center or a hospital. For some patients, the urologist will apply an anesthetic gel around the urethral opening or inject a local anesthetic into the urethra. Some patients may require sedation or general anesthesia. The urologist often gives patients sedatives and general anesthesia for a

  • ureteroscopy
  • cystoscopy with biopsy
  • cystoscopy to inject material into the wall of the urethra
  • cystoscopy to inject medication into the bladder

For sedation and general anesthesia, a nurse or technician places an intravenous (IV) needle in a vein in the arm or hand to give the medication. Sedation helps the patient relax and be comfortable. General anesthesia puts the patient into a deep sleep during the procedure. The medical staff will monitor the patient’s vital signs and try to make him or her as comfortable as possible. During both procedures, a woman will lie on her back with the knees up and spread apart. During a cystoscopy, a man can lie on his back or be in a sitting position.

After the anesthetic has taken effect, the urologist gently inserts the tip of the cystoscope or ureteroscope into the urethra and slowly glides it through the urethra and into the bladder. A sterile liquid—water or saltwater, called saline—flows through the cystoscope or ureteroscope to slowly fill the bladder and stretch it so the urologist has a better view of the bladder wall. As the bladder fills with liquid, the patient may feel some discomfort and the urge to urinate. The urologist may remove some of the liquid from the bladder during the procedure. As soon as the procedure is over, the urologist may remove the liquid from the bladder or the patient may empty the bladder.

For a cystoscopy, the urologist examines the lining of the urethra as he or she passes the cystoscope into the bladder. The urologist then examines the lining of the bladder. The urologist can insert small instruments through the cystoscope to treat problems in the urethra and bladder or perform a biopsy.

For a ureteroscopy, the urologist passes the ureteroscope through the bladder and into a ureter. The urologist then examines the lining of the ureter. He or she may pass the ureteroscope all the way up into the kidney. The urologist can insert small instruments through the ureteroscope to treat problems in the ureter or kidney or perform a biopsy.

When a urologist performs a cystoscopy or a ureteroscopy to make a diagnosis, both procedures—including preparation—take 15 to 30 minutes. The time may be longer if the urologist removes a stone in the bladder or a ureter or if he or she performs a biopsy.

What can a patient expect after a cystoscopy or ureteroscopy?

After a cystoscopy or ureteroscopy, a patient may

  • have a mild burning feeling when urinating
  • see small amounts of blood in the urine
  • have mild discomfort in the bladder area or kidney area when urinating
  • need to urinate more frequently or urgently

These problems should not last more than 24 hours. The patient should tell a health care provider right away if bleeding or pain is severe or if problems last more than a day.

The health care provider may recommend that the patient

  • drink 16 ounces of water each hour for 2 hours after the procedure
  • take a warm bath to relieve the burning feeling
  • hold a warm, damp washcloth over the urethral opening to relieve discomfort
  • take an over-the-counter pain reliever

The health care provider may prescribe an antibiotic to take for 1 or 2 days to prevent an infection. A patient should report any signs of infection—including severe pain, chills, or fever—right away to the health care provider.

Most patients go home the same day as the procedure. Recovery depends on the type of anesthesia. A patient who receives only a local anesthetic can go home immediately. A patient who receives general anesthesia may have to wait 1 to 4 hours before going home. A health care provider usually asks the patient to urinate before leaving. In some cases, the patient may need to stay overnight in the hospital. A health care provider will provide discharge instructions for rest, driving, and physical activities after the procedure.

What are the risks of cystoscopy and ureteroscopy?

The risks of cystoscopy and ureteroscopy include

  • UTIs
  • abnormal bleeding
  • abdominal pain
  • a burning feeling or pain during urination
  • injury to the urethra, bladder, or ureters
  • urethral narrowing due to scar tissue formation
  • the inability to urinate due to swelling of surrounding tissues
  • complications from anesthesia

References

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

Cystourethroscopy – Indications, Procedure, Result

Cystourethroscopy is one of the most common procedures performed by a urologic surgeon. It allows for direct visualization of the urethra, urethral sphincter, prostate, bladder, and ureteral orifices. There are various indications to perform a cystoscopy, and it can be performed as a simple office procedure or as a procedure in the operating room with the patient under general anesthesia. This activity describes the indications, contraindications of cystoscopy, and highlights the role of the interprofessional team in managing patients with urological problems.

Cystoscopy and ureteroscopy are common procedures performed by a urologist to look inside the urinary tract. A urologist is a doctor who specializes in urinary tract problems.

Cystoscopy – A cystoscopy uses a cystoscope to look inside the urethra and bladder. A cystoscope is a long, thin optical instrument with an eyepiece at one end, a rigid or flexible tube in the middle, and a tiny lens and light at the other end of the tube. By looking through the cystoscope, the urologist can see detailed images of the lining of the urethra and bladder. The urethra and bladder are part of the urinary tract.

Ureteroscopy – Ureteroscopy uses a ureteroscope to look inside the ureters and kidneys. Like a cystoscope, a ureteroscope has an eyepiece at one end, a rigid or flexible tube in the middle, and a tiny lens and light at the other end of the tube. However, a ureteroscope is longer and thinner than a cystoscope so the urologist can see detailed images of the lining of the ureters and kidneys. The ureters and kidneys are also part of the urinary tract.

What is the urinary tract and how does it work?

The urinary tract is the body’s drainage system for removing urine, which is composed of wastes and extra fluid. In order for normal urination to occur, all body parts in the urinary tract need to work together in the correct order.

  • Kidneys – The kidneys are two bean-shaped organs, each about the size of a fist. They are located just below the rib cage, one on each side of the spine. Every day, the kidneys filter about 120 to 150 quarts of blood to produce about 1 to 2 quarts of urine. The kidneys work around the clock; a person does not control what they do.
  • Ureters – Ureters are the thin tubes of muscle—one on each side of the bladder—that carry urine from each of the kidneys to the bladder.
  • Bladder – The bladder, located in the pelvis between the pelvic bones, is a hollow, muscular, balloon-shaped organ that expands as it fills with urine. Although a person does not control kidney function, a person does control when the bladder empties. Bladder emptying is known as urination. The bladder stores urine until the person finds an appropriate time and place to urinate. A normal bladder acts like a reservoir and can hold 1.5 to 2 cups of urine. How often a person needs to urinate depends on how quickly the kidneys produce the urine that fills the bladder. The muscles of the bladder wall remain relaxed while the bladder fills with urine. As the bladder fills to capacity, signals sent to the brain tell a person to find a toilet soon. During urination, the bladder empties through the urethra, located at the bottom of the bladder. Three sets of muscles work together like a dam, keeping urine in the bladder.

The first set is the muscles of the urethra itself. The area where the urethra joins the bladder is the bladder neck. The bladder neck, composed of the second set of muscles known as the internal sphincter, helps urine stay in the bladder. The third set of muscles in the pelvic floor muscles also referred to as the external sphincter, which surrounds and supports the urethra.

To urinate, the brain signals the muscular bladder wall to tighten, squeezing urine out of the bladder. At the same time, the brain signals the sphincters to relax. As the sphincters relax, urine exits the bladder through the urethra.

Why is a cystoscopy or ureteroscopy performed?

A urologist performs a cystoscopy or ureteroscopy to find the cause of, and sometimes treat, urinary tract problems.

Cystoscopy. A urologist performs a cystoscopy to find the cause of urinary tract problems such as

  • frequent urinary tract infections (UTIs)
  • hematuria—blood in the urine
  • urinary frequency—urination eight or more times a day
  • urinary urgency—the inability to delay urination
  • urinary retention—the inability to empty the bladder completely
  • urinary incontinence—the accidental loss of urine
  • pain or burning before, during, or after urination
  • trouble starting urination, completing urination, or both
  • abnormal cells, such as cancer cells, found in a urine sample

During a cystoscopy, a urologist can see

  • stones—solid pieces of material in the bladder that may have formed in the kidneys or in the bladder when substances that are normally in the urine become highly concentrated.
  • abnormal tissue, polyps, tumors, or cancer in the urethra or bladder.
  • stricture, a narrowing of the urethra. Stricture can be a sign of an enlarged prostate in men or of scar tissue in the urethra.

During a cystoscopy, a urologist can treat problems such as bleeding in the bladder and blockage in the urethra. A urologist may also use cystoscopy to

  • remove a stone in the bladder or urethra.
  • remove or treat abnormal tissue, polyps, and some types of tumors.
  • take small pieces of urethral or bladder tissue for examination with a microscope—a procedure called a biopsy.
  • inject material into the wall of the urethra to treat urinary leakage.
  • inject medication into the bladder to treat urinary leakage.
  • obtain urine samples from the ureters.
  • perform retrograde pyelography—an x-ray procedure in which a urologist injects a special dye, called contrast medium, into a ureter to the kidney to create images of urinary flow. The test can show causes of obstruction, such as kidney stones and tumors.
  • remove a stent that was placed in the ureter after a ureteroscopy with biopsy or stone removal. A stent is a small, soft tube.

Ureteroscopy. In addition to the causes of urinary tract problems he or she can find with a cystoscope, a urologist performs a ureteroscopy to find the cause of urine blockage in a ureter or to evaluate other abnormalities inside the ureters or kidneys.

During a ureteroscopy, a urologist can see

  • a stone in a ureter or kidney
  • abnormal tissue, polyps, tumors, or cancer in a ureter or in the lining of a kidney

During a ureteroscopy, a urologist can treat problems such as urine blockage in a ureter. The urologist can also

  • remove a stone from a ureter or kidney
  • remove or treat abnormal tissue, polyps, and some types of tumors
  • perform a biopsy of a ureter or kidney

After a ureteroscopy, the urologist may need to place a stent in a ureter to drain urine from the kidney to the bladder while swelling in the ureter goes away. The stent, which is completely inside the body, may cause some discomfort in the kidney or bladder area. The discomfort is generally mild. The stent may be left in the ureter for a few days to a week or more. The urologist may need to perform a cystoscopy to remove the stent in the ureter.

How does a patient prepare for a cystoscopy or ureteroscopy?

In many cases, a patient does not need special preparations for a cystoscopy. A health care provider may ask the patient to drink plenty of liquids before the procedure, as well as urinate immediately before the procedure.

The patient may need to give a urine sample to test for a UTI. If the patient has a UTI, the urologist may treat the infection with antibiotics before performing a cystoscopy or ureteroscopy. A health care provider will provide instructions before the cystoscopy or ureteroscopy. These instructions may include

  • when to stop certain medications, such as blood thinners
  • when to stop eating and drinking
  • when to empty the bladder before the procedure
  • arranging for a ride home after the procedure

The urologist will ask about the patient’s medical history, current prescription and over-the-counter medications, and allergies to medications, including anesthetics. The urologist will talk about which anesthetic is best for the procedure and explain what the patient can expect after the procedure.

Indications of Cystourethroscopy

There are many indications for office-based cystourethroscopy. Most office cystoscopy is performed for diagnostic purposes. One of the most common reasons for a patient to be referred to a urologist is the presence of hematuria, gross or microscopic. Gross hematuria is defined as blood in the urine that can be seen with the naked eye. Microscopic hematuria is defined as 3 or greater red blood cells per high-powered field. Another common indication for regular cystoscopy is any history of malignancy including urethral, bladder, or upper tract UCC. This is often done on a surveillance basis with intervals depending on the type of cancer. Lower urinary tract symptoms (LUTS) are another indication of cystourethroscopy. These symptoms can include obstructive voiding symptoms, irritative voiding symptoms, urinary incontinence, chronic pelvic pain syndrome, or recurrent UTIs. Any trauma in which there is a concern for injury to the lower urinary tract necessitates cystourethroscopy, as well as any bladder abnormalities discovered during imaging studies. Removal of foreign bodies, for example, if a patient has an indwelling urinary stent that requires removal, hematospermia, azoospermia, or concern for a bladder or lower urinary tract fistula are also reasons for cystourethroscopy.

Rigid cystoscopy in the operating room is indicated for more therapeutic indications. In this setting, it is possible to have fluoroscopy and perform retrograde pyelography. There is also the ability to use multiple additional instruments including resectoscopes to perform procedures such as transurethral resection of bladder tumors, transurethral resection of the prostate, direct vision internal urethrotomy, injection of Botox into the detrusor muscle, and numerous other interventions. Further discussion of these different procedures is beyond the scope of this article.

Indications include:

  • Hematuria, gross or microscopic
  • Surveillance/evaluation of malignancy (bladder, urethra, upper tract UCC, abnormal cytology)
  • Lower Urinary Tract Symptoms (LUTS): The irritative voiding symptoms, obstructive voiding symptoms, urinary incontinence, chronic pelvic pain syndrome, recurrent UTIs
  • Trauma, abnormal imaging of bladder, concern for fistula, removal of foreign body, hematospermia, azoospermia

Contraindications of Cystourethroscopy

Contraindications to cystoscopy are relatively straightforward. If there is any evidence of acute urinary infection, the procedure would be contraindicated as it could put the patient at risk for developing sepsis from a urinary source. For this reason, it is recommended to obtain a urinalysis 5 to 7 days before any scheduled cystoscopy procedure. If a UTI is identified, the patient should be treated appropriately prior to the procedure. A contraindication for flexible cystoscopy in the office would be any intolerance to pain or discomfort with the procedure. This may necessitate a trip to the operating room (OR) for cystoscopy under anesthesia. A urethral stricture can sometimes make cystoscopy impossible, as the scope will not be able to pass.

Equipment

Cystoscopes come in both flexible and rigid options. They are manufactured in a variety of sizes expressed in French (Fr) gauge. A 1 French instrument has a circumference of one-third of a millimeter. Rigid cystoscopes use the Hopkins rod-lens optical system which has the advantage of providing improved optical clarity when compared with the fiberoptic bundles used in flexible cystoscopes. However, this is becoming less noticeable with the adoption of flexible digital cystoscopes. Visualization is also enhanced in the rigid model due to the greater irrigant flow rate. Rigid scopes also have larger working channels which allow for a wider variety of instruments that can be used with them. The advantage of the flexible scopes is that they are smaller in size and provide greater patient comfort, which is why they are used for routine flexible cystourethroscopy in the office setting. The flexible endoscope can also be passed easily with a patient in the supine position; whereas, in rigid cystoscopy, the patient must be in the frog-leg or lithotomy position. Another excellent advantage is the movement of the tip of the flexible cystoscope which allows for easier inspection of the bladder and negotiating around an elevated bladder neck or large median lobe of the prostate. With a rigid cystoscope, it is necessary to use multiple lenses with varying degrees of angle to achieve proper inspection of the entire bladder.

Rigid Cystourethroscopy

Rigid cystoscopes are produced in sets that consist of an optical lens, bridge, sheath, and obturator. These configurations are different depending on the vendor. Vendors that produce these sets include Karl Storz, Olympus, Gyrus/ACMI, and Wolf.

The optical lenses come with tip angles that range from 0 to 120 degrees. The most common lens degrees used during a typical rigid cystourethroscopy include the 30-degree lens and the 70-degree lens. The urethra is best visualized using the 0 to 12-degree lens. A 30-degree lens is most often used for therapeutic purposes. The 70 or 120-degree lens are often required to inspect the anterior and inferolateral walls, dome, and neck of the bladder.

The bridge connects the optical lens to the sheath. There are varying types of bridges. A diagnostic bridge has no working channels. Bridges used for therapeutic cases can have 1 to 2 working channels. An Albarran bridge is a specialized bridge that contains a lever that can deflect wires and catheters that pass through the working channel to facilitate ureteral orifice cannulation. This can sometimes be required in patients that have elevated bladder necks or large median lobes of the prostate. It can also be helpful when attempting to cannulate a transplanted ureter or ureters entering the bladder at odd locations.

The cystourethroscopy sheaths come in a variety of sizes. Sheaths can range in size from 15/17 Fr to 25 Fr. Smaller sheaths are ideal for diagnostic cystoscopy and cause less trauma. Larger sheaths are used for therapeutic procedures as they allow more irrigant flow and larger working channels for instruments. Each sheath has an obturator that blunts the distal end of the sheath for passage into the bladder without visual assistance. Blind endoscope passage is generally only recommended to be performed in a female.

Flexible Cystourethroscopy

Flexible cystoscopes range between 16 and 17 Fr. There are differences in all models with regard to their dip deflection, the direction of view, the field of view, working channel size, illumination and optics. Vendors that manufacture these scopes include Karl Storz, Olympus, and Wolf. Most models provide a field of view of approximately 120 degrees and do not have an offset lens. Tip deflection ranges between 120 to 210 degrees and can either be intuitive (same direction as lever deflection) or counterintuitive (opposite direction of lever deflection). The irrigation and instruments have to pass through the same working channel. This necessitates discontinuing the irrigation to pass a flexible grasper through the scope, for example. However, adaptors have been developed to allow the irrigation to be connected while passing instruments. The amount of irrigation is significantly decreased with the instrument passing through the channel. Photodynamic and narrow-band imaging capabilities are available in some models.

Both Karl Storz and Olympus produce fiberoptic and digital models. Digital scopes are now available in high definition (1920 x 1080 pixels) and standard definition (720 x 480 pixels). These scopes do not require focusing or white balancing. Studies have been performed to compare the resolution, contrast evaluation, depth of field, color representation and illumination of fiberoptic, standard, and high-definition flexible cystoscopes. One study demonstrated that the high definition scope had significantly higher resolution and depth of field, with slightly improved color representation and no difference in contrast evaluation. Illumination was significantly better in the fiberoptic models when compared to digital. A randomized study performed by Okhunov et al. in 2009 compared optics, performance, and durability of fiberoptic and standard-definition digital scopes. This showed a trend of surgeon optical ranking in favor of digital scopes. There was no difference in durability between models.

Irrigant material depends on the situation, but sterile water or normal saline is most commonly used. Nonionic irrigants (water, glycine, sorbitol) are required when using monopolar electrocautery. Isotonic irrigating fluids (normal saline/lactated ringers) can be used when using bipolar electrocautery instruments. This offers the advantage of eliminating the risk of electrolyte disturbance from systemic uptakes, such as Transurethral Resection of the Prostate (TURP) syndrome. Sterile water should be used when bladder samples are collected for cytologic evaluation.

Personnel

The personnel required for cystoscopy depends on if it is being performed in the office or the operating room. A simple office cystoscopy requires minimal personnel as there is no anesthesia. It is beneficial to have a nurse as an assistant, especially if doing procedures that can be performed more smoothly with an extra set of hands. For example, if performing a cystoscopy to remove an indwelling ureteral stent, it can be beneficial for the surgeon to operate the cystoscope and have his/her assistant operate the flexible grasper. This is not necessary, however. When performing cystoscopy in the operating room, it is necessary to have anesthesia staff as well as circulating nurses and possibly scrub techs for assistance.

Preparation

Informed consent must be obtained before the procedure. A urinalysis and urine culture is commonly performed before cystoscopy. The AUA best practice policy statement on antimicrobial prophylaxis does not recommend antibiotic administration for routine diagnostic cystoscopy in the absence of patient-related risk factors. The risk factors that require antimicrobial prophylaxis include:

  • Advanced age
  • Anatomic anomalies of the urinary tract
  • Chronic corticosteroid use
  • Colonized endogenous or exogenous material
  • Distant coexistent infection
  • Immunodeficiency
  • Poor nutritional status
  • Prolonged coexistent infection
  • Smoking history

Prophylaxis lasting less than 24 hours with either a fluoroquinolone or trimethoprim-sulfamethoxazole is recommended for therapeutic procedures. Two-line alternatives include an aminoglycoside with or without ampicillin, a first or second-generation cephalosporin, or amoxicillin/clavulanate.

Prior to the procedure, the skin should be prepared with an antiseptic agent. Both chlorhexidine gluconate and alcohol-based solutions can be damaging to mucous membranes and are therefore not recommended for use on the genitalia. Aqueous-based iodophor-containing products such as Betadine are safe on all skin surfaces and are most commonly used for preparation.

After application of the antiseptic agent, a lubricating gel is injected into the urethra. A plain or lidocaine gel may be used. One meta-analysis of four randomized trials found that patients who received lidocaine gel were 1.7 times less likely to experience moderate to severe pain during the procedure.

Technique

Before inserting the cystourethroscopy, the external genitalia is inspected for any lesions or anatomic abnormalities. In women, rigid cystourethroscopy insertion can be implemented using a sheath obturator. The scope will need to be directed anteriorly as it is advanced into the bladder. A flexible scope can be inserted similarly to a Foley catheter, with active deflection being used as needed.

In men, the penis is placed on the maximal stretch to straighten the urethra. When a rigid scope is passed, the penis is grasped with 5 fingers of the surgeon’s non-dominant hand. When a flexible scope is passed, the penis is pinched between the third and fourth digits of the non-dominant hand, allowing the thumb and index finger to be free to help guide the scope into the urethra. The penis should be angled 45 to 90 degrees relative to the abdominal wall as the scope passes through the anterior urethra. Once beyond the membranous urethra, the scope is directed anteriorly to enter the bladder. This is accomplished with active upward flexion when using the flexible scope and by dropping the distal end of the scope toward the operative table when using a rigid scope.

The lower urinary tract is systematically evaluated as the scope is advanced, with maximal irrigation running. The penile and bulbar urethra should be evaluated for any sign of stricture. The patient should be encouraged to relax when the scope is advanced through the membranous urethra. Once the scope is in the prostatic urethra, the verumontanum and utricle can be identified posteriorly. The size of the prostatic lobe, length of the prostatic urethra and presence of a median lobe or bladder neck obstruction should be noted.

Upon entering the bladder, the mucosa should be carefully inspected. When using a rigid cystoscope, generally a 30-degree scope is used initially to inspect as much of the bladder as can be visualized. The floor and trigone of the bladder are initially inspected, with the identification of the ureteral orifices, noting their location and number. Efflux from each ureter should be observed for the presence of blood. The remainder of the bladder should be inspected for bladder stones, trabeculation, bladder diverticula, erythematous patches or papillary/sessile bladder lesions. The surgeon can visualize the lateral walls by rotating the cystoscope and keeping the camera orientation fixed. The dome and posterolateral walls of the bladder are inspected using a 70 or 120-degree lens on a rigid scope, or by retroflection on a flexible scope. Prior to removing the scope, the bladder should be drained.

How is a cystoscopy or ureteroscopy performed?

A urologist performs a cystoscopy or ureteroscopy during an office visit or in an outpatient center or a hospital. For some patients, the urologist will apply an anesthetic gel around the urethral opening or inject a local anesthetic into the urethra. Some patients may require sedation or general anesthesia. The urologist often gives patients sedatives and general anesthesia for a

  • ureteroscopy
  • cystoscopy with biopsy
  • cystoscopy to inject material into the wall of the urethra
  • cystoscopy to inject medication into the bladder

For sedation and general anesthesia, a nurse or technician places an intravenous (IV) needle in a vein in the arm or hand to give the medication. Sedation helps the patient relax and be comfortable. General anesthesia puts the patient into a deep sleep during the procedure. The medical staff will monitor the patient’s vital signs and try to make him or her as comfortable as possible. During both procedures, a woman will lie on her back with the knees up and spread apart. During a cystoscopy, a man can lie on his back or be in a sitting position.

After the anesthetic has taken effect, the urologist gently inserts the tip of the cystoscope or ureteroscope into the urethra and slowly glides it through the urethra and into the bladder. A sterile liquid—water or saltwater, called saline—flows through the cystoscope or ureteroscope to slowly fill the bladder and stretch it so the urologist has a better view of the bladder wall. As the bladder fills with liquid, the patient may feel some discomfort and the urge to urinate. The urologist may remove some of the liquid from the bladder during the procedure. As soon as the procedure is over, the urologist may remove the liquid from the bladder or the patient may empty the bladder.

For a cystoscopy, the urologist examines the lining of the urethra as he or she passes the cystoscope into the bladder. The urologist then examines the lining of the bladder. The urologist can insert small instruments through the cystoscope to treat problems in the urethra and bladder or perform a biopsy.

For a ureteroscopy, the urologist passes the ureteroscope through the bladder and into a ureter. The urologist then examines the lining of the ureter. He or she may pass the ureteroscope all the way up into the kidney. The urologist can insert small instruments through the ureteroscope to treat problems in the ureter or kidney or perform a biopsy.

When a urologist performs a cystoscopy or a ureteroscopy to make a diagnosis, both procedures—including preparation—take 15 to 30 minutes. The time may be longer if the urologist removes a stone in the bladder or a ureter or if he or she performs a biopsy.

What can a patient expect after a cystoscopy or ureteroscopy?

After a cystoscopy or ureteroscopy, a patient may

  • have a mild burning feeling when urinating
  • see small amounts of blood in the urine
  • have mild discomfort in the bladder area or kidney area when urinating
  • need to urinate more frequently or urgently

These problems should not last more than 24 hours. The patient should tell a health care provider right away if bleeding or pain is severe or if problems last more than a day.

The health care provider may recommend that the patient

  • drink 16 ounces of water each hour for 2 hours after the procedure
  • take a warm bath to relieve the burning feeling
  • hold a warm, damp washcloth over the urethral opening to relieve discomfort
  • take an over-the-counter pain reliever

The health care provider may prescribe an antibiotic to take for 1 or 2 days to prevent an infection. A patient should report any signs of infection—including severe pain, chills, or fever—right away to the health care provider.

Most patients go home the same day as the procedure. Recovery depends on the type of anesthesia. A patient who receives only a local anesthetic can go home immediately. A patient who receives general anesthesia may have to wait 1 to 4 hours before going home. A health care provider usually asks the patient to urinate before leaving. In some cases, the patient may need to stay overnight in the hospital. A health care provider will provide discharge instructions for rest, driving, and physical activities after the procedure.

What are the risks of cystoscopy and ureteroscopy?

The risks of cystoscopy and ureteroscopy include

  • UTIs
  • abnormal bleeding
  • abdominal pain
  • a burning feeling or pain during urination
  • injury to the urethra, bladder, or ureters
  • urethral narrowing due to scar tissue formation
  • the inability to urinate due to swelling of surrounding tissues
  • complications from anesthesia

References

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

Urodynamic Testing – Indications, Procedure, Result

Urodynamic testing is any procedure that looks at how well the bladder, sphincters, and urethra are storing and releasing urine. Most urodynamic tests focus on the bladder’s ability to hold urine and empty it steadily and completely. Urodynamic tests can also show whether the bladder is having involuntary contractions that cause urine leakage. A health care provider may recommend urodynamic tests if symptoms suggest problems with the lower urinary tract. Lower urinary tract symptoms (LUTS) include

Urodynamic tests range from simple observation to precise measurements using sophisticated instruments. For simple observation, a health care provider may record

  • the length of time it takes a person to produce a urinary stream
  • the volume of urine produced
  • ability or inability to stop the urine flow in midstream

For precise measurements, imaging equipment takes pictures of the bladder filling and emptying, pressure monitors record the pressures inside the bladder, and sensors record muscle and nerve activity. The health care provider will decide the type of urodynamic test based on the person’s health information, physical exam, and LUTS. The urodynamic test results help diagnose the cause and nature of a lower urinary tract problem.

Most urodynamic tests do not involve special preparations, though some tests may require a person to make a change in fluid intake or to stop taking certain medications. Depending on the test, a person may be instructed to arrive for testing with a full bladder.

What are the urodynamic tests?

Urodynamic tests include

  • uroflowmetry
  • postvoid residual measurement
  • cystometric test
  • leak point pressure measurement
  • pressure-flow study
  • electromyography
  • video urodynamic tests

Uroflowmetry

Uroflowmetry is the measurement of urine speed and volume. Special equipment automatically measures the amount of urine and the flow rate—how fast the urine comes out. Uroflowmetry equipment includes a device for catching and measuring urine and a computer to record the data. During a uroflowmetry test, the person urinates privately into a special toilet or funnel that has a container for collecting the urine and a scale. The equipment creates a graph that shows changes in flow rate from second to second so the health care provider can see when the flow rate is the highest and how many seconds it takes to get there. Results of this test will be abnormal if the bladder muscles are weak or urine flow is blocked. Another approach to measuring flow rate is to record the time it takes to urinate into a special container that accurately measures the volume of urine. Uroflowmetry measurements are performed in a health care provider’s office; no anesthesia is needed.

Postvoid Residual Measurement

This urodynamic test measures the amount of urine left in the bladder after urination. The remaining urine is called the postvoid residual. Postvoid residual can be measured with ultrasound equipment that uses harmless sound waves to create a picture of the bladder. Bladder ultrasounds are performed in a health care provider’s office, radiology center, or hospital by a specially trained technician and interpreted by a doctor, usually a radiologist. Anesthesia is not needed. Postvoid residual can also be measured using a catheter—a thin flexible tube. A health care provider inserts the catheter through the urethra up into the bladder to remove and measure the amount of remaining urine. A postvoid residual of 100 milliliters or more is a sign that the bladder is not emptying completely. Catheter measurements are performed in a health care provider’s office, clinic, or hospital with local anesthesia.

Cystometric Test

A cystometric test measures how much urine the bladder can hold, how much pressure builds up inside the bladder as it stores urine, and how full it is when the urge to urinate begins. A catheter is used to empty the bladder completely. Then a special, smaller catheter is placed in the bladder. This catheter has a pressure-measuring device called a manometer. Another catheter may be placed in the rectum to record pressure there.

Once the bladder is emptied completely, the bladder is filled slowly with warm water. During this time, the person is asked to describe how the bladder feels and indicate when the need to urinate arises. When the urge to urinate occurs, the volume of water and the bladder pressure are recorded. The person may be asked to cough or strain during this procedure to see if the bladder pressure changes. A cystometric test can also identify involuntary bladder contractions. Cystometric tests are performed in a health care provider’s office, clinic, or hospital with local anesthesia.

Leak Point Pressure Measurement

This urodynamic test measures pressure at the point of leakage during a cystometric test. While the bladder is being filled for the cystometric test, it may suddenly contract and squeeze some water out without warning. The manometer measures the pressure inside the bladder when this leakage occurs. This reading may provide information about the kind of bladder problem that exists. The person may be asked to apply abdominal pressure to the bladder by coughing, shifting position, or trying to exhale while holding the nose and mouth. These actions help the health care provider evaluate the sphincters.

Pressure Flow Study

A pressure flow study measures the bladder pressure required to urinate and the flow rate a given pressure generates. After the cystometric test, the person empties the bladder, during which time a manometer is used to measure bladder pressure and flow rate. This pressure flow study helps identify bladder outlet blockage that men may experience with prostate enlargement. Bladder outlet blockage is less common in women but can occur with a cystocele or, rarely, after a surgical procedure for urinary incontinence. Pressure flow studies are performed in a health care provider’s office, clinic, or hospital with local anesthesia.

Electromyography

Electromyography uses special sensors to measure the electrical activity of the muscles and nerves in and around the bladder and the sphincters. If the health care provider thinks the urinary problem is related to nerve or muscle damage, the person may be given an electromyography. The sensors are placed on the skin near the urethra and rectum or on a urethral or rectal catheter. Muscle and nerve activity is recorded on a machine. The patterns of the nerve impulses show whether the messages sent to the bladder and sphincters are coordinated correctly. Electromyography is performed by a specially trained technician in a health care provider’s office, outpatient clinic, or hospital. Anesthesia is not needed if sensors are placed on the skin. Local anesthesia is needed if sensors are placed on a urethral or rectal catheter.

Video Urodynamic Tests

Video urodynamic tests take pictures and videos of the bladder during filling and emptying. The imaging equipment may use x-rays or ultrasound. If x-ray equipment is used, the bladder will be filled with a special fluid, called contrast medium, that shows up on x-rays. X-rays are performed by an x-ray technician in a health care provider’s office, outpatient facility, or hospital; anesthesia is not needed. If ultrasound equipment is used, the bladder is filled with warm water and harmless sound waves are used to create a picture of the bladder. The pictures and videos show the size and shape of the bladder and help the health care provider understand the problem. Bladder ultrasounds are performed in a health care provider’s office, radiology center, or hospital by a specially trained technician and interpreted by a doctor, usually a radiologist. Although anesthesia is not needed for the ultrasound, local anesthesia is needed to insert the catheter to fill the bladder.

Procedures

The indication for performing urodynamics should be discussed with the patient before arranging the test along with a written information leaflet. This approach assists in understanding and promotes cooperation, though studies have shown that it may not necessarily improve overall patient satisfaction. The patient should arrive with a comfortably full bladder on the day of the procedure to allow for the performing of uroflowmetry at the beginning of the assessment.

Before the procedure, the clinician should review all relevant clinical information. Appropriate contemporaneous consent should be gained and documented where necessary. Patient allergies should be reviewed, following the standard World Health Organization surgical checklist protocols. Adequate counseling regarding the relevant risks of the procedure is essential. These include dysuria, haematuria, urinary tract infection, failure to catheterize, urinary retention, failure to reproduce symptoms, and failure to arrive at a urodynamic diagnosis.

A uroflowmetry is the initial step, followed by the measurement of post micturition residual volume using transabdominal ultrasound or urinary catheter.

During urodynamics, the pressure measurement is by using transducers, and the bladder is filled with a pump. A computer screen displays live pressure traces and infuse volume.

Both fluid-filled and air-charged urodynamic catheters exist; however, the ICS has set standardized pressures based on fluid-filled catheters. The pressures measured by the two catheter systems are not interchangeable. The air-charged catheters can transmit rapid changes in pressure less effectively, for example, during a cough. The fluid-filled system is primed with fluid to flush away any air from the lines; this ensures a continuous column of fluid between the patient and the transducer. By convention, the zero point of the transducer is leveled at the superior border of the patient’s symphysis pubis and set to atmospheric pressure. Therefore when the system is closed to the atmosphere and open to the patient, any increase in pressure is representative of an increase in pressure in the relative body cavity.

The patient is placed supine, and a multi-lumen urodynamic catheter is inserted into the bladder. This specialist catheter is usually 6-7Fr and made of polyvinyl chloride or polyurethane. It has multiple lumens for concurrent pressure monitoring and fluid infusion simultaneously. The catheter is introduced into the bladder with an aseptic technique using local anesthetic lubricant gel. A second catheter is introduced into the rectum or vagina to measure abdominal pressure. Other cavities such as an intestinal stoma and stomach are also options. These catheters and taped to the patient to avoid their inadvertent movement and expulsion.

The transducers for the fluid-filled system are external and adjusted to the height of the superior border of the symphysis pubis, the approximate anatomical level of the base of the bladder. It is set to this level to avoid artifacts occurring due to hydrostatic pressure effects. If the patient changes position during the urodynamic test, the height of the transducer should be adjusted accordingly. In the case of air-charged catheters, the transducers are placed at the tip of the catheter and lie within the body cavity.

The vesical pressure at the beginning of the test should be zero or close to zero. A cough test is performed, and pressure change should reflect on both vesical and abdominal pressure traces. The peaks should be roughly equal in amplitude. If one peak is less than 70% of the other, the line with the lesser peak should be flushed with fluid and cough test repeated until similar pressure amplitudes are measured.

The filling phase occurs with the infusion of warmed sterile water or physiological saline. Filling rates can either be physiological or nonphysiological. The maximum physiological filling rate is estimated to be roughly a quarter of body mass (kg) in ml/min, usually between 20 to 30 ml/min, which should be the standard filling rate. A nonphysiological filling rate is any filling rate higher than the maximum physiological filling rate. A balance is necessary between a filling rate, which is physiological enough to reproduce the patient’s symptoms, and a rate fast enough to complete the test promptly. In such circumstances, a rate in ml/min of 10% of the largest voided volume recorded on the bladder diary can be used, but should not exceed 50 ml/min. The patient should be in a position for filling that most accurately reflects their normal physiology to reproduce their symptoms. The three traces displayed on the screen indicate the abdominal pressure, vesical pressure, and the calculated detrusor pressure. If the patient is independently mobile, then this should occur while standing, as this can increase the chance of detection of detrusor overactivity by 21%.

During cystometry, the pressure trace should be marked with annotations of the patient’s subjective sensations. These markers should signify the patient’s ‘first sensation of filling,’ ‘first desire to void,’ and ‘strong desire to void.’ The patient may be asked to cough, strain, or perform other stressing actions (crouching, exercises), to reproduce any of their usual incontinence symptoms. Regular cough tests at intervals of one minute or every 50 ml of infusate assure that the maintenance of the quality of pressure transmission throughout the test. Cystometry also measures bladder volume and bladder compliance.

A “permission to void” command follows after stopping the infusion pump. A pressure flow study is the next step, with the observation of pressures during uroflowmetry for the voided volume.

Indications

The American Urological Association (AUA) in collaboration with the Society for Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU) summarises the main indications for performing urodynamic studies into 5 categories :

  • Identifying LUT dysfunction
  • Predicting the consequences of LUT dysfunction on the upper urinary tract
  • Predicting outcomes of management
  • Assessing the outcomes of an intervention
  • Assessing treatment failure

Standard urodynamic testing is useful where there is an unclear diagnosis if surgical interventions are a consideration, in the presence of multiple coexisting pathologies and a decision is necessary regarding which symptoms to manage first, or in patients with complex urological/anatomical issues. Urodynamics aims to evaluate the nature and cause of a patient’s symptoms and uses the assessment to replicate them, enabling symptomatology to be correlated with urodynamic measurements to aid diagnosis and treatment.

Potential Diagnosis

Female

Incontinence

1. Detrusor overactivity (DO): Detrusor overactivity is characterized by involuntary contractions of the bladder detrusor muscle during bladder filling, which may be provoked or unprovoked. It shows on urodynamic traces as an increase in vesical pressure along with a corresponding increase in the detrusor pressure trace. When DO is present following a cough, it is termed cough-induced DO. DO can be classified as idiopathic (with no defined cause), or neurogenic (related to an underlying neurological pathology). DO does not always cause incontinence and should be correlated with the patient’s symptoms, which may range from urinary frequency/urgency to UUI. Studies have shown that up to 70% of female patients who experience UUI will have DO. DO can have the following patterns observed during urodynamics:

  • Phasic DO: intermittent DO, which occurs during filling, does not necessarily cause incontinence.
  • Terminal DO: DO occurring near-maximum bladder capacity, usually results in incontinence.
  • Compound DO: phasic DO, with an increase in detrusor and baseline detrusor pressure with each contraction during filling.; it occurs relative to underlying neurological disease.
  • High and sustained DO involves continuous detrusor contractions, with detrusor pressure not returning to baseline.
  • Post micturition DO: DO occurs after voiding, usually in the presence of detrusor and/or urethral instability.

2. Stress urinary incontinence (SUI): SUI is diagnosed with urodynamics with involuntary leakage seen as a result of an increase in abdominal pressure without detrusor contraction. SUI arises due to 2 underlying mechanisms; bladder neck/urethral hypermobility and intrinsic sphincter deficiency (ISD). The resting urethral pressure profile measurement is low in intrinsic sphincter deficiency. These mechanisms can be further classified during video urodynamics into SUI types 1-3, with hypermobility contributing to types 1 and 2, and ISD causing type 3. SUI types:

  • Bladder neck descent <2 cm below the inferior border of the pubic symphysis with the bladder neck is closed at rest.
  • Rotational descent/cystocele and the bladder neck closed at rest 
  • Normal bladder position with the bladder neck open at rest and weak urethral closure 
  • Mixed urinary incontinence (MUI): MUI is incontinence resulting from the co-existence of both DO and SUI. The advice is to treat the most bothersome cause of symptoms first.

Bladder Outlet Obstruction (BOO)

BOO may occur as a result of anatomical obstruction, such as stricture, previous incontinence surgery, cystocele, urethral diverticulum, or as a result of functional sphincteric obstruction due to high-tone non-relaxing sphincter.

Detrusor underactivity (DU)

DU is a lack of adequate detrusor pressure or short contraction time, leading to poor bladder emptying, often in the presence of a high PVR. The etiology may be idiopathic, neurogenic, myogenic, or pharmacologic. In 23% of women, DU is the cause of LUTS.

Male

Incontinence

  • Detrusor overactivity (DO): The above characteristics of DO also apply in men. However, the cause of DO in men is known to be associated with benign prostatic obstruction, as well as other causes of BOO. DO is present in 60 to 80% of men with LUTS, and in up to 93% of men with UUI. Other causes for UUI in men include neurological conditions, bladder inflammation, old age, psychosocial stressors, and idiopathic.
  • SUI: The most prevalent cause of SUI in adult men is radical prostatectomy (RP). Post-operative incontinence rates are generally quoted at <10% but can be as high as 74%. The cause is most commonly due to post-operative ISD, but may also be contributed by DO. Other causes of male SUI include previous transurethral resection of the prostate, previous pelvic trauma or pelvic surgery, and neuromuscular disorders resulting in either pudendal nerve or urethral sphincter dysfunction.
  • MUI: Incontinence due to DO as well as SUI.

Bladder Outlet Obstruction

Male BOO is defined as an abnormally poor urinary flow with increased detrusor pressures seen on the pressure-flow study. The ICS nomogram is useful to diagnose BOO, and the bladder outlet obstruction index (BOOI) classifies men into unobstructed (BOOI <20), equivocal (BOOI of 20 to 40), and obstructed (BOOI >40). High PVR volumes are not part of diagnostic criteria but are a common sequela of BOO. BOO may arise as a consequence of anatomical obstruction, such as benign prostatic obstruction, bladder neck stenosis, urethral stricture, meatal stenosis, or as a result of functional obstruction such as bladder neck obstruction, sphincter dysfunction, or pelvic floor overactivity.

Detrusor underactivity

The urodynamic criteria to diagnose  DU in men include a  bladder contractility index (BCI) <100, bladder voiding efficiency (BVE) of <90%, and bladder outlet obstruction index (BOOI) <20. Up to 40% of men with LUTS will have underlying DU.

Loss of Compliance

Compliance is the measure of bladder distensibility. Normally, the bladder stores urine under low pressure; however, a pathological bladder with low compliance will exhibit high-pressure storage, with potential pressure transmission to upper urinary tracts leading to impairment of renal function. Compliance is calculated by dividing the change in bladder volume by the change in bladder pressure and is expressed in ml/cm H2O. The beginning and endpoints used for calculating pressure change is the detrusor pressure at the start of filling (0 cmH20), and the detrusor pressure at cystometric capacity.  There is insufficient data to precisely define the cut-off values between normal or abnormal compliance, but values in the range 12.5 to 30 ml/cm H2O have been suggested as the lower limit of normal.

Functional BOO

Detrusor sphincter dyssynergia (DSD) is characterized by disordered involuntary contraction of the external urethral sphincter and detrusor muscle. Normally, the external sphincter relaxes during detrusor contraction to facilitate voiding. Such incoordination arises with neurological pathologies. Up to 95% of patients with spinal cord injury will have DO and DSD (dependent on the level of injury).

DU occurs in up to 83% of spinal cord injury patients and up to 25% in patients with multiple sclerosis.

Normal and Critical Findings

General

Uroflowmetry assesses flow pattern, flow curve shape, maximum urinary flow (Qmax), voided volume (VV), voiding time (VT), PVR volume (PVR). A minimum of 150ml is required to provide an accurate assessment in men .

The normal abdominal and vesical resting pressures are as follows :

  • Supine: 0 to 18 cm H2O
  • Sitting: 15 to 40 cm H2O
  • Standing: 20 to 50 cm H2O

The detrusor pressure (Pdet) is calculated by subtracting abdominal pressure (Pabd) from vesical pressure (Pves). Pdet = Pves – Pabd .

Resting detrusor pressure: between -5 and +5 cm H2O 

The detrusor pressure reached during maximum urinary flow (PdetQmax) is a crucial measurement in the assessment of bladder function during pressure-flow studies.

Bladder compliance (C) is the change of bladder volume (ΔV) divided by the change in detrusor pressure (ΔPdet) during filling cystometry. C = ΔV / ΔPdet. 

  • Non-neurogenic bladders 

    • Normal compliance: >40 ml/cm H20
    • Low compliance: <30 ml/cm H2O
  • Neurogenic bladders 

    • Normal compliance: >30 ml/cm H2O
    • Low compliance: <10 ml/cm H2O

Straining can be seen in the form of temporary increases in vesical and abdominal pressure, lasting more than 2 seconds, usually in response to anatomical or function BOO.

Female

Bladder capacity: 300 to 500 ml.

Flow rate:

  • 14 to 45 years: 18mL/s
  • 46 to 65 years: 15mL/s

Abdominal leak point pressure (ALPP) : A test performed with the cooperation of the patient to intentionally increase abdominal pressure to provoke urinary leakage in the absence of a detrusor contraction. This provocation can be in the form of a cough (CLPP) or a Valsalva maneuver (VLPP).

Valsalva leak point pressure (VLPP) :

  • <60 cm H2O: ISD
  • 60 to 90 cm H2O: equivocal
  • >90 cm H2O: urethral hypermobility

Maximum urethral closure pressure (MUCP) : MUCP is the maximum difference between urethral pressure and intravesical pressure measured during urethral closure pressure profile (UCPP) in urethral pressure profilometry (UPP):

  • <20 cm H2O: suggests ISD

Bladder outlet obstruction index for female (BOOIf): BOOIf = PdetQmax – 2.2 * Qmax 

  • <0: <10% probability of BOO
  • >5: 50% probability of BOO
  • >18: >90% probability of BOO

Male

Bladder capacity: 300 to 600 ml 

Flow rate:

  • 14 to 45 years: 21mL/s
  • 46 to 65 years: 12mL/s

Qmax in men :

  • <10 ml/s: likely obstructed
  • 10 to 15 ml/s: equivocal
  • >15 ml/s: likely unobstructed

Bladder outlet obstruction index (BOOI) for male: BOOI = PdetQmax – 2 * Qmax 

  • <20: Unobstructed
  • 20 to 40: Equivocal
  • >40: Obstructed

Bladder contractility index (BCI): BCI = PdetQmax + 5 * Qmax 

  • >150: Strong
  • 100 to 150: Normal
  • <100: Weak

Bladder voiding efficiency (BVE): BE = VV / (VV+PVR) * 100% 

  • 100%: Normal
  • <90%: indicative of DU
  • >90%: indicative of BOO

Interfering Factors

Pressure Transmission and Quality Control

Pressure transmission assessment is via cough signal, live signal, and baseline resting pressures.

A cough signal should show as similar peaks in amplitude in both the abdominal and vesical pressure traces. A cough should have a peak height of at least 15 cm H2O above resting pressure. There should be minimal change in detrusor pressure seen on a cough. However, in reality, a small biphasic signal may be seen reflecting the cough signal. If one peak is less than 70% of the other, the line with the lesser peak can be flushed with fluid, and the cough test repeated. If the issue persists, then assess the affected catheter.

A live signal should detect small physiological fluctuations up to 10 cm H20 and should never be a constant flat trace . A good quality pressure reading should have these fluctuations mirrored between in the vesical and abdominal traces, causing a net detrusor pressure of close to 0. If such a live signal is not detected, the system should be examined.

Initial resting pressure is the pressure recorded at the beginning of the test. Detrusor pressure should be 0 or close to 0 cm H2O at the beginning of bladder filling.

Normal ranges of vesical and abdominal pressures if appropriate calibration and quality control have been performed :

  • Supine: 0 to 18 cm H2O
  • Seated: 15 to 40 cm H2O
  • Standing: 20 to 50 cm H2O

If initial resting pressures are outside of the above plausible ranges, then quality control measures should be repeated. These measures would include zeroing transducer to atmospheric pressure, positioning transducer to level of the superior border of the symphysis pubis, and flushing the lines.

Other causes of poor signal or lack of pressure transmission include air in the line (line should be flushed), tap not open, kinking of the catheter or tubes, catheter resting on bladder wall causing inappropriate pressure transmission, or catheter displaced into the urethra. Such issues are easily rectifiable when identified.

Position Change

If the patient changes position, this reflects in pressure changes of equal magnitude in both vesical and abdominal pressure. This change in resting pressure is usually between 8 and 30 cm H2O. The transducer height should be adjusted to the level of the superior border of the symphysis pubis to compensate for this.

Rectal Contractions

Spasms or contractions of the rectum will present as low amplitude temporary pressure changes, which cause equal and opposite detrusor pressure changes. There is no concurrent change in the vesical pressure; this is important to distinguish from DO, where a pressure increase is mirrored between the vesical and detrusor traces. No remedial action is required other than recognition of the fact.

Rapid Filling

If the filling is too rapid, it may give a false-positive diagnosis of loss of compliance. The filling should be according to maximum physiological rate (approximately 25% of body mass (kg) in ml/min) or a nonphysiological filling rate of 10% of the largest voided volume recorded on the bladder diary while not exceeding 50 ml/min.

Situational Inability to Void 

The patient’s ability to void is affected by emotional and psychological circumstances. Therefore an environment that replicates their normal voiding as closely as possible should be created with privacy and dignity maintained where possible .

Pump Vibrations

Vibrations from the infusion pump can transmit and detected along a pressure monitoring tube, seen as constant frequency oscillations of small amplitude, usually <4 cm H2O, in the affected pressure line, and reflected in the detrusor pressure trace. Lines should be disentangled so as not to touch each other and prevent artifactual pressure transmission. In double lumen catheters, pressures should be recorded with the pump switched off.

Tube Knock

A sharp and short increase in pressure traces of one or more lines is demonstrated when moving the affected tube. Movements can lead to errors in pressure transmission. A cough test should be repeated following any movements to ensure quality control.

What happens after urodynamic tests?

After having urodynamic tests, a person may feel mild discomfort for a few hours when urinating. Drinking an 8-ounce glass of water every half-hour for 2 hours may help to reduce the discomfort. The health care provider may recommend taking a warm bath or holding a warm, damp washcloth over the urethral opening to relieve the discomfort.

An antibiotic may be prescribed for 1 or 2 days to prevent infection, but not always. People with signs of infection—including pain, chills, or fever—should call their health care provider immediately.

Complications

Risks of invasive urodynamic testing include :

  • Dysuria
  • Hematuria
  • Urinary tract infection
  • Urinary retention
  • Inability to catheterize the bladder
  • Failure of diagnosis

Prophylactic antibiotics reduce the risk of bacteriuria following urodynamic testing, but there is insufficient evidence to suggest it reduces rates of symptomatic urinary tract infections. Therefore current advice is against giving prophylactic antibiotics for invasive urodynamic testing in all patients.

AUA/SUFU recommends antibiotic prophylaxis in the following patients undergoing urodynamic testing due to their higher risk of developing peri-procedural urinary tract infections :

  • Known neurogenic LUT dysfunction
  • Elevated PVR
  • Asymptomatic bacteriuria
  • Immunosuppression
  • Age over 70
  • Patients with an indwelling catheter or external urinary collection device
  • Patients who perform intermittent catheterization

Patient Safety and Education

Prior to invasive urodynamic testing, patients should receive clear and concise written information to enable understanding and cooperation. It should be made clear to patients before testing that urodynamics is a diagnostic procedure, that there is a possibility of failure to progress diagnosis, and that it is not a therapeutic procedure.

Urodynamics are generally well tolerated by patients. Embarrassment can be a significant cause of apprehension. Efforts should, therefore, focus on creating a relaxed atmosphere through informed and effective communication.

The only absolute contraindication for urodynamics is the presence of a urinary tract infection. In such cases, urodynamics should be postponed until this is treated.

Relative contraindications for urodynamics include patient inability to comply with instructions or communicate sensations, inability to catheterize bladder, medications for bladder dysfunction (which can be stopped 48 hours before testing), indwelling catheter, and autonomic dysreflexia.

Autonomic dysreflexia (AD) is a potentially life-threatening condition that arises in patients with spinal cord injury (SCI), particularly in those with an injury above the level of T6. AD is more prevalent in spinal injuries at the cervical level compared to the thoracic level. It is a condition that all clinicians who perform urodynamics must promptly recognize and aggressively treat. It happens as a result of an uncoordinated autonomic response triggered by an offending stimulus, most commonly bladder or bowel distension, which causes subsequent hypertension and reflex bradycardia and can occur during the filling cystometry of urodynamics and necessitates urgent recognition with immediate management.

Patients most commonly describing headache, discomfort, nausea, anxiety, blurred vision, and pain. Physical examination may reveal a significantly elevated systolic blood pressure, bradycardia, spasticity, flushing, or sweating above the level of the lesion and piloerection below the level of the lesion. Uncontrolled hypertension can lead to catastrophic outcomes such as cerebrovascular accidents, intracranial hemorrhage, and even death. AD arising from urodynamics is most likely the result of bladder distension; therefore, this stimulus requires immediate reversal and rapid draining of the bladder. If AD persists, then medical therapy in the form of immediate-release antihypertensive medication should be administered; this can be in the form of sublingual glyceryl trinitrate spray or ‘bite and release’ nifedipine.

Main Points

  • Urodynamics with pressure flow studies remains the gold standard for diagnosing bladder outlet obstruction (BOO) and other voiding and storage abnormalities responsible for lower urinary tract symptoms (LUTS) and voiding dysfunction. Urodynamic studies are most useful when their results will affect treatment and therefore should be used judiciously.
  • Simultaneously measuring detrusor pressure and urinary flow rate during voluntary voiding is the best way currently available to access 2 critical parameters of bladder and outlet function: detrusor contractility (normal vs impaired) and outlet resistance (obstructed vs unobstructed).
  • Noninvasive techniques that measure bladder pressure involve the measurement of isovolumetric bladder pressure combined with a free flow rate to diagnose obstruction. Although there are downsides to noninvasive techniques, including the lack of abdominal pressure monitoring and assessment of the storage phase, they hold promise and may offer an additional diagnostic test for the assessment of men with LUTS.
  • Definitions and nomograms used to describe BOO in men do not apply to women, and there is great interest in defining BOO in women. The causes of obstruction in women can vary greatly from anatomic (pelvic prolapse, pelvic masses) to functional (dysfunctional voiding, primary bladder neck obstruction) without one predominant diagnosis.
  • Although pressure-flow analysis for BOO in women is not yet as standardized as it is in men, the concept of relatively high pressure and relatively low flow when compared to normals as a measure of obstruction prevails. Future studies will help standardize the diagnosis of obstruction in women.

References

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

Chronic Bacterial Prostatitis – Causes, Symptoms, Treatment

Chronic Bacterial Prostatitis /Prostatitis is inflammation or swelling of the prostate gland. When symptoms start gradually and linger for more than a couple of weeks, the condition is called chronic prostatitis. The prostate is a walnut-shaped gland that is part of the male reproductive system. The main function of the prostate is to make a fluid that goes into semen. Prostate fluid is essential for a man’s fertility. The gland surrounds the urethra at the neck of the bladder. The bladder neck is the area where the urethra joins the bladder. The bladder and urethra are parts of the lower urinary tract. The prostate has two or more lobes, or sections, enclosed by an outer layer of tissue, and it is in front of the rectum, just below the bladder. The urethra is the tube that carries urine from the bladder to the outside of the body. In men, the urethra also carries semen out through the penis

Types of Prostatitis

Scientists have identified four types of prostatitis

  • Chronic prostatitis or chronic pelvic pain syndrome
  • Acute bacterial prostatitis
  • Chronic bacterial prostatitis
  • Asymptomatic inflammatory prostatitis

Prostatitis can be an acute illness or a chronic condition, The NIH consensus definition and classification of prostatitis is

Prostatitis is classified into four categories, each with its own treatment approach

  • Acute infection of the prostate – This sudden-onset infection is caused by bacteria that travel from the urethra, and perhaps from the rectum to the prostate. It’s the least common but most dramatic form of prostatitis, beginning abruptly with high fever, chills, joint and muscle aches, and profound fatigue. In addition, you may have pain around the base of the penis and behind the scrotum, pain in the lower back, and the feeling of a full rectum. As the prostate becomes more swollen, you may find it more difficult to urinate, and the urine stream may become weak. (If you can’t urinate at all, it’s a medical emergency; this usually means the prostate is so swollen that it’s completely blocking urine flow. Depending on the severity of symptoms, hospitalization may be necessary.)
  • Chronic bacterial prostatitis – This type of prostatitis is also caused by bacteria. It’s more common in older men who have BPH. It sometimes follows a bout of acute bacterial prostatitis. Unlike the acute form, however, chronic bacterial prostatitis is a subtle, low-grade infection that can begin insidiously and persist for weeks or even months. A man with chronic bacterial prostatitis usually doesn’t have a fever but is troubled by intermittent symptoms such as a sudden urge to urinate, frequent urination, painful urination, or the need to get up at night to urinate. Some men have low back pain, pain in the rectum, or a feeling of heaviness behind the scrotum. Others have pain after ejaculation, and the semen may be tinged with blood. These symptoms wax and wane and they are sometimes so understated that they aren’t noticeable.
  • Chronic nonbacterial prostatitis – Chronic nonbacterial prostatitis, also known as chronic pelvic pain syndrome is the most common form of prostatitis. Its symptoms resemble those of chronic bacterial prostatitis. Yet no bacteria are evident, and pinpointing a cause or causes has been difficult. Research suggests that chronic nonbacterial prostatitis may result from a cascade of interconnected events. The initiating event may be stress, an undetectable infectious agent, or physical trauma that causes inflammation or nerve damage in the genitourinary area. Over time, this may lead to heightened sensitivity of the nervous system. In other words, CP/CPPS may be an overactive pain syndrome. What’s more, some physicians and researchers are beginning to think that the condition may affect the entire pelvic floor—all of the muscles involved with bowel, bladder, and sexual function—not just the prostate gland.
  • Asymptomatic inflammatory prostatitis – This is usually discovered during tests for another medical condition, such as infertility or other prostate disorders. White blood cells are present in the urine or prostate secretions, but there are no symptoms. With no symptoms and no known cause, it isn’t treated.

Prostatitis describes a combination of infectious diseases (acute and chronic bacterial prostatitis), CPPS or asymptomatic prostatitis. The NIH classification of prostatitis syndromes includes:

  • Category I Acute bacterial prostatitis (ABP) which is associated with severe prostatitis symptoms, systemic infection, and acute bacterial UTI.
  • Category II  Chronic bacterial prostatitis (CBP) which is caused by chronic bacterial infection of the prostate with or without prostatitis symptoms and usually with recurrent UTIs caused by the same bacterial strain.
  • Category III  Chronic prostatitis/chronic pelvic pain syndrome which is characterized by chronic pelvic pain symptoms and possibly voiding symptoms in the absence of UTI.
  • Category IV  Asymptomatic inflammatory prostatitis (AIP) which is characterized by prostate inflammation in the absence of genitourinary tract symptoms.

What Is Prostatitis?

 

Causes of Prostatitis

Most cases of urinary tract infections and burning sensations or dysuria, prostatitis, urethritis, vaginitis, of the urinary tract are due to the colonization of the urogenital tract with rectal and perineal flora. The most common organisms include Escherichia coli, Enterococcus, Klebsiella, Pseudomonas, and other Enterococcus or Staphylococcus species. Residential care patients, diabetics, and those with indwelling catheters or any form of immunocompromise can also colonize with Candida Albicans.

In these scenarios, one can always find protective factors that failed to prevent infection or risk factors that lead to poor resolution of sepsis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, higher morbidity, treatment failures, and reinfection.

  • Neisseria gonorrhea – It is the leading cause of urethritis and dysuria, urinary tract infection, prostatitis, urethritis, vaginitis. Neisseria gonorrhea is a gram-negative bacteria transmitted through sexual intercourse. The incubation period is 2-5 days. Patients are commonly co-infected with Chlamydia trachomatis.
  • Chlamydia trachomatis – It is the most common nongonococcal cause of urethritis, dysuria, urinary tract infection, prostatitis, vaginitis, and is also transmittable through sexual intercourse. Chlamydia trachomatis is one of the smallest gram-negative obligate intracellular parasitic bacteria. The incubation period is usually 7-14 days even it becomes more. It is commonly associate or co-infected with Mycoplasma genitalium and Neisseria gonorrhea.
  • Complicated – Anatomical or systemic factors that increase the chance of infection like male gender, diabetes, immunosuppression, polycystic kidney, hospital-acquired, bladder outflow obstruction, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, (prostate hypertrophy, urethral stricture), neuropathic bladder (multiple sclerosis, diabetes mellitus), catheterization or ureter stent, ureterolithiasis, genitourinary surgery or malignancy, vesicoureteral reflux
  • Mycoplasma genitalium a –  Its cause of recurrent or persistent urethritis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, and is commonly a causative agent in men with nongonococcal urethritis. This organism is small self-replicating bacteria lacking a cell wall synthesis. This organism can be difficult to detect to identifying or given its slow-growing nature.
  • Trichomonas vaginitis – It is a flagellated parasitic protozoal STI, is a common infection affecting the urogenital tract of both men and women in most commonly. 
  • Herpes Simplex virus – It is a double-stranded DNA virus, can cause genital dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, infection involving the urethra.
  • Adenovirus – is an uncommon cause of urethritis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, in men. However, it should be considered in all males presenting with dysuria, mastitis, and associated conjunctivitis or constitutional symptoms.
  • Treponema pallidum – It may cause urethritis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, from an endourethral syphilitic chancre; uncommon.
  • Haemophilus influenza  It is an uncommon cause of dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, transmitted through oral sex from respiratory secretions.
  • Neisseria meningitides  It is a gram-negative diplococcus that colonizes the nasopharynx. Transmission of this organism is through oral sex is most common and is a less common cause of urethritis.
  • Ureaplasma urealyticum and ureaplasma parvum  In some scientific studies show uncommon links to urethritis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis.  In patients that have tested positive, it is usually in younger men and men with fewer sexual partners.  This causative agent should be of suspicion when other identifiable nongonococcal urethritis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, is absent.
  • Candida – species are a common fungal yeast that can cause infections and irritation to the urogenital tract, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis.

Non-infectious etiologies associated with urethritis include

  • Trauma – It is less commonly the cause of dysuria, urinary tract infection, prostatitis, urethritis, vaginitis. However, inflammation and irritation may occur with intermittent catheterization and surgical problems, after urethral instrumentation, or from a foreign body or any particle insertion.
  • Irritation – of the genital area may also result in urethritis from
    • Rubbing or pressure resulting from tight clothing or sex and associate system.
    • Physical activity including activities such as bicycle riding, cricket playing, running, stairs climbing.
    • Irritants including various soaps, body powders, fungal infection, protozoa, and spermicides.
    • Menopausal females with insufficient estrogen levels in the body may develop dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, due to the tissues of the urethra and bladder becoming thinner and dryer, causing irritation. This is a very common cause of urethritis with dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, in older women.
  • Vaginitis – It is one of the presence of vaginal discharge, odor, pruritus, dyspareunia. No frequency/urgency.
  • Urethritis – Urinalysis shows dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, but no bacteria. Common in sexually active women.
  • Painful bladder syndrome – It is also found in the diagnosis of exclusion. Dysuria, frequency, urgency, but no evidence of infection in some cases.
  • Pelvic inflammatory disorder – It causes lower abdominal/ pelvic pain, fever, cervical discharge, cervical motion tenderness.
  • Prostatitis – It is considered in men. May present with pain during ejaculation and tender prostate on digital and manual rectal examination.
  • Anatomical defects – It leads to stasis, obstruction, urinary reflux all result in an increased predisposition to recurrent urinary tract infections, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis. Vesicoureteric reflux (VUR) is identified in up to 40% of women being investigated for a first UTI. Cystocele is also an important risk factor for recurrent dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, in women.
  • Functional defects – like overactive bladder and urinary incontinence also lead to recurrent infections with dysuria, urinary tract infection, prostatitis, urethritis, vaginitis.
  • Recurrent urinary tract infections – It may be commonly seen in sexually active women without any identifiable structural abnormality or another associated condition. Older men can often develop urinary tract infections due to obstruction or neurogenic bladder in urinary stasis dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, and an increased risk of recurrent infection.
  • Several other lesions – It may indicate recurrent dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, including intraluminal (bladder stones, neoplasms, indwelling catheter), intramural (ureteral stenosis/strictures), and extramural lesions (inflammatory mass, fibrosis, or neoplasm).

Examples of a complicated UTI include

  • Infections occurring despite the presence of anatomical protective measures (dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, in males are by definition considered complicated UTI)
  • Infections occurring due to anatomical abnormalities, for example, an obstruction, hydronephrosis, renal tract calculi, or colovesical fistula  with dysuria, urinary tract infection, prostatitis, urethritis, vaginitis,
  • Infections occurring due to an immune-compromised state, for example, steroid use, post-chemotherapy, tumor, neoplasm, diabetes, elderly population, HIV)
  • Atypical organisms causing dysuria, urinary tract infection, prostatitis, urethritis, vaginitis.
  • Recurrent infections adequate treatment (multi-drug resistant organisms)
  • Infections are occurring in pregnancy or non-pregnant women (including asymptomatic bacteriuria)
  • Infections are occurring after instrumentation, nephrostomy tubes, ureteric stents, suprapubic tubes, or Foley catheters, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis,
  • Infections in renal transplant patients with dysuria, urinary tract infection, prostatitis, urethritis, vaginitis,
  • Infections are occurring with impaired renal function
  • Infections following dysuria, urinary tract infection, prostatitis, urethritis, vaginitis,or radiotherapy

Inflammation and irritation

A range of problems may lead to inflammation or irritation dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, of the urinary tract or genital area, leading to the symptom of a painful urination. Besides infections, other reasons that area may be irritated or inflamed that are included

  • Stones in the urinary tract, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis,
  • Irritation of the urethra from sexual activity or after
  • Interstitial cystitis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, a condition caused by bladder inflammation
  • Vaginal changes or vaginal discharge related to menopause
  • Activities such as horseback riding or bicycling, bike riding.
  • Vaginal sensitivity or irritation related to the use of scented unqualified soaps or bubble baths, toilet paper, or other products such as douches or spermicides.
  • Side effects from certain medications, supplements, and treatments, cosmetic use.
  • Tumor, neoplasm in the urinary tract

Symptoms of Prostatitis

Each type of prostatitis has a range of symptoms that vary depending on the cause and may not be the same for every man. Many symptoms are similar to those of other conditions.

Chronic prostatitis/chronic pelvic pain syndrome – The main symptoms of chronic prostatitis/chronic pelvic pain syndrome can include pain or discomfort lasting 3 or more months in one or more of the following areas:

  • between the scrotum and anus
  • the central lower abdomen
  • the penis
  • the scrotum
  • the lower back

Pain during or after ejaculation is another common symptom. A man with chronic prostatitis/chronic pelvic pain syndrome may have pain spread out around the pelvic area or may have pain in one or more areas at the same time. The pain may come and go and appear suddenly or gradually. Other symptoms may include

  • pain in the urethra during or after urination.
  • pain in the penis during or after urination.
  • urinary frequency—urination eight or more times a day. The bladder begins to contract even when it contains small amounts of urine, causing more frequent urination.
  • urinary urgency—the inability to delay urination.
  • a weak or an interrupted urine stream.

Acute bacterial prostatitis – The symptoms of acute bacterial prostatitis come on suddenly and are severe. Men should seek immediate medical care. Symptoms of acute bacterial prostatitis may include

  • urinary frequency
  • urinary urgency
  • fever
  • chills
  • a burning feeling or pain during urination
  • pain in the genital area, groin, lower abdomen, or lower back
  • nocturia—frequent urination during periods of sleep
  • nausea and vomiting
  • body aches
  • urinary retention—the inability to empty the bladder completely
  • trouble starting a urine stream
  • a weak or an interrupted urine stream
  • urinary blockage—the complete inability to urinate
  • a UTI—as shown by bacteria and infection-fighting cells in the urine

Chronic bacterial prostatitis – The symptoms of chronic bacterial prostatitis are similar to those of acute bacterial prostatitis, though not as severe. This type of prostatitis often develops slowly and can last 3 or more months. The symptoms may come and go, or they may be mild all the time. Chronic bacterial prostatitis may occur after previous treatment of acute bacterial prostatitis or a UTI. The symptoms of chronic bacterial prostatitis may include

  • urinary frequency
  • urinary urgency
  • a burning feeling or pain during urination
  • pain in the genital area, groin, lower abdomen, or lower back
  • nocturia
  • painful ejaculation
  • urinary retention
  • trouble starting a urine stream
  • a weak or an interrupted urine stream
  • urinary blockage
  • a UTI

Patient with cystitis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis may present with the following symptoms

  • Frequency, dysuria, urgency, suprapubic pain, abdominal pain, cloudy urine, hematuria, nausea, vomiting, and fever
  • Similar symptoms of  cystitis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis but usually will have flank pain, fever, and other systemic symptoms
  • Apart from a typical presentation, they tend to have altered mental status, lethargy, and, mental, emotional weakness.
  • Recurrent or resistant with urinary tract infection
  • Irritative urinary symptoms like frequency, dysuria, cystitis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, and urgency
  • Flank pain, the renal mass, tumors may be present in the case of renal TB.
  • Testicular mass, perineal pain, abdominal or lower abdominal, and urethral discharge may be seen in genital TB.
  • Menstrual irregularity, abdominal pain, infertility, or pelvic inflammatory cystitis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis disease in case of female genital involvement
  • Unexplained infertility in both sexes man and women.
  • Non-specific symptoms in some cases like fever, weight loss, and backache

Associated symptoms include

  • Flank pain is more common in cystitis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis
  • Lower abdominal pain
  • Painful urination and burning sensation.
  • Urinary urgency or frequency with cystitis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis
  • Fever
  • Active menstruation
  • Passing stone or grits
  • Recent throat or skin infection, skin rash
  • Joint pains, oral ulcers in the mouth and another organ, rash
  • Hemoptysis
  • Leg swelling
  • Hearing loss
  • Flank mass
  • Constitutional associate symptoms like weight loss, anorexia, cachexia
  • Back pain and chronic lower back pain, sciatica.

Diagnosis of Prostatitis

Medical History

  • Taking a personal and family medical history is one of the first things a health care provider may do to help diagnose prostatitis.
  • A mandatory history is required for all patients at the time of evaluation (4:C). The following presenting symptoms should be elicited: pain location (severity, frequency, and duration), lower urinary tract symptoms (obstructive/voiding and irritative/storage), associated symptoms (fever, other pain syndromes), and impact on activities/quality of life. A comprehensive systems review should document past medical and surgical (particularly urologic) history, history of trauma, medications, and allergies.

Physical Exam

A physical exam may help diagnose prostatitis. During a physical exam, a health care provider usually

  • Examines a patient’s body, which can include checking for discharge from the urethra enlarged or tender lymph nodes in the groin a swollen or tender scrotum performs a digital rectal exam;
  • A digital rectal exam, or rectal exam, is a physical exam of the prostate. To perform the exam, the health care provider asks the man to bend over a table or lie on his side while holding his knees close to his chest.
  • The health care provider slides a gloved, lubricated finger into the rectum and feels the part of the prostate that lies next to the rectum. The man may feel slight, brief discomfort during the rectal exam. A health care provider usually performs a rectal exam during an office visit, and the man does not need anesthesia.
  • The exam helps the health care provider see if the prostate is enlarged or tender or has any abnormalities that require more testing.

1. Acute bacterial prostatitis (NIH category I)

  • Physical examination – Mandatory (4:C): The abdomen, external genitalia, perineum, and prostate must be examined. Prostate massage during a digital rectal examination (DRE) is not recommended.
  • Imaging – Optional (2:A) –  A transrectal prostatic ultrasonography (TRUS) or computed tomography scan is indicated in ABP patients refractory to initial therapy to rule out prostate abscess/pathology. Pelvic ultrasound (or bladder scan) is indicated in ABP patients with severe obstructive symptoms, poor bladder emptying, or physical examination findings of possible urinary retention. Initial imaging of the prostate is not recommended (3:B).
  • Serum PSA – Not recommended (3:C): Elevated prostate-specific antigen (PSA) associated with ABP usually leads to confusion and worry.

2. Chronic bacterial prostatitis (NIH category II)

  • Physical examination Mandatory (4:C) – This must include examination of the abdomen, external genitalia, perineum, prostate, and pelvic floor.
  • Microbiological localization cultures of the lower urinary tract (4-Glass Test or 2-Glass Pre- and Post-Massage Test [PPMT]) – Recommended (3:A): The 4-glass test is the criterion standard for the diagnosis of CBP. The 2- glass pre- and post-massage test (PPMT) is a simple and reasonably accurate screen for bacteria. Microscopy is optional. Rationale and description can be found in reference.
  • Semen cultures – Not recommended (3:D): Based on limited evidence, semen cultures have not been shown to be significantly helpful in identifying men with CBP, unless the same organism causing recurrent UTIs is cultured.
  • Transrectal prostatic ultrasonography – Not recommended (3:B): A TRUS cannot be relied upon for differential diagnosis of categories of prostatitis. A TRUS can be considered optional (4:D) if there is a specific indication.
  • Urodynamics – Optional (4:D) – Uroflow may be helpful to confirm obstruction. Urodynamics cannot be relied upon for differential diagnosis of categories of prostatitis but may help document obstruction and/or bladder problems.

3. Chronic prostatitis/chronic pelvic pain syndrome (NIH category IIIA, IIIB)

  • Symptom scoring questionnaire – Recommended (3:A)- the NIH-CPSI has become the established international standard for symptom evaluation (not for diagnosis) of prostatitis. The index has been shown to be reliable and can evaluate the severity of current symptoms and be used as an outcome measure to evaluate the longitudinal course of symptoms with time or treatment. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) captures the three most important domains of the prostatitis experience: pain (location, frequency, and severity), voiding (irritative and obstructive symptoms), and quality of life (including impact). This index is useful in research studies and clinical practice. Adapted from Litwin et al. Reprinted with permission.
  • Physical examinations Mandatory (4:C) – Examination of the abdomen, external genitalia, perineum, and prostate is mandatory. Exacerbation of typical pelvic pain with normal DRE pressure is helpful in determining prostate centricity while evaluating myofascial trigger points and/or possible musculoskeletal dysfunction of the pelvis and pelvic floor during DRE is believed to be helpful in treatment decisions.
  • 4-Glass test and 2-glass pre- and post-massage test (PPMT) – Recommended (3:A): Culture of the lower urinary tract urine specimens is recommended. The 4-glass test is the criterion standard to rule out CBP. The 2-glass PMT is a simple and reasonably accurate screen for bacteria. A rationale and description for this recommendation are available. At this time, there is no evidence that suggests that microscopy of the EPS or urine sediment adds any clinical value (microscopy optional).
  • Cystoscopy – Not recommended (4:D) for routine evaluation. Optional (4:D): For selected patients. Endoscopy may be indicated in selected patients with obstructive voiding symptoms (refractory to medical therapy), patients with hematuria, or other suspected lower urinary tract pathology.
  • Transrectal ultrasound – Not recommended (3:B) in routine practice, unless there is a specific indication.
  • CT scan and/or magnetic resonance imaging (MRI) – Not recommended (3:B): At present, the value is unknown.
  • Urodynamics – Optional (3:C): In selected men with obstructive voiding symptoms, it is reasonable to consider urodynamic evaluation (e.g., flow rates, post-void residual, pressure flow studies).
  • Serum PSA Levels – Not recommended (3:B) – There is no evidence that serum PSA levels in patients with CP/CPPS will help diagnosis and direct therapy. Indications for serum PSA determinations should be the same as for men without CP/CPPS.
  • Psychological Assessment Optional (3:B) –There is accumulating evidence that psychosocial parameters, such as depression, maladaptive coping mechanisms (catastrophizing, resting as a coping mechanism), and poor social support impact symptoms and results of therapy. The physician should screen for these psychological problems. There is a practical algorithm to assess a man presenting with presumed CP/CPPS.

Lab  Tests

A health care provider may refer men to a urologist—a doctor who specializes in the urinary tract and male reproductive system. A urologist uses medical tests to help diagnose lower urinary tract problems related to prostatitis and recommend treatment. Medical tests may include

  • Urinalysis – Urinalysis involves testing a urine sample. The patient collects a urine sample in a special container in a health care provider’s office or a commercial facility. A health care provider tests the sample during an office visit or sends it to a lab for analysis. For the test, a nurse or technician places a strip of chemically treated paper, called a dipstick, into the urine. Patches on the dipstick change color to indicate signs of infection in the urine.
  • Blood tests – Blood tests involve a health care provider drawing blood during an office visit or in a commercial facility and sending the sample to a lab for analysis. Blood tests can show signs of infection and other prostate problems, such as prostate cancer.
  • Urodynamic tests – Urodynamic tests include a variety of procedures that look at how well the bladder and urethra store and release urine. A health care provider performs urodynamic tests during an office visit or in an outpatient center or a hospital. Some urodynamic tests do not require anesthesia; others may require local anesthesia. Most urodynamic tests focus on the bladder’s ability to hold urine and empty steadily and completely and may include the following uroflowmetry, which measures how rapidly the bladder releases urine postvoid residual measurement, which evaluates how much urine remains in the bladder after urination.
  • Cystoscopy – Cystoscopy is a procedure that uses a tubelike instrument, called a cystoscope, to look inside the urethra and bladder. A urologist inserts the cystoscope through the opening at the tip of the penis and into the lower urinary tract. He or she performs cystoscopy during an office visit or in an outpatient center or a hospital. He or she will give the patient local anesthesia. In some cases, the patient may require sedation and regional or general anesthesia. A urologist may use cystoscopy to look for narrowing, blockage, or stones in the urinary tract.
  • Transrectal ultrasound – Transrectal ultrasound uses a device, called a transducer, that bounces safe, painless sound waves off organs to create an image of their structure. The health care provider can move the transducer to different angles to make it possible to examine different organs. A specially trained technician performs the procedure in a health care provider’s office, an outpatient center, or a hospital, and a radiologist—a doctor who specializes in medical imaging—interprets the images; the patient does not require anesthesia. Urologists most often use transrectal ultrasound to examine the prostate. In a transrectal ultrasound, the technician inserts a transducer slightly larger than a pen into the man’s rectum next to the prostate. The ultrasound image shows the size of the prostate and any abnormalities, such as tumors. Transrectal ultrasound cannot reliably diagnose prostate cancer.
  • Biopsy – A biopsy is a procedure that involves taking a small piece of prostate tissue for examination with a microscope. A urologist performs the biopsy in an outpatient center or a hospital. He or she will give the patient light sedation and local anesthetic; however, in some cases, the patient will require general anesthesia. The urologist uses imaging techniques such as ultrasound, a computerized tomography scan, or magnetic resonance imaging to guide the biopsy needle into the prostate. A pathologist—a doctor who specializes in examining tissues to diagnose diseases—examines the prostate tissue in a lab. The test can show whether prostate cancer is present.
  • Semen analysis – Semen analysis is a test to measure the amount and quality of a man’s semen and sperm. The man collects a semen sample in a special container at home, a health care provider’s office, or a commercial facility. A health care provider analyzes the sample during an office visit or sends it to a lab for analysis. A semen sample can show blood and signs of infection.

Treatment

amitriptyline, gabapentin, biofeedback, massage therapy, acupuncture, neurostimulation

1. Acute bacterial prostatitis (NIH Category I)

  • Antimicrobials: Patients with severe symptomatic febrile acute bacterial prostatitis: Aminoglycosides in combination with ampicillin, broad-spectrum penicillin in combination with a beta-lactamase inhibitor, a 3rd generation cephalosporin, or a fluoroquinolone is required until defervescence and normalization of associated urosepsis. (Recommended 2:A). Following the resolution of severe infection and for less severely ill patients, outpatient oral fluoroquinolones for 2-4 weeks are appropriate. (Recommendation 4:B)
  • Alpha-blocker medications, such as tamsulosin (Flomax) or terazosin (Hytrin), may be prescribed to relax the muscles that control the bladder. These may relieve symptoms of urgency, hesitancy, or dribbling. Similar effects may be seen with drugs that shrink the size of the prostate, including finasteride (Proscar).
  • Pain relievers, anti-inflammatory drugs, and muscle relaxants may help with pain and muscle spasms. Some men find relief with warm baths or with biofeedback programs designed to reduce tension in the pelvic muscles.
  • Hospitalization if indicated (Recommended 3:B)
  • Urinary drainage if indicated (Recommended 3:B)
  • Imagine if indicated (Recommended 4:A)
  • Drainage of prostatic abscess if indicated (Recommended 4:A)

2. Chronic Bacterial Prostatitis (NIH Category II)

  • Oral fluoroquinolone therapy for susceptible bacteria for 4-6 weeks. (Recommended 2:A)
  • Trimethoprim-sulfamethoxazole (or other antimicrobials) for fluoroquinolone-resistant bacteria. (Recommended 3:B)
  • Alpha-blocker medications, such as tamsulosin (Flomax) or terazosin (Hytrin), may be prescribed to relax the muscles that control the bladder. These may relieve symptoms of urgency, hesitancy or dribbling. Similar effects may be seen with drugs that shrink the size of the prostate, including finasteride (Proscar).
  • Pain relievers, anti-inflammatory drugs, and muscle relaxants may help with pain and muscle spasms. Some men find relief with warm baths or with biofeedback programs designed to reduce tension in the pelvic muscles.
  • intermittent antimicrobial treatment of acute symptomatic cystitis; (Recommended 3:A)
  • radical TURP or simple prostatectomy (as a last resort if all other options have failed). (Recommended 4:C)
  •  low-dose antimicrobial suppression; (Recommended 3:A)
  • Alpha-blocker medications, such as tamsulosin (Flomax) or terazosin (Hytrin), may be prescribed to relax the muscles that control the bladder. These may relieve symptoms of urgency, hesitancy or dribbling. Similar effects may be seen with drugs that shrink the size of the prostate, including finasteride (Proscar).
  • Pain relievers, anti-inflammatory drugs and muscle relaxants may help with pain and muscle spasms. Some men find relief with warm baths or with biofeedback programs designed to reduce tension in the pelvic muscles.

3. Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Category IIIb)

  • Antibiotic therapy for newly diagnosed, antimicrobial naïve patients (Recommended 4:D); Antibiotic therapy for patients who have failed previous antibiotic therapy (Not recommended 1:A)
  • Alpha-blocker as first-line monotherapy (not recommended 1:A); Alpha-blocker therapy for newly diagnosed, alpha-blocker naïve patients with voiding symptoms as part of a multi-modal treatment strategy (Optional 1:A)
  • Anti-inflammatory monotherapy (Not-recommended 1:B); Anti-inflammatory therapy as part of a multimodal treatment strategy (Optional 2:C)
  • Pain relievers, anti-inflammatory drugs, and muscle relaxants may help with pain and muscle spasms. Some men find relief with warm baths or with biofeedback programs designed to reduce tension in the pelvic muscles.
  • The phytotherapy quercetin and pollen extract (recommended 2:B) but are likely most effective as a part of a multimodal treatment strategy (3:C)
  • Five alpha-reductase inhibitor monotherapy. (Not recommended 1:A); Five alpha-reductase inhibitor therapy in older men with lower urinary tract symptoms and/or as part of a multimodal treatment strategy (Optional 2:C)
  • Individualized multimodal therapy directed towards defined clinical phenotype. (Recommended 3:C)
  • Minimally invasive therapies such as TUNA, laser therapies, etc. (Not recommended 2:A)
  • Invasive surgical therapies such as TURP and radical prostatectomy. (Not recommended 4:D)
  • The following potentially effective therapies can be considered in selected patients (Optional 4:D)
  • Heat therapy in the form of microwave
  • Pudendal nerve modulation
  • Neuromodulating agents (gabapentinoids, tricyclic antidepressants)
  • Muscle relaxants (diazepam, baclofen, cyclobenzaprine)
  • Electromagnetic stimulation
  • Acupuncture
  • Psychotherapy (Mandatory for severe depression and/or suicidal tendencies)
  • Physical therapy
  • Biofeedback

4. Asymptomatic Inflammatory Prostatitis (NIH Category IV)

  • Definitive therapy (Not recommended: 3:A)Antimicrobial therapy for selected patients with elevated PSA, infertility, or manipulation (biopsy) warrants consideration. (Optional 3:C)

1. Acute bacterial prostatitis (NIH category I)

ABP can be a serious infection with fever, intense local pain, and general symptoms. Septicemia and urosepsis are always potential risks. The following factors must be taken into account when treating ABP: potential urosepsis, choice of antimicrobial agent, urinary drainage, risk factors justifying hospitalization, and auxiliary measures intended to improve treatment outcomes.

  • Antimicrobial Therapy (2:A) – The choice and duration of antimicrobial therapy for ABP are based on experience and expert opinion and are supported by many uncontrolled clinical studies., For initial treatment of severely ill patients, the following regimens are recommended: intravenous administration of high doses of bactericidal antimicrobials, such as aminoglycosides in combination with ampicillin, broad-spectrum penicillin in combination with a beta-lactamase inhibitor, a third-generation cephalosporin or a fluoroquinolone is required until defervescence and normalization of associated urosepsis (this recommendation is based on the treatment of complicated UTIs and urosepsis). Patients who are not severely ill or vomiting may be treated with an oral fluoroquinolone., Trimethoprim-sulfamethoxazole (TMP/SMX) is no longer recommended as first-line empirical therapy in areas where TMP/SMX resistance for E. coli, the most frequent pathogen, is greater than 10% to 20%. Treatment should continue for 2 to 4 weeks.,
  • Urinary drainage (3:B) – A single catheterization with the trial of voiding or short-term small-caliber urethral catheterization is recommended for patients with severe obstructive voiding symptoms or urinary retention. Suprapubic tube placement is optional for patients who cannot tolerate a urethral catheter.
  • Hospitalization (3:B) – Hospitalization is mandatory in cases of hyperpyrexia, prolonged vomiting, severe dehydration, tachycardia, tachypnea, hypotension, and other symptoms related to urosepsis. Hospitalization is recommended in high-risk patients (diabetes, immunosuppressed patient, old age or prostatic abscess) and those with severe voiding disorders.
  • Drainage of a prostate abscess (4:A) – Incision and drainage of prostate abscesses are required in selected treatment-refractory patients. The transurethral route appears to be the modality of choice but abscess may be drained via perineum, rectum, or transperineal route.
  • Auxiliary measures – Nonsteroidal anti-inflammatory agents have been suggested for reducing symptoms including fever. Alpha-blockers may be considered, particularly in men with moderately severe obstructive voiding symptoms to reduce the risk of urinary retention and facilitate micturition.

2. Chronic bacterial prostatitis (NIH category II)

  • Antimicrobial therapy (2:A) – Because of their unique and favorable pharmacokinetic properties, their broad antibacterial spectra, and comparative clinical trial evidence, fluoroquinolones are the recommended agents of choice for the antimicrobial treatment of CBP., Data from CBP fluoroquinolone treatment trials with a follow-up of at least 6 months support the use of fluoroquinolones as first-line therapy. The recommended 4- to 6-week duration of antimicrobial treatment is based on experience and expert opinion and is supported by many clinical studies., In general, therapeutic results (defined as bacterial eradication) are good in CBP due to E. coli and other members of the family Enterobacteriaceae. CBP due to P. aeruginosa and Enterococci shows a poorer response to antimicrobial therapy.CBP associated with a confirmed uropathogenic that is resistant to the fluoroquinolones can be considered for treatment with trimethoprim-sulfamethoxazole (or other antimicrobials), but the treatment duration should be 8 to12 weeks.
  • Alpha-Blockers (3:C) – The combination of antimicrobials and alpha-blockers has been suggested to reduce the high recurrence rate and this combination of two therapeutic regimens is considered optional for in-patients with obstructive voiding symptoms.
  • Treatment refractory cases – For treatment-refractory patients with confirmed uropathogenic localized to the prostate, the following are optional treatment strategies are the intermittent antimicrobial treatment of acute symptomatic episodes (cystitis) (3:A); low-dose antimicrobial suppression (3:A); or radical TURP or open prostatectomy if all other options have failed (4:C).

3. Chronic prostatitis/chronic pelvic pain syndrome (NIH category III)

The introduction of an internationally accepted classification system, a validated outcome index, the NIH-CPSI, and the significant number of randomized placebo-controlled clinical trials published over the last decade and a half has permitted best-evidence-based guideline recommendations. Twenty-three clinical trials were available at time of this guideline development. These English-language trials evaluated medical therapies using a prospective, randomized controlled design; these trials were used to support these recommendations. These have been recently reviewed and analyzed. We also used a literature search strategy. In addition, a best-evidence-based treatment algorithm was used

  • Antimicrobials – Antimicrobials cannot be recommended for men with longstanding, previously treated CP/CPPS (1:A). However, uncontrolled clinical studies suggest that some clinical benefits can be obtained with antimicrobial therapy in antimicrobial naïve early-onset prostatitis patients (4:D).
  • Alpha-blockers – Alpha-blockers cannot be recommended as a first-line monotherapy (1:A). However, there is some evidence that alpha-blocker naïve men with moderately severe symptoms who have relatively recent onset of symptoms may experience benefit (1:A). Alpha-blocker therapy appears to provide benefit in a multimodal therapeutic algorithm for men with voiding symptoms (2:C)). Alpha-blockers must be continued for over 6 weeks (likely over 12 weeks).
  • Anti-inflammatory – Anti-inflammatory therapy is helpful for some patients, but is not recommended as a primary treatment (1:B); however, it may be useful in an adjunctive role in a multimodal therapeutic regimen (2:C).
  • Phytotherapies – Phytotherapies (specifically quercetin and the pollen extract, cernilton) are optional recommendations for first-line (2:B) and combination multimodal therapy (3:C).
  • Other medical therapies – Other medical therapies, such as 5-alpha-reductase inhibitor therapy, pentosan polysulfate, and pregabalin, while not recommended as primary monotherapy (1:A), may provide benefit in selected patients (older men with LUTS for 5-ARI therapy, men with associated pain perceived bladder pain and irritative voiding symptoms for pentosan polysulfate and neuropathic type pain for pregabalin).
  • Other potential medical therapies – Muscle relaxants, saw palmetto, corticosteroids, and tricyclic antidepressants have all been suggested and used, but recommendations will have to wait for results from properly designed randomized placebo-controlled trials (4:D).
  • Physiotherapies – A number of physical therapies have been recommended, but they also suffer from a lack of perspective controlled data obtained from properly designed controlled studies. Prostatic massage, perineal or pelvic floor massage, and myofascial trigger point release have also been suggested as a beneficial treatment modality for patients, however, focused pelvic physiotherapy has yet to be shown to provide more benefit compared to SHAM physiotherapy. Biofeedback, acupuncture, and electromagnetic therapy also show promise, but like all the other physical therapeutic modalities, require sham-controlled trials before recommendations can be made (3:C).
  • Psychotherapies – Psychological support and therapy have been advocated based on new psycho-social modeling of this syndrome. This treatment ideally would include a cognitive behavioral therapy program. A referral to a psychologist or psychiatrist should be considered mandatory in patients with severe depression and/or suicidal tendencies.
  • Multimodal Therapy (POINT) – A number of uncontrolled clinical studies have strongly suggested that multimodal therapy is more effective than monotherapy in patients with long-term symptoms., Individualized personal therapy algorithms directed toward clinically defined presenting phenotypes (POINT) have been proposed and the early results of such a strategy look promising. Based on the fact that monotherapies provide (at best) modest efficacy, a multimodal approach using specific clinical phenotypes to choose therapies is considered an optional recommendation. An algorithm has been proposed.

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

Acute Infection of The Prostate – Causes, Symptoms, Treatment

Acute Infection of Prostate /Prostatitis is inflammation or swelling of the prostate gland. When symptoms start gradually and linger for more than a couple of weeks, the condition is called chronic prostatitis. The prostate is a walnut-shaped gland that is part of the male reproductive system. The main function of the prostate is to make a fluid that goes into semen. Prostate fluid is essential for a man’s fertility. The gland surrounds the urethra at the neck of the bladder. The bladder neck is the area where the urethra joins the bladder. The bladder and urethra are parts of the lower urinary tract. The prostate has two or more lobes, or sections, enclosed by an outer layer of tissue, and it is in front of the rectum, just below the bladder. The urethra is the tube that carries urine from the bladder to the outside of the body. In men, the urethra also carries semen out through the penis

Types of Prostatitis

Scientists have identified four types of prostatitis

  • Chronic prostatitis or chronic pelvic pain syndrome
  • Acute bacterial prostatitis
  • Chronic bacterial prostatitis
  • Asymptomatic inflammatory prostatitis

Prostatitis can be an acute illness or a chronic condition, The NIH consensus definition and classification of prostatitis is

Prostatitis is classified into four categories, each with its own treatment approach

  • Acute infection of the prostate – This sudden-onset infection is caused by bacteria that travel from the urethra, and perhaps from the rectum to the prostate. It’s the least common but most dramatic form of prostatitis, beginning abruptly with high fever, chills, joint and muscle aches, and profound fatigue. In addition, you may have pain around the base of the penis and behind the scrotum, pain in the lower back, and the feeling of a full rectum. As the prostate becomes more swollen, you may find it more difficult to urinate, and the urine stream may become weak. (If you can’t urinate at all, it’s a medical emergency; this usually means the prostate is so swollen that it’s completely blocking urine flow. Depending on the severity of symptoms, hospitalization may be necessary.)
  • Chronic bacterial prostatitis – This type of prostatitis is also caused by bacteria. It’s more common in older men who have BPH. It sometimes follows a bout of acute bacterial prostatitis. Unlike the acute form, however, chronic bacterial prostatitis is a subtle, low-grade infection that can begin insidiously and persist for weeks or even months. A man with chronic bacterial prostatitis usually doesn’t have a fever but is troubled by intermittent symptoms such as a sudden urge to urinate, frequent urination, painful urination, or the need to get up at night to urinate. Some men have low back pain, pain in the rectum, or a feeling of heaviness behind the scrotum. Others have pain after ejaculation, and the semen may be tinged with blood. These symptoms wax and wane and they are sometimes so understated that they aren’t noticeable.
  • Chronic nonbacterial prostatitis – Chronic nonbacterial prostatitis, also known as chronic pelvic pain syndrome is the most common form of prostatitis. Its symptoms resemble those of chronic bacterial prostatitis. Yet no bacteria are evident, and pinpointing a cause or causes has been difficult. Research suggests that chronic nonbacterial prostatitis may result from a cascade of interconnected events. The initiating event may be stress, an undetectable infectious agent, or physical trauma that causes inflammation or nerve damage in the genitourinary area. Over time, this may lead to heightened sensitivity of the nervous system. In other words, CP/CPPS may be an overactive pain syndrome. What’s more, some physicians and researchers are beginning to think that the condition may affect the entire pelvic floor—all of the muscles involved with bowel, bladder, and sexual function—not just the prostate gland.
  • Asymptomatic inflammatory prostatitis – This is usually discovered during tests for another medical condition, such as infertility or other prostate disorders. White blood cells are present in the urine or prostate secretions, but there are no symptoms. With no symptoms and no known cause, it isn’t treated.

Prostatitis describes a combination of infectious diseases (acute and chronic bacterial prostatitis), CPPS or asymptomatic prostatitis. The NIH classification of prostatitis syndromes includes:

  • Category I Acute bacterial prostatitis (ABP) which is associated with severe prostatitis symptoms, systemic infection, and acute bacterial UTI.
  • Category II  Chronic bacterial prostatitis (CBP) which is caused by chronic bacterial infection of the prostate with or without prostatitis symptoms and usually with recurrent UTIs caused by the same bacterial strain.
  • Category III  Chronic prostatitis/chronic pelvic pain syndrome which is characterized by chronic pelvic pain symptoms and possibly voiding symptoms in the absence of UTI.
  • Category IV  Asymptomatic inflammatory prostatitis (AIP) which is characterized by prostate inflammation in the absence of genitourinary tract symptoms.

What Is Prostatitis?

 

Causes of Prostatitis

Most cases of urinary tract infections and burning sensations or dysuria, prostatitis, urethritis, vaginitis, of the urinary tract are due to the colonization of the urogenital tract with rectal and perineal flora. The most common organisms include Escherichia coli, Enterococcus, Klebsiella, Pseudomonas, and other Enterococcus or Staphylococcus species. Residential care patients, diabetics, and those with indwelling catheters or any form of immunocompromise can also colonize with Candida Albicans.

In these scenarios, one can always find protective factors that failed to prevent infection or risk factors that lead to poor resolution of sepsis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, higher morbidity, treatment failures, and reinfection.

  • Neisseria gonorrhea – It is the leading cause of urethritis and dysuria, urinary tract infection, prostatitis, urethritis, vaginitis. Neisseria gonorrhea is a gram-negative bacteria transmitted through sexual intercourse. The incubation period is 2-5 days. Patients are commonly co-infected with Chlamydia trachomatis.
  • Chlamydia trachomatis – It is the most common nongonococcal cause of urethritis, dysuria, urinary tract infection, prostatitis, vaginitis, and is also transmittable through sexual intercourse. Chlamydia trachomatis is one of the smallest gram-negative obligate intracellular parasitic bacteria. The incubation period is usually 7-14 days even it becomes more. It is commonly associate or co-infected with Mycoplasma genitalium and Neisseria gonorrhea.
  • Complicated – Anatomical or systemic factors that increase the chance of infection like male gender, diabetes, immunosuppression, polycystic kidney, hospital-acquired, bladder outflow obstruction, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, (prostate hypertrophy, urethral stricture), neuropathic bladder (multiple sclerosis, diabetes mellitus), catheterization or ureter stent, ureterolithiasis, genitourinary surgery or malignancy, vesicoureteral reflux
  • Mycoplasma genitalium a –  Its cause of recurrent or persistent urethritis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, and is commonly a causative agent in men with nongonococcal urethritis. This organism is small self-replicating bacteria lacking a cell wall synthesis. This organism can be difficult to detect to identifying or given its slow-growing nature.
  • Trichomonas vaginitis – It is a flagellated parasitic protozoal STI, is a common infection affecting the urogenital tract of both men and women in most commonly. 
  • Herpes Simplex virus – It is a double-stranded DNA virus, can cause genital dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, infection involving the urethra.
  • Adenovirus – is an uncommon cause of urethritis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, in men. However, it should be considered in all males presenting with dysuria, mastitis, and associated conjunctivitis or constitutional symptoms.
  • Treponema pallidum – It may cause urethritis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, from an endourethral syphilitic chancre; uncommon.
  • Haemophilus influenza  It is an uncommon cause of dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, transmitted through oral sex from respiratory secretions.
  • Neisseria meningitides  It is a gram-negative diplococcus that colonizes the nasopharynx. Transmission of this organism is through oral sex is most common and is a less common cause of urethritis.
  • Ureaplasma urealyticum and ureaplasma parvum  In some scientific studies show uncommon links to urethritis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis.  In patients that have tested positive, it is usually in younger men and men with fewer sexual partners.  This causative agent should be of suspicion when other identifiable nongonococcal urethritis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, is absent.
  • Candida – species are a common fungal yeast that can cause infections and irritation to the urogenital tract, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis.

Non-infectious etiologies associated with urethritis include

  • Trauma – It is less commonly the cause of dysuria, urinary tract infection, prostatitis, urethritis, vaginitis. However, inflammation and irritation may occur with intermittent catheterization and surgical problems, after urethral instrumentation, or from a foreign body or any particle insertion.
  • Irritation – of the genital area may also result in urethritis from
    • Rubbing or pressure resulting from tight clothing or sex and associate system.
    • Physical activity including activities such as bicycle riding, cricket playing, running, stairs climbing.
    • Irritants including various soaps, body powders, fungal infection, protozoa, and spermicides.
    • Menopausal females with insufficient estrogen levels in the body may develop dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, due to the tissues of the urethra and bladder becoming thinner and dryer, causing irritation. This is a very common cause of urethritis with dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, in older women.
  • Vaginitis – It is one of the presence of vaginal discharge, odor, pruritus, dyspareunia. No frequency/urgency.
  • Urethritis – Urinalysis shows dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, but no bacteria. Common in sexually active women.
  • Painful bladder syndrome – It is also found in the diagnosis of exclusion. Dysuria, frequency, urgency, but no evidence of infection in some cases.
  • Pelvic inflammatory disorder – It causes lower abdominal/ pelvic pain, fever, cervical discharge, cervical motion tenderness.
  • Prostatitis – It is considered in men. May present with pain during ejaculation and tender prostate on digital and manual rectal examination.
  • Anatomical defects – It leads to stasis, obstruction, urinary reflux all result in an increased predisposition to recurrent urinary tract infections, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis. Vesicoureteric reflux (VUR) is identified in up to 40% of women being investigated for a first UTI. Cystocele is also an important risk factor for recurrent dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, in women.
  • Functional defects – like overactive bladder and urinary incontinence also lead to recurrent infections with dysuria, urinary tract infection, prostatitis, urethritis, vaginitis.
  • Recurrent urinary tract infections – It may be commonly seen in sexually active women without any identifiable structural abnormality or another associated condition. Older men can often develop urinary tract infections due to obstruction or neurogenic bladder in urinary stasis dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, and an increased risk of recurrent infection.
  • Several other lesions – It may indicate recurrent dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, including intraluminal (bladder stones, neoplasms, indwelling catheter), intramural (ureteral stenosis/strictures), and extramural lesions (inflammatory mass, fibrosis, or neoplasm).

Examples of a complicated UTI include

  • Infections occurring despite the presence of anatomical protective measures (dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, in males are by definition considered complicated UTI)
  • Infections occurring due to anatomical abnormalities, for example, an obstruction, hydronephrosis, renal tract calculi, or colovesical fistula  with dysuria, urinary tract infection, prostatitis, urethritis, vaginitis,
  • Infections occurring due to an immune-compromised state, for example, steroid use, post-chemotherapy, tumor, neoplasm, diabetes, elderly population, HIV)
  • Atypical organisms causing dysuria, urinary tract infection, prostatitis, urethritis, vaginitis.
  • Recurrent infections adequate treatment (multi-drug resistant organisms)
  • Infections are occurring in pregnancy or non-pregnant women (including asymptomatic bacteriuria)
  • Infections are occurring after instrumentation, nephrostomy tubes, ureteric stents, suprapubic tubes, or Foley catheters, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis,
  • Infections in renal transplant patients with dysuria, urinary tract infection, prostatitis, urethritis, vaginitis,
  • Infections are occurring with impaired renal function
  • Infections following dysuria, urinary tract infection, prostatitis, urethritis, vaginitis,or radiotherapy

Inflammation and irritation

A range of problems may lead to inflammation or irritation dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, of the urinary tract or genital area, leading to the symptom of a painful urination. Besides infections, other reasons that area may be irritated or inflamed that are included

  • Stones in the urinary tract, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis,
  • Irritation of the urethra from sexual activity or after
  • Interstitial cystitis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, a condition caused by bladder inflammation
  • Vaginal changes or vaginal discharge related to menopause
  • Activities such as horseback riding or bicycling, bike riding.
  • Vaginal sensitivity or irritation related to the use of scented unqualified soaps or bubble baths, toilet paper, or other products such as douches or spermicides.
  • Side effects from certain medications, supplements, and treatments, cosmetic use.
  • Tumor, neoplasm in the urinary tract

Symptoms of Prostatitis

Each type of prostatitis has a range of symptoms that vary depending on the cause and may not be the same for every man. Many symptoms are similar to those of other conditions.

Chronic prostatitis/chronic pelvic pain syndrome – The main symptoms of chronic prostatitis/chronic pelvic pain syndrome can include pain or discomfort lasting 3 or more months in one or more of the following areas:

  • between the scrotum and anus
  • the central lower abdomen
  • the penis
  • the scrotum
  • the lower back

Pain during or after ejaculation is another common symptom. A man with chronic prostatitis/chronic pelvic pain syndrome may have pain spread out around the pelvic area or may have pain in one or more areas at the same time. The pain may come and go and appear suddenly or gradually. Other symptoms may include

  • pain in the urethra during or after urination.
  • pain in the penis during or after urination.
  • urinary frequency—urination eight or more times a day. The bladder begins to contract even when it contains small amounts of urine, causing more frequent urination.
  • urinary urgency—the inability to delay urination.
  • a weak or an interrupted urine stream.

Acute bacterial prostatitis – The symptoms of acute bacterial prostatitis come on suddenly and are severe. Men should seek immediate medical care. Symptoms of acute bacterial prostatitis may include

  • urinary frequency
  • urinary urgency
  • fever
  • chills
  • a burning feeling or pain during urination
  • pain in the genital area, groin, lower abdomen, or lower back
  • nocturia—frequent urination during periods of sleep
  • nausea and vomiting
  • body aches
  • urinary retention—the inability to empty the bladder completely
  • trouble starting a urine stream
  • a weak or an interrupted urine stream
  • urinary blockage—the complete inability to urinate
  • a UTI—as shown by bacteria and infection-fighting cells in the urine

Chronic bacterial prostatitis – The symptoms of chronic bacterial prostatitis are similar to those of acute bacterial prostatitis, though not as severe. This type of prostatitis often develops slowly and can last 3 or more months. The symptoms may come and go, or they may be mild all the time. Chronic bacterial prostatitis may occur after previous treatment of acute bacterial prostatitis or a UTI. The symptoms of chronic bacterial prostatitis may include

  • urinary frequency
  • urinary urgency
  • a burning feeling or pain during urination
  • pain in the genital area, groin, lower abdomen, or lower back
  • nocturia
  • painful ejaculation
  • urinary retention
  • trouble starting a urine stream
  • a weak or an interrupted urine stream
  • urinary blockage
  • a UTI

Patient with cystitis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis may present with the following symptoms

  • Frequency, dysuria, urgency, suprapubic pain, abdominal pain, cloudy urine, hematuria, nausea, vomiting, and fever
  • Similar symptoms of  cystitis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis but usually will have flank pain, fever, and other systemic symptoms
  • Apart from a typical presentation, they tend to have altered mental status, lethargy, and, mental, emotional weakness.
  • Recurrent or resistant with urinary tract infection
  • Irritative urinary symptoms like frequency, dysuria, cystitis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis, and urgency
  • Flank pain, the renal mass, tumors may be present in the case of renal TB.
  • Testicular mass, perineal pain, abdominal or lower abdominal, and urethral discharge may be seen in genital TB.
  • Menstrual irregularity, abdominal pain, infertility, or pelvic inflammatory cystitis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis disease in case of female genital involvement
  • Unexplained infertility in both sexes man and women.
  • Non-specific symptoms in some cases like fever, weight loss, and backache

Associated symptoms include

  • Flank pain is more common in cystitis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis
  • Lower abdominal pain
  • Painful urination and burning sensation.
  • Urinary urgency or frequency with cystitis, dysuria, urinary tract infection, prostatitis, urethritis, vaginitis
  • Fever
  • Active menstruation
  • Passing stone or grits
  • Recent throat or skin infection, skin rash
  • Joint pains, oral ulcers in the mouth and another organ, rash
  • Hemoptysis
  • Leg swelling
  • Hearing loss
  • Flank mass
  • Constitutional associate symptoms like weight loss, anorexia, cachexia
  • Back pain and chronic lower back pain, sciatica.

Diagnosis of Prostatitis

Medical History

  • Taking a personal and family medical history is one of the first things a health care provider may do to help diagnose prostatitis.
  • A mandatory history is required for all patients at the time of evaluation (4:C). The following presenting symptoms should be elicited: pain location (severity, frequency, and duration), lower urinary tract symptoms (obstructive/voiding and irritative/storage), associated symptoms (fever, other pain syndromes), and impact on activities/quality of life. A comprehensive systems review should document past medical and surgical (particularly urologic) history, history of trauma, medications, and allergies.

Physical Exam

A physical exam may help diagnose prostatitis. During a physical exam, a health care provider usually

  • Examines a patient’s body, which can include checking for discharge from the urethra enlarged or tender lymph nodes in the groin a swollen or tender scrotum performs a digital rectal exam;
  • A digital rectal exam, or rectal exam, is a physical exam of the prostate. To perform the exam, the health care provider asks the man to bend over a table or lie on his side while holding his knees close to his chest.
  • The health care provider slides a gloved, lubricated finger into the rectum and feels the part of the prostate that lies next to the rectum. The man may feel slight, brief discomfort during the rectal exam. A health care provider usually performs a rectal exam during an office visit, and the man does not need anesthesia.
  • The exam helps the health care provider see if the prostate is enlarged or tender or has any abnormalities that require more testing.

1. Acute bacterial prostatitis (NIH category I)

  • Physical examination – Mandatory (4:C): The abdomen, external genitalia, perineum, and prostate must be examined. Prostate massage during a digital rectal examination (DRE) is not recommended.
  • Imaging – Optional (2:A) –  A transrectal prostatic ultrasonography (TRUS) or computed tomography scan is indicated in ABP patients refractory to initial therapy to rule out prostate abscess/pathology. Pelvic ultrasound (or bladder scan) is indicated in ABP patients with severe obstructive symptoms, poor bladder emptying, or physical examination findings of possible urinary retention. Initial imaging of the prostate is not recommended (3:B).
  • Serum PSA – Not recommended (3:C): Elevated prostate-specific antigen (PSA) associated with ABP usually leads to confusion and worry.

2. Chronic bacterial prostatitis (NIH category II)

  • Physical examination Mandatory (4:C) – This must include examination of the abdomen, external genitalia, perineum, prostate, and pelvic floor.
  • Microbiological localization cultures of the lower urinary tract (4-Glass Test or 2-Glass Pre- and Post-Massage Test [PPMT]) – Recommended (3:A): The 4-glass test is the criterion standard for the diagnosis of CBP. The 2- glass pre- and post-massage test (PPMT) is a simple and reasonably accurate screen for bacteria. Microscopy is optional. Rationale and description can be found in reference.
  • Semen cultures – Not recommended (3:D): Based on limited evidence, semen cultures have not been shown to be significantly helpful in identifying men with CBP, unless the same organism causing recurrent UTIs is cultured.
  • Transrectal prostatic ultrasonography – Not recommended (3:B): A TRUS cannot be relied upon for differential diagnosis of categories of prostatitis. A TRUS can be considered optional (4:D) if there is a specific indication.
  • Urodynamics – Optional (4:D) – Uroflow may be helpful to confirm obstruction. Urodynamics cannot be relied upon for differential diagnosis of categories of prostatitis but may help document obstruction and/or bladder problems.

3. Chronic prostatitis/chronic pelvic pain syndrome (NIH category IIIA, IIIB)

  • Symptom scoring questionnaire – Recommended (3:A)- the NIH-CPSI has become the established international standard for symptom evaluation (not for diagnosis) of prostatitis. The index has been shown to be reliable and can evaluate the severity of current symptoms and be used as an outcome measure to evaluate the longitudinal course of symptoms with time or treatment. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) captures the three most important domains of the prostatitis experience: pain (location, frequency, and severity), voiding (irritative and obstructive symptoms), and quality of life (including impact). This index is useful in research studies and clinical practice. Adapted from Litwin et al. Reprinted with permission.
  • Physical examinations Mandatory (4:C) – Examination of the abdomen, external genitalia, perineum, and prostate is mandatory. Exacerbation of typical pelvic pain with normal DRE pressure is helpful in determining prostate centricity while evaluating myofascial trigger points and/or possible musculoskeletal dysfunction of the pelvis and pelvic floor during DRE is believed to be helpful in treatment decisions.
  • 4-Glass test and 2-glass pre- and post-massage test (PPMT) – Recommended (3:A): Culture of the lower urinary tract urine specimens is recommended. The 4-glass test is the criterion standard to rule out CBP. The 2-glass PMT is a simple and reasonably accurate screen for bacteria. A rationale and description for this recommendation are available. At this time, there is no evidence that suggests that microscopy of the EPS or urine sediment adds any clinical value (microscopy optional).
  • Cystoscopy – Not recommended (4:D) for routine evaluation. Optional (4:D): For selected patients. Endoscopy may be indicated in selected patients with obstructive voiding symptoms (refractory to medical therapy), patients with hematuria, or other suspected lower urinary tract pathology.
  • Transrectal ultrasound – Not recommended (3:B) in routine practice, unless there is a specific indication.
  • CT scan and/or magnetic resonance imaging (MRI) – Not recommended (3:B): At present, the value is unknown.
  • Urodynamics – Optional (3:C): In selected men with obstructive voiding symptoms, it is reasonable to consider urodynamic evaluation (e.g., flow rates, post-void residual, pressure flow studies).
  • Serum PSA Levels – Not recommended (3:B) – There is no evidence that serum PSA levels in patients with CP/CPPS will help diagnosis and direct therapy. Indications for serum PSA determinations should be the same as for men without CP/CPPS.
  • Psychological Assessment Optional (3:B) –There is accumulating evidence that psychosocial parameters, such as depression, maladaptive coping mechanisms (catastrophizing, resting as a coping mechanism), and poor social support impact symptoms and results of therapy. The physician should screen for these psychological problems. There is a practical algorithm to assess a man presenting with presumed CP/CPPS.

Lab  Tests

A health care provider may refer men to a urologist—a doctor who specializes in the urinary tract and male reproductive system. A urologist uses medical tests to help diagnose lower urinary tract problems related to prostatitis and recommend treatment. Medical tests may include

  • Urinalysis – Urinalysis involves testing a urine sample. The patient collects a urine sample in a special container in a health care provider’s office or a commercial facility. A health care provider tests the sample during an office visit or sends it to a lab for analysis. For the test, a nurse or technician places a strip of chemically treated paper, called a dipstick, into the urine. Patches on the dipstick change color to indicate signs of infection in the urine.
  • Blood tests – Blood tests involve a health care provider drawing blood during an office visit or in a commercial facility and sending the sample to a lab for analysis. Blood tests can show signs of infection and other prostate problems, such as prostate cancer.
  • Urodynamic tests – Urodynamic tests include a variety of procedures that look at how well the bladder and urethra store and release urine. A health care provider performs urodynamic tests during an office visit or in an outpatient center or a hospital. Some urodynamic tests do not require anesthesia; others may require local anesthesia. Most urodynamic tests focus on the bladder’s ability to hold urine and empty steadily and completely and may include the following uroflowmetry, which measures how rapidly the bladder releases urine postvoid residual measurement, which evaluates how much urine remains in the bladder after urination.
  • Cystoscopy – Cystoscopy is a procedure that uses a tubelike instrument, called a cystoscope, to look inside the urethra and bladder. A urologist inserts the cystoscope through the opening at the tip of the penis and into the lower urinary tract. He or she performs cystoscopy during an office visit or in an outpatient center or a hospital. He or she will give the patient local anesthesia. In some cases, the patient may require sedation and regional or general anesthesia. A urologist may use cystoscopy to look for narrowing, blockage, or stones in the urinary tract.
  • Transrectal ultrasound – Transrectal ultrasound uses a device, called a transducer, that bounces safe, painless sound waves off organs to create an image of their structure. The health care provider can move the transducer to different angles to make it possible to examine different organs. A specially trained technician performs the procedure in a health care provider’s office, an outpatient center, or a hospital, and a radiologist—a doctor who specializes in medical imaging—interprets the images; the patient does not require anesthesia. Urologists most often use transrectal ultrasound to examine the prostate. In a transrectal ultrasound, the technician inserts a transducer slightly larger than a pen into the man’s rectum next to the prostate. The ultrasound image shows the size of the prostate and any abnormalities, such as tumors. Transrectal ultrasound cannot reliably diagnose prostate cancer.
  • Biopsy – A biopsy is a procedure that involves taking a small piece of prostate tissue for examination with a microscope. A urologist performs the biopsy in an outpatient center or a hospital. He or she will give the patient light sedation and local anesthetic; however, in some cases, the patient will require general anesthesia. The urologist uses imaging techniques such as ultrasound, a computerized tomography scan, or magnetic resonance imaging to guide the biopsy needle into the prostate. A pathologist—a doctor who specializes in examining tissues to diagnose diseases—examines the prostate tissue in a lab. The test can show whether prostate cancer is present.
  • Semen analysis – Semen analysis is a test to measure the amount and quality of a man’s semen and sperm. The man collects a semen sample in a special container at home, a health care provider’s office, or a commercial facility. A health care provider analyzes the sample during an office visit or sends it to a lab for analysis. A semen sample can show blood and signs of infection.

Treatment

amitriptyline, gabapentin, biofeedback, massage therapy, acupuncture, neurostimulation

1. Acute bacterial prostatitis (NIH Category I)

  • Antimicrobials: Patients with severe symptomatic febrile acute bacterial prostatitis: Aminoglycosides in combination with ampicillin, broad-spectrum penicillin in combination with a beta-lactamase inhibitor, a 3rd generation cephalosporin, or a fluoroquinolone is required until defervescence and normalization of associated urosepsis. (Recommended 2:A). Following the resolution of severe infection and for less severely ill patients, outpatient oral fluoroquinolones for 2-4 weeks are appropriate. (Recommendation 4:B)
  • Alpha-blocker medications, such as tamsulosin (Flomax) or terazosin (Hytrin), may be prescribed to relax the muscles that control the bladder. These may relieve symptoms of urgency, hesitancy, or dribbling. Similar effects may be seen with drugs that shrink the size of the prostate, including finasteride (Proscar).
  • Pain relievers, anti-inflammatory drugs, and muscle relaxants may help with pain and muscle spasms. Some men find relief with warm baths or with biofeedback programs designed to reduce tension in the pelvic muscles.
  • Hospitalization if indicated (Recommended 3:B)
  • Urinary drainage if indicated (Recommended 3:B)
  • Imagine if indicated (Recommended 4:A)
  • Drainage of prostatic abscess if indicated (Recommended 4:A)

2. Chronic Bacterial Prostatitis (NIH Category II)

  • Oral fluoroquinolone therapy for susceptible bacteria for 4-6 weeks. (Recommended 2:A)
  • Trimethoprim-sulfamethoxazole (or other antimicrobials) for fluoroquinolone-resistant bacteria. (Recommended 3:B)
  • Alpha-blocker medications, such as tamsulosin (Flomax) or terazosin (Hytrin), may be prescribed to relax the muscles that control the bladder. These may relieve symptoms of urgency, hesitancy or dribbling. Similar effects may be seen with drugs that shrink the size of the prostate, including finasteride (Proscar).
  • Pain relievers, anti-inflammatory drugs, and muscle relaxants may help with pain and muscle spasms. Some men find relief with warm baths or with biofeedback programs designed to reduce tension in the pelvic muscles.
  • intermittent antimicrobial treatment of acute symptomatic cystitis; (Recommended 3:A)
  • radical TURP or simple prostatectomy (as a last resort if all other options have failed). (Recommended 4:C)
  •  low-dose antimicrobial suppression; (Recommended 3:A)
  • Alpha-blocker medications, such as tamsulosin (Flomax) or terazosin (Hytrin), may be prescribed to relax the muscles that control the bladder. These may relieve symptoms of urgency, hesitancy or dribbling. Similar effects may be seen with drugs that shrink the size of the prostate, including finasteride (Proscar).
  • Pain relievers, anti-inflammatory drugs and muscle relaxants may help with pain and muscle spasms. Some men find relief with warm baths or with biofeedback programs designed to reduce tension in the pelvic muscles.

3. Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Category IIIb)

  • Antibiotic therapy for newly diagnosed, antimicrobial naïve patients (Recommended 4:D); Antibiotic therapy for patients who have failed previous antibiotic therapy (Not recommended 1:A)
  • Alpha-blocker as first-line monotherapy (not recommended 1:A); Alpha-blocker therapy for newly diagnosed, alpha-blocker naïve patients with voiding symptoms as part of a multi-modal treatment strategy (Optional 1:A)
  • Anti-inflammatory monotherapy (Not-recommended 1:B); Anti-inflammatory therapy as part of a multimodal treatment strategy (Optional 2:C)
  • Pain relievers, anti-inflammatory drugs, and muscle relaxants may help with pain and muscle spasms. Some men find relief with warm baths or with biofeedback programs designed to reduce tension in the pelvic muscles.
  • The phytotherapy quercetin and pollen extract (recommended 2:B) but are likely most effective as a part of a multimodal treatment strategy (3:C)
  • Five alpha-reductase inhibitor monotherapy. (Not recommended 1:A); Five alpha-reductase inhibitor therapy in older men with lower urinary tract symptoms and/or as part of a multimodal treatment strategy (Optional 2:C)
  • Individualized multimodal therapy directed towards defined clinical phenotype. (Recommended 3:C)
  • Minimally invasive therapies such as TUNA, laser therapies, etc. (Not recommended 2:A)
  • Invasive surgical therapies such as TURP and radical prostatectomy. (Not recommended 4:D)
  • The following potentially effective therapies can be considered in selected patients (Optional 4:D)
  • Heat therapy in the form of microwave
  • Pudendal nerve modulation
  • Neuromodulating agents (gabapentinoids, tricyclic antidepressants)
  • Muscle relaxants (diazepam, baclofen, cyclobenzaprine)
  • Electromagnetic stimulation
  • Acupuncture
  • Psychotherapy (Mandatory for severe depression and/or suicidal tendencies)
  • Physical therapy
  • Biofeedback

4. Asymptomatic Inflammatory Prostatitis (NIH Category IV)

  • Definitive therapy (Not recommended: 3:A)Antimicrobial therapy for selected patients with elevated PSA, infertility, or manipulation (biopsy) warrants consideration. (Optional 3:C)

1. Acute bacterial prostatitis (NIH category I)

ABP can be a serious infection with fever, intense local pain, and general symptoms. Septicemia and urosepsis are always potential risks. The following factors must be taken into account when treating ABP: potential urosepsis, choice of antimicrobial agent, urinary drainage, risk factors justifying hospitalization, and auxiliary measures intended to improve treatment outcomes.

  • Antimicrobial Therapy (2:A) – The choice and duration of antimicrobial therapy for ABP are based on experience and expert opinion and are supported by many uncontrolled clinical studies., For initial treatment of severely ill patients, the following regimens are recommended: intravenous administration of high doses of bactericidal antimicrobials, such as aminoglycosides in combination with ampicillin, broad-spectrum penicillin in combination with a beta-lactamase inhibitor, a third-generation cephalosporin or a fluoroquinolone is required until defervescence and normalization of associated urosepsis (this recommendation is based on the treatment of complicated UTIs and urosepsis). Patients who are not severely ill or vomiting may be treated with an oral fluoroquinolone., Trimethoprim-sulfamethoxazole (TMP/SMX) is no longer recommended as first-line empirical therapy in areas where TMP/SMX resistance for E. coli, the most frequent pathogen, is greater than 10% to 20%. Treatment should continue for 2 to 4 weeks.,
  • Urinary drainage (3:B) – A single catheterization with the trial of voiding or short-term small-caliber urethral catheterization is recommended for patients with severe obstructive voiding symptoms or urinary retention. Suprapubic tube placement is optional for patients who cannot tolerate a urethral catheter.
  • Hospitalization (3:B) – Hospitalization is mandatory in cases of hyperpyrexia, prolonged vomiting, severe dehydration, tachycardia, tachypnea, hypotension, and other symptoms related to urosepsis. Hospitalization is recommended in high-risk patients (diabetes, immunosuppressed patient, old age or prostatic abscess) and those with severe voiding disorders.
  • Drainage of a prostate abscess (4:A) – Incision and drainage of prostate abscesses are required in selected treatment-refractory patients. The transurethral route appears to be the modality of choice but abscess may be drained via perineum, rectum, or transperineal route.
  • Auxiliary measures – Nonsteroidal anti-inflammatory agents have been suggested for reducing symptoms including fever. Alpha-blockers may be considered, particularly in men with moderately severe obstructive voiding symptoms to reduce the risk of urinary retention and facilitate micturition.

2. Chronic bacterial prostatitis (NIH category II)

  • Antimicrobial therapy (2:A) – Because of their unique and favorable pharmacokinetic properties, their broad antibacterial spectra, and comparative clinical trial evidence, fluoroquinolones are the recommended agents of choice for the antimicrobial treatment of CBP., Data from CBP fluoroquinolone treatment trials with a follow-up of at least 6 months support the use of fluoroquinolones as first-line therapy. The recommended 4- to 6-week duration of antimicrobial treatment is based on experience and expert opinion and is supported by many clinical studies., In general, therapeutic results (defined as bacterial eradication) are good in CBP due to E. coli and other members of the family Enterobacteriaceae. CBP due to P. aeruginosa and Enterococci shows a poorer response to antimicrobial therapy.CBP associated with a confirmed uropathogenic that is resistant to the fluoroquinolones can be considered for treatment with trimethoprim-sulfamethoxazole (or other antimicrobials), but the treatment duration should be 8 to12 weeks.
  • Alpha-Blockers (3:C) – The combination of antimicrobials and alpha-blockers has been suggested to reduce the high recurrence rate and this combination of two therapeutic regimens is considered optional for in-patients with obstructive voiding symptoms.
  • Treatment refractory cases – For treatment-refractory patients with confirmed uropathogenic localized to the prostate, the following are optional treatment strategies are the intermittent antimicrobial treatment of acute symptomatic episodes (cystitis) (3:A); low-dose antimicrobial suppression (3:A); or radical TURP or open prostatectomy if all other options have failed (4:C).

3. Chronic prostatitis/chronic pelvic pain syndrome (NIH category III)

The introduction of an internationally accepted classification system, a validated outcome index, the NIH-CPSI, and the significant number of randomized placebo-controlled clinical trials published over the last decade and a half has permitted best-evidence-based guideline recommendations. Twenty-three clinical trials were available at time of this guideline development. These English-language trials evaluated medical therapies using a prospective, randomized controlled design; these trials were used to support these recommendations. These have been recently reviewed and analyzed. We also used a literature search strategy. In addition, a best-evidence-based treatment algorithm was used

  • Antimicrobials – Antimicrobials cannot be recommended for men with longstanding, previously treated CP/CPPS (1:A). However, uncontrolled clinical studies suggest that some clinical benefits can be obtained with antimicrobial therapy in antimicrobial naïve early-onset prostatitis patients (4:D).
  • Alpha-blockers – Alpha-blockers cannot be recommended as a first-line monotherapy (1:A). However, there is some evidence that alpha-blocker naïve men with moderately severe symptoms who have relatively recent onset of symptoms may experience benefit (1:A). Alpha-blocker therapy appears to provide benefit in a multimodal therapeutic algorithm for men with voiding symptoms (2:C)). Alpha-blockers must be continued for over 6 weeks (likely over 12 weeks).
  • Anti-inflammatory – Anti-inflammatory therapy is helpful for some patients, but is not recommended as a primary treatment (1:B); however, it may be useful in an adjunctive role in a multimodal therapeutic regimen (2:C).
  • Phytotherapies – Phytotherapies (specifically quercetin and the pollen extract, cernilton) are optional recommendations for first-line (2:B) and combination multimodal therapy (3:C).
  • Other medical therapies – Other medical therapies, such as 5-alpha-reductase inhibitor therapy, pentosan polysulfate, and pregabalin, while not recommended as primary monotherapy (1:A), may provide benefit in selected patients (older men with LUTS for 5-ARI therapy, men with associated pain perceived bladder pain and irritative voiding symptoms for pentosan polysulfate and neuropathic type pain for pregabalin).
  • Other potential medical therapies – Muscle relaxants, saw palmetto, corticosteroids, and tricyclic antidepressants have all been suggested and used, but recommendations will have to wait for results from properly designed randomized placebo-controlled trials (4:D).
  • Physiotherapies – A number of physical therapies have been recommended, but they also suffer from a lack of perspective controlled data obtained from properly designed controlled studies. Prostatic massage, perineal or pelvic floor massage, and myofascial trigger point release have also been suggested as a beneficial treatment modality for patients, however, focused pelvic physiotherapy has yet to be shown to provide more benefit compared to SHAM physiotherapy. Biofeedback, acupuncture, and electromagnetic therapy also show promise, but like all the other physical therapeutic modalities, require sham-controlled trials before recommendations can be made (3:C).
  • Psychotherapies – Psychological support and therapy have been advocated based on new psycho-social modeling of this syndrome. This treatment ideally would include a cognitive behavioral therapy program. A referral to a psychologist or psychiatrist should be considered mandatory in patients with severe depression and/or suicidal tendencies.
  • Multimodal Therapy (POINT) – A number of uncontrolled clinical studies have strongly suggested that multimodal therapy is more effective than monotherapy in patients with long-term symptoms., Individualized personal therapy algorithms directed toward clinically defined presenting phenotypes (POINT) have been proposed and the early results of such a strategy look promising. Based on the fact that monotherapies provide (at best) modest efficacy, a multimodal approach using specific clinical phenotypes to choose therapies is considered an optional recommendation. An algorithm has been proposed.

Loading

If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]
Translate »